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Bacteria possess complex machinery for uptake of essential iron. Studying iron-uptake 
provides insight into requirements for bacterial growth, and for development of applications, 
including novel antibiotics and diagnostic tools. 
The presented project investigates the binding of periplasmic binding proteins CeuE, FepB 
and VctP with a range of iron(III)-siderophore and siderophore-mimic compounds. CeuE 
was shown to bind iron(III)-n-LICAM (n= 6, 8) (N,N'-hexane-1,6-diylbis (2,3-
dihydroxybenzamide and N,N'-octane-1,8-diylbis (2,3-dihydroxybenzamide)) tetradentate 
siderophore mimics, with Λ-configuration in both crystal and solution phase, with binding 
constants of 33 ±8 and 58 ± 8 nM respectively. Comparing these results to those for iron(III)-
n-LICAM (n= 4, 5) (N,N'-butane-1,4-diylbis (2,3-dihydroxybenzamide) and N,N'-pentane-
1,5-diylbis (2,3-dihydroxybenzamide)) revealed that the highest affinity was found for a 
five-atom linker. Mutagenesis of His 227 and Tyr 288 that coordinate the iron(III)-centre, 
proved that Tyr 288 is essential for iron(III)-n-LICAM binding to CeuE. Binding affinity is 
slightly reduced for all iron(III)-n-LICAM (n= 4, 5, 6, 8) ligands with mutation to His 227. 
CeuE-H227L-iron(III)-5-LICAM crystal structure determination revealed that iron(III)-5-
LICAM bound in the Λ-configuration with one aqua-ligand.  
Salmochelin mimic siderophores Sal-n-LICAM (n= 4, 5) were synthesised and iron(III)-
binding established via Job plot. For both compounds, equilibria of 1:1 and 3:2 ligand:metal 
ratios were observed, with 3:2 predominating over time. CeuE bound both iron(III)-
complexes weakly in the Λ-configuration. Iron(III)-Sal-5-LICAM bound with higher 
affinity (511 ±76 nM) than iron(III)-Sal-4-LICAM (15.6 ± 2.3 µM). 
FepB was overexpressed, purified, and its siderophore-binding profile compared with that 
of CeuE and VctP. It was shown that FepB bound iron(III)-enterobactin with nanomolar 
affinity, and had micromolar affinity for tetradentate catecholate complexes. CeuE bound 
tetradentate catecholate complexes with nanomolar affinity, and iron(III)-enterobactin with 
micromolar affinity. VctP bound tetradentate catecholate complexes with picomolar affinity, 
iron(III)-enterobactin with mid-nanomolar affinity, and iron(III)-Sal-n-LICAM (n= 4, 5) 
with low-nanomolar affinity. All three proteins bound iron(III)-MECAM (1,3,5-N,N',N″-
tris-(2,3-dihydroxybenzoyl)-triaminomethylbenzene) with low nanomolar affinity. 
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Figure 52: Overlay of the A chain of all mutant structures, showing high similarity in 
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green with Zinc(II) ions shown as grey spheres, H227L/Y288F in light blue and 
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Figure 53: Stereo view of overlay of the A chain of all mutant structures with that of wild-
type CeuE bound to iron(III)-5-LICAM, showing residues 227 and 288 in cylinders. There 
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shown as grey spheres, H227L/Y288F in light blue and H227A/Y288F in lilac. CeuE-
iron(III)-5-LICAM is shown in light crimson, with the ligand shown in translucent 
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Figure 54: Stereo view of iron(III)-siderophore binding residues Tyr 228, Arg 118, Arg 
205 and Arg 249 in the binding cleft of chain A of CeuE-H227L. The electron density for 
the maximum likelihood weighted map was contoured at the 1.5 level. Figure produced 
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230. Residues 222-226, 288-230 shown in lemon cylinders. Leu 227 is shown in cylinders 
coloured by atom type. The electron density for the maximum likelihood weighted map 
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288 shown as pale brown cylinders. The electron density for the maximum likelihood 
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Protein backbone is depicted in light green ribbons. His 210 and Glu 220 sidechains are 
displayed as cylinders coloured by atom type. Zinc(II) is shown as a grey sphere with 
protein contacts as black dashed lines with bond distances annotated in Å. The electron 
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for the maximum likelihood weighted map was contoured at the 1.5 level. Figure 
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Figure 64: Fluorescence quenching titration curves, as a plot of normalised fluorescence 
emission vs ligand concentration in µM for CeuE-H227L/Y288F titrated with iron(III)-5-
LICAM. CeuE at a concentration of 240 nM in 40 mM Tris-HCl pH 7.5, 150 mM NaCl 
was titrated with aliquots of 12 M iron(III)-6-LICAM in 40 mM Tris-HCl pH 7.5, 150 
mM NaCl The titration was performed in triplicate, and a binding curve calculated using 
Dynafit.326 The data were plotted alongside the normalised fluorescence quenching 
observed when CeuE-H227L/Y288F is diluted with the same amount of 40 mM Tris-HCl 
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emission vs ligand concentration in µM for CeuE-H227L/Y288F titrated with iron(III)-5-
LICAM. CeuE-H227L/Y288F at a concentration of 12 µM in 40 mM Tris-HCl pH 7.5, 150 
mM NaCl was titrated with aliquots of 60 M iron(III)-6-LICAM in 40 mM Tris-HCl pH 
7.5, 150 mM NaCl. A binding curve was calculated using Dynafit.326 The quenching was 
not sufficient for determination of a dissociation constant. ............................................... 128 
Figure 66: Fluorescence quenching titration curves, as a plot of normalised fluorescence 
emission vs ligand concentration in µM for CeuE-Y288F titrated with iron(III)-5-LICAM. 
CeuE-Y288F at a concentration of 12 µM in 40 mM Tris-HCl pH 7.5, 150 mM NaCl was 
titrated with aliquots of 60 M iron(III)-6-LICAM in 40 mM Tris-HCl pH 7.5, 150 mM 
NaCl. A binding curve was calculated using Dynafit.326 The quenching was not sufficient 
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associated non-linear regression fitting data from Dynafit.326 CeuE-H227L at a 
concentration of 240 nM in 40 mM Tris-HCl pH 7.5, 150 mM NaCl was titrated with 
aliquots of 12 M iron(III)-5-LICAM in 40 mM Tris-HCl pH 7.5, 150 mM NaCl. ......... 130 
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emission vs ligand concentration in µM for CeuE-H227A-iron(III)-5-LICAM and their 
associated non-linear regression fitting data from Dynafit.326 CeuE-H227A at a 
concentration of 240 nM in 40 mM Tris-HCl pH 7.5, 150 mM NaCl was titrated with 
aliquots of 12 M iron(III)-5-LICAM in 40 mM Tris-HCl pH 7.5, 150 mM NaCl. ......... 131 
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concentration of 240 nM in 40 mM Tris-HCl pH 7.5, 150 mM NaCl was titrated with 
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Figure 71: CeuE-H227L co-crystallised with iron(III)-5-LICAM. Three protein monomers 
are present in the asymmetric unit, with an iron(III)-5-LICAM in each binding cleft. Chain 
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Figure 72: Crystal structure of CeuE-H227L-iron(III)-5-LICAM showing just chain A. 
iron(III)-5-LICAM is shown as ball and stick coloured by atom type. The aqua (or 
hydroxo) ligand is shown as a red sphere. Iron(III) contacts are shown as black lines. 
Figure produced using CCP4mg. ....................................................................................... 137 
Figure 73: Co-crystal structure of CeuE-H227L-iron(III)-5-LICAM, showing the binding 
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hydroxo) ligand is shown as a red sphere. Iron(III) bond distances in Å are labelled. The 
electron density for the maximum likelihood weighted map was contoured at the 1.5 
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electron density for the maximum likelihood weighted map was contoured at the 1.5 
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cylinders, with key residues coloured by atom type. The water/hydroxide molecule in the 
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without a ligand is shown as lemon cylinders. The flexible loop upon which residue 227 is 
located is folded away from the iron(III) centre when the H227L mutation is present. 
Figure produced using CCP4mg. ....................................................................................... 139 
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Figure 77: Circular Dichroism spectra for CeuE-H227L with each iron(III)-n-LICAM (n= 
4, 5, 6, 8) complex. Ellipticity in mdeg was plotted vs wavelength from 300 to 700 nm. 
The spectra were run for 50 µM CeuE-H227L in 0.11M Tris-HCl pH 7.5, 150 mM NaCl 
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This thesis is concerned with the study of periplasmic binding proteins involved in bacterial 
iron uptake, the iron(III)-siderophore complexes that are bound by such proteins, and the 
characterisation of the resulting protein-iron(III)-siderophore complexes. This chapter 
provides a summary of the area of research that surrounds this project, and puts the 
succeeding work into context. 
1.2 Iron Co-ordination 
Iron, the second most abundant metal in the Earth’s crust, possesses an electronic 
configuration with unfilled d-orbitals, enabling access to multiple oxidation states for a range 
of redox activities.1, 2 As such, iron is employed in a broad spectrum of biological systems 
as both an electron donor and electron acceptor and participates in a range of redox 
chemistries for functions in catalysis and electron transfer.2, 3 Iron can exist in oxidation 
states between -2 and +6, however the most common are +2 (d6) and +3 (d5), for which both 
high and low spin states can be accessed.2, 4 
Iron(III) oxides are the most common iron source in the biosphere, and the most common 
coordination geometry for iron(III) compounds is octahedral with six coordinating atoms.5 
Iron(III) is a small and highly-charged cation, with an ionic radius of 0.65 Å and is a hard 
Lewis acid.6 This leads to a preference for ligands that have donor atoms with hard Lewis 
base character, such as charge-dense cyanide ions, or negatively-charged oxygen donors.2, 5 
In aqueous solution above pH 1, iron(III) undergoes hydrolytic polymerisation, causing 
precipitation of insoluble hydroxo and oxo species unless coordinated by suitably stabilising 
ligands.5, 7, 8  
The stereochemistry of metal complexes is important for receptor recognition in biology.9, 
10 Multidenticity of ligands around the metal centre can result in chirality, and for iron(III) 
produces either Λ- or Δ-configured octahedral complexes (Figure 1).11, 12 The Λ-
configuration is often referred to as an octahedral ‘left-handed propeller’ of three bidentate 
ligands around a metal centre, and the Δ-configuration the ‘right-handed propeller’. These 
configurations are possible for hexadentate ligands, or combinations of multidentate 
ligands.11, 13 Complexes may be kinetically inert, such as tris-catecholate chromium(III) 
complexes, where the Λ- and Δ-configured isomers do not exchange.13, 14 Alternatively, 




iron(III), for which it is possible for chiral ligands to influence the preference for one 
stereoisomer over the other.15-17 
 
Figure 1: A tris-bidentate octahedral metal complex in a Λ- and Δ-configuration.11 
1.3 Iron Homeostasis in Bacteria and Mammalian Host 
Iron is the most widely employed transition metal in biology, likely due to its versatility as 
a redox active centre, and maintenance of strict iron concentrations within living cells is 
essential.1 Iron(II) complexes can be used in one-electron reductions, and one-electron 
oxidation reactions.18 If the concentration of free iron is too high, this can lead to the 
production of damaging reactive oxygen species, such as hydroxyl radicals, via Fenton 
chemistry (Scheme 1).19-21  
 
Scheme 1: The Fenton reaction showing the generation of damaging reactive oxygen 
species.20 
In a eukaryotic host, the acquisition of excess iron allows the proliferation of unwanted 
microbial infections.1, 21 However, if iron concentrations are too low then key metabolic 
processes will not function correctly. Iron is incorporated in both eukaryotic and prokaryotic 
enzymes in the form of organic co-factors such as haem, as inorganic cofactors or iron-sulfur 
clusters.19 Although oxidation states of iron(II) and iron(III) are most common in biology, 
iron(IV) or even iron(V) can be achieved in haem containing proteins.18 The reduction 
potentials of biological iron complexes can vary greatly depending on the ligand 
environment, from +310 mV in oxyhaemoglobin, to -500 mV in transferrin.3, 18 The versatile 
range of enzymes that result from incorporation of iron are required in key cellular processes 
including respiration, amino acid synthesis, DNA replication and electron transport.22 
Animals obtain the iron they need through diet; however, bacteria must acquire iron from 
whatever sources are present in their environment. Iron(II) is soluble, but is not abundant in 




iron(III), which is largely insoluble in aqueous media, with a solubility product generally 
estimated at around 10-18-10-17 mol dm-3,3, 23 but more recently estimated by more complex 
models as 1.4 × 10-9 mol dm-3 at pH 7,24 due to the formation of soluble ferric hydroxide 
species.
20, 25, 26
 This means that free iron is not immediately accessible for uptake by living 
cells. In a mammalian host, iron is locked up in proteins such as haemoglobin, transferrin, 
and ferritin, and this iron cannot be easily accessed by bacteria.20 Requiring concentrations 
between 10-8 and 10-6 mol dm-3 for growth,3 iron is almost always restricted, and complex 
strategies must be employed for acquiring enough iron for survival.19, 25 
Bacterial metal-acquisition systems are generally classed into importers of elemental ions, 
acquisition via host iron-sources and extracellular capture via secretion of chelating 
compounds that are named siderophores.1 Host iron sources are commonly in the form of a 
haem-containing protein, as in mammals, the majority of iron is found in haemoglobin.20, 27 
Haem can either be directly taken up through the outer membrane of a bacterial cell via a 
specific receptor, or first sequestered by secreted proteins named haemophores.19, 20, 25 
1.4 Siderophores 
Siderophores are low molecular weight (<1500 Da) compounds that have a high affinity for 
iron(III),3 and are used by bacteria, fungi and some plants for iron(III) uptake when under 
iron deficiency.25, 28 They can be endogenous - synthesised and secreted for the specific 
purpose of iron(III) sequestration or exogenous - as an existing biomolecule that happens to 
coordinate iron(III). Siderophores must be selective for iron(III) over other metals, so these 
ligands contain ‘hard’ oxygen donor atoms, to satisfy the binding requirements of small 
highly charged iron(III). Although aluminium(III) is abundant in the Earth’s crust, 
siderophores are able to select for iron(III), due to the differences in ionic radius (0.54 Å for 
aluminium(III) and 0.65 Å for iron(III)).28, 29 Siderophores contain one or a mixture of iron-
coordinating functional groups, and the most common of these are catecholates, 
hydroxamates, carboxylates, α-hydroxycarboxylates and phenolates (Figure 2).28, 30 The 
most effective siderophores are hexadentate, that arrange all six iron-coordinating atoms into 






Figure 2: Oxygen containing functional groups common to siderophores. Oxygen atoms that 
must be deprotonated for iron(III) binding are shown in red.28 
As iron(III)-binding units must first be deprotonated, proton competition in aqueous media 
must be considered when estimating the iron(III)-binding affinity of a siderophore. It is 
therefore necessary to report true affinities as pFe(III) at a known pH (commonly 7.4), rather 
than as a simple formation constant (Kf).
28 The pFe(III) value is the -log[Fe(III)]free in an 
aqueous solution where [Fe]total=1 mM and [siderophore]total=10 mM, and therefore a large 
pFe(III) value suggests high iron(III) affinity.2, 6, 28, 30  
Discovery of Siderophores 
Siderophores were discovered as microbial growth factors in the 1950s and the first isolated 
were ferric complexes of mycobactins, coprogen and ferrichrome (Figure 3).2, 28, 33-38 
Mycobactins are mixed-type hydrophobic siderophores produced by mycobacteria that are 
located within the cell envelope, thought to require additional extracellular siderophores to 
effectively supply the cell with iron(III).25 Coprogen is a fungal hydroxamate siderophore, 
and has been shown to be taken up by Escherichia coli.38, 39 Ferrichrome is also a fungal 
hydroxamate siderophore, but has been shown to support growth of Pseudomonas 
aeruginosa.40, 41 The first report to show that siderophore production is iron-regulated 
involved the observation that ferrichrome A (Figure 3) was produced by iron deficient 
Ustilago sphaerogena,36 followed by confirmation of the structures of both ferrichrome and 
ferrichrome A in 1961.40, 42  
Siderophore identification assays were developed in the 1980s for the rapid identification of 
natural iron-binding compounds.43 Today, over 500 natural siderophores have been isolated 
and characterised.28 In marine environments there is a prevalence for amphiphilic 
siderophores including the marinobactins, aquachelins and amphibactins.44, 45 Siderophore 
units usually contains hydroxamate and/or α-hydroxycarboxylate functional groups, which 
are appended to an aliphatic chain, that can vary in length depending on the required partition 
coefficient. It is thought that such siderophores do not diffuse away from the cell envelope, 
and are in fact embedded in the outer-membrane- and prove a particularly useful feature for 





Figure 3: Structures of the earliest siderophores discovered, and an example of a fluorescent 




Notable are the pyoverdine class of siderophores (Figure 3), for which there are over 70 
structural analogues.28, 49 Pyoverdines are mixed-type fluorescent siderophores produced by 
Pseudomonas spp., containing two hydroxamate groups, and one catecholate group attached 
to a fluorophore.48-52 Pseudomonas aeruginosa produces a pyoverdine that is known to be 
important for virulence and biofilm formation, which is a particular threat of lung infections 
in cystic fibrosis patients.50 These siderophores are very effective at iron(III) sequestration, 
as they act by delivering iron to the periplasm, where the iron is released by reduction to 
iron(II), and can be recycled without the need for degradation of the siderophore.53, 54 
Reducing iron(III) to iron(II) decreases thermodynamic stability of the siderophore complex, 
by decreasing charge density on the metal centre, decreasing the Lewis acidity of the metal, 
hence decreasing the affinity for the negatively charged donor oxygen atoms and increasing 
the capacity for ligand exchange.55, 56 
Enterobactin and Catecholate Siderophores 
Enterobactin, the first triscatecholate siderophore to be identified, was isolated and 
characterised in 1970, from cultures of both E. coli and Salmonella typhimurium.57-62  
 
Enterobactin is one of the highest affinity iron(III) binding compounds known at 
physiological pH with a pFe(III) of 35.5.29 The siderophore has a number of properties that 
enable such effective iron(III) binding, including a cyclic trilactone backbone, iron binding 
catecholate units, and the way in which the catecholamides form favourable hydrogen 
bonds.37, 63 The triserine lactone backbone was shown to be the optimum size for spacing 
and arrangement of the catecholamide groups for iron(III) binding.64 The rigidity that is 
conferred from pre-organisation of the ring provides an entropic contribution to the stability 
of the iron(III) complex of enterobactin.37, 64 Indeed when the ring is hydrolysed, liberating 
the more hydrophilic trisDHBS, complex-stability is lost.6, 65 The backbone also constrains 




The optimum donor-metal-donor angle is created between iron(III) and the two catechol 
oxygens of each bidentate catecholamide unit, as observed in the bonding of iron(III)-
enterobactin by single-crystal polarized absorption and magnetic circular dichroism 
spectroscopy.37, 66, 67 Fe L-edge X-ray absorption spectroscopy showed that the high stability 
constants of catecholate complexes are due to a large contribution of σ and π-donation from 
ligand to metal.67 The primary amide adjacent to the catecholate unit is of vital importance 
to stability of the iron(III)-complex.37 The hydrogen bond that forms between the amide and 
the ortho-phenolate allows for a lower pKa, and reduces proton competition, enhancing 
iron(III)-complex stability. Similar ligands that lack this hydrogen-bonded arrangement only 
form stable iron(III) complexes at basic pH.37 This amide confers stability of the complex 
under acidic conditions, and allows for protonation of the meta-phenolate without loss of 
iron(III). This is achieved via adoption of the less stable salicylate binding mode, whereby 
rotation of the amide allows for direct coordination of the amide carbonyl oxygen with the 
metal centre (Figure 4).68, 69 The salicylate binding mode has been extensively studied, and 
this less stable form is thought to be important for intracellular iron-release.68-72 
 
Figure 4: Protonation resulting in a switch between catecholate and salicylate binding mode. 
Top: Representation of the iron(III)-bound catecholate and salicylate modes of enterobactin. 






Figure 5: Triscatecholate siderophores with varied amino acid backbones.28, 73 
Since the discovery of enterobactin, many catecholate siderophores have been characterised 
from a range of bacterial species. These include hexadentate, tetradentate and bidentate 
systems, and a number of these are close variations of enterobactin, incorporating a variety 
of amino acids in the cyclic trilactone backbone structure (Figure 5).73 Producing structurally 
similar but slightly different siderophores allows for high-affinity iron(III)-binding but limits 
theft by other species. This concept is well documented for the range of siderophores 
synthesised and employed by Streptomyces species.74 Examples of catecholate siderophore 
variations are bacillibactin (also commonly named corynebactin) produced by Bacillus 
subtilis and lysine-corynebactin that cannot be used by the E. coli for iron delivery,10 but 
still have a high iron(III)-affinity cyclic triscatecholate structure.75, 76 This may be related to 
the fact that enterobactin produces a predominantly Δ-configured iron(III) complex, while 
bacillibactin and lysine-corynebactin, with glycine spacers, both produce a Λ-configured 
major complex, causing incompatibilities with uptake receptors or the esterases required for 
iron(III) release.17, 37, 77 In addition, the introduction of threonine instead of serine, as is the 
case in paenibactin produced by Paenibacillus elgii and griseobactin produced by 
Streptomyces spp., increases stability of the backbone against acid or enzymatic 
hydrolysis.10,78, 79 Other modifications include the insertion of an acylated serine into the 
trilactone backbone, creating a tetralactone with a fatty acid unit attached in addition to the 
three catecholamides, as is the case in amphienterobactin siderophores, biosynthesised by 
Vibrio campbellii (Figure 6).73, 80, 81 This modification confers hydrophobic character to the 
siderophore, altering the partition coefficient, whilst still maintaining high selectivity for 
iron(III). Linear hexadentate catecholate siderophores also exist, including agrobactin, 
agrobactin A, vibriobactin, fluvibactin, protochelin and trisDHBS (Figure 6).28, 82-87 In 




catecholate units, such as the one hydroxamate siderophore fuscachelin A (Figure 6) 
produced by Thermobifida fusca,81, 88 or the one phenolate siderophore parabactin (Figure 6) 
produced in Paracoccus denitrificans.28, 37, 89 
 
Figure 6: Amphienterobactin, a range of structurally similar linear hexadentate catecholate 




Tetradentate Catecholate Siderophores 
Siderophores were once thought to form exclusively hexadentate octahedral iron(III) 
complexes.3 However a number of lower denticity iron(III)-siderophores are known to be of 
biological relevance.90-93 The lower the denticity, the weaker the iron(III)-complex stability 
(as demonstrated later in section 1.4),28 and a range of stabilities may prove useful in natural 
iron-uptake and release mechanisms. There are a diverse range of tetradentate catecholate 
siderophores known in nature produced by a wide number of bacterial species.28 Although 
they are unified in their structures by containing two catecholate iron(III)-binding units, the 
backbones often vary in functionality and length. Most contain a 5-atom linker, including 
azotochelin, myxochelin, bisDHBS and salmochelin S1, the enterobactin and salmochelin 
S4 hydrolysis products respectively and fimsbactins D and E (Figure 7).94-97 The linker can 
be extended to 6 atoms as in serratiochelin, 8 atoms in pistillarin, or even up to 16 atoms as 
in amonabactin P 750.92, 93, 98 This variation demonstrates that the desirable iron(III)-binding 
properties are achieved in all structures, but by incorporating an unusual linker design, each 
species is able to evade the outer-membrane receptors of other species, and thereby limit 
competition.73, 74, 99 Hexadentate siderophores generally form 1:1 octahedral iron(III) 
complexes, however tetradentate siderophores have two vacant coordination sites when 
bound in a 1:1 ratio. This phenomenon means that other siderophore: iron(III) ratios are often 
favourable, with the self-assembly of a 3:2 complex common in aqueous solution.28, 90, 100, 
101 In addition, several natural tridentate and bidentate catecholate siderophores are known 
to promote bacterial growth and include chrysobactin, aminochelin, DHBS, itoic acid and 






Figure 7: Tetradentate catecholate siderophores from a range of bacterial species with 





Figure 8: Tridentate and bidentate catecholate siderophores.28 
Properties of Siderophores 
With very high formation constants for iron(III), siderophores can strip iron from host 
proteins such as ferritin, transferrin and lactoferrin as well as allowing chelation of any 
available insoluble ferric hydroxide.25 Catecholate siderophores have a pKa of between 6.5 
and 8 for deprotonation of the first proton, and around 11.5 for the second proton.30 
Carboxylates have low pKa values around 4, and hydroxamates around 8.5. This means that 
carboxylate siderophores are best employed in acidic environments, while catecholate 
siderophores at better suited to neutral pH.30, 62 
Cyclic siderophores tend to have high iron(III) binding affinity, due to their rigid pre-
organised structure that is entropically favourable for iron(III) chelation as discussed for 
enterobactin.26 This is demonstrated by ferrioxamine E having higher affinity for iron(III) 
than linear ferrioxamine B, enterobactin a higher affinity for iron(III) than linear mimic 
TRENCAM and alcaligin a higher affinity for iron(III) than linear rhodotorulic acid as 
demonstrated by their pFe(III) values (Figure 9) (Table 1).26, 63 Furthermore, hexadentate 
siderophores tend to have higher iron(III) affinity than lower denticity siderophores, and this 
is reflected in lower pFe(III) values and less negative redox potentials for the resulting 
iron(III) complexes.108 This is demonstrated by the lower pFe(III) values for both 
tetradentate hydroxamate siderophores alcaligin and rhodotorulic acid when compared to 
hexadentate hydroxamates Ferrioxamine E and B (Figure 9), as well as for the tetradentate 
catecholate siderophore amonabactin T789 when compared to enterobactin (Table 1).109 This 
phenomenon allows tetradentate siderophore complexes to be more labile, with a greater rate 
of iron(III) exchange than hexadentate analogues, which may be useful for rapid iron(III) 





Table 1: Properties of a representative set of cyclic and linear siderophores. 
Siderophore Structure Type Denticity pFe(III) 
Ferrioxamine E Cyclic Hydroxamate 6 27.7110 
Ferrioxamine B Linear Hydroxamate 6 26.6110 
Enterobactin Cyclic Catecholate 6 35.529 
TRENCAM Linear Catecholate 6 27.863 
Alcaligin Cyclic Hydroxamate 4 23.0110, 111 
Rhodotorulic Acid Linear Hydroxamate 4 21.8110 
Amonabactin T789 Linear Catecholate 4 25.8109 
 
 
Figure 9: Linear and cyclic hydroxamate siderophores.39, 110 
Redox potentials can also be used as a measure of iron(III) complex stability of 
siderophores.18 The lower the redox potential, the more energy required to release iron from 
the complex via reduction. Enterobactin has a very low redox potential of -750 mV (E1/2 vs 
NHE), meaning the complex is very stable, and a strong reducing agent is required for iron 
release. Ferrioxamine B has a higher redox potential of -468 mV (E1/2 vs NHE) and so forms 
a less stable iron(III) complex than enterobactin, and iron release by reduction does not 
require such a strong reducing agent.18, 26, 110 A correlation between redox potential and 
pFe(III) value has been shown for a number of siderophore and siderophore mimics.108  
1.5 Bacterial Iron Uptake 
Competitive versus cooperative behaviour in bacterial siderophore production and uptake is 
a topic of debate.112-114 It is commonly suggested that bacteria attempt to outcompete each 




that the siderophores may contribute to the overall growth of a symbiotic colony of mixed 
species. If bacterial species are able to take up siderophores that they do not produce 
themselves, then these species benefit from co-colonisation of a host.115 Siderophore 
biosynthesis comes at a metabolic cost, but the more closely related species are to each other, 
the more likely they are to be able to share siderophores, so it is possible that similar bacterial 
species work in a cooperative manner rather than a competitive one.113 However shared 
siderophores are downregulated, and more complex specialised siderophores are upregulated 
in the presence of significantly different opposing species,112, 116 and the diversity of 
siderophores structures is thought to arise due to the advantages of limiting piracy between 
species.73 
Iron Uptake in Gram-Positive Bacteria 
Gram-positive bacteria with a thick cell wall and only one cell membrane, have specific 
binding proteins, often termed ‘substrate binding proteins’ that are anchored in the cell 
membrane.25 These proteins bind iron sources, and deliver them to ATP-binding cassette 
transporter systems, which act to deliver the iron complexes into the cytoplasm. A simplified 
diagram of Gram-positive bacterial iron(III) uptake is depicted in Figure 10.19, 20, 117 These 
systems exist for siderophore complexes as well as haem and transferrin.20 
 
Figure 10: General mechanism for iron(III)-uptake in Gram-positive bacteria.22 
Iron Uptake in Gram-Negative Bacteria 
Gram-negative bacteria acquire iron from a number of sources. Iron(II), a soluble ion in 
anaerobic media can be taken up into the periplasm through porins.118 Active transport by a 
specific uptake channel then allows the passage of iron(II) into the cytoplasm. The most 
widespread pathway for iron(II) uptake is the Feo system, and is important for virulence of 




iron(III) predominates, and must be obtained from soluble sources such as haem and 
siderophore complexes. A general overview for siderophore and haem derived iron uptake 
in Gram-negative bacteria is illustrated in Figure 11. 
 
Figure 11: General iron(III)-uptake mechanisms for Gram-negative bacteria.20 
Iron(III) complexes are generally too large to be taken up through porins, which have a 
molecular weight cut-off at around 600 Da, so must be taken up by a specific outer 
membrane receptor (Figure 11).119 Outer membrane receptors commonly recognise and 
transport a range of related iron sources,19, 20 however Gram-negative bacteria are unable to 
employ direct active transport of substrates through outer membrane receptors, as there is no 
transmembrane ATPase for generation of the necessary energy.20 As such, outer membrane 
receptors are coupled to the inner membrane via the inner-membrane anchored proteins 
TonB, ExbB and ExbD, providing energy generated by the proton motive force of the 
cytoplasmic membrane to actively transport substrates into the cytoplasm.20, 117, 120 Outer 
membrane receptors, known to uptake catecholate, hydroxamate and carboxylate 
siderophores, as well as a wide range of other substrates, generally have a 22 stranded β-
barrel structure, with a cork domain at the centre of the barrel. The cork domain is involved 
in the regulation of substrate uptake, acting as a gate between the extracellular matrix and 
the periplasm.20 The crystal structure of FpvA, the siderophore receptor from Pseudomonas 





Figure 12: Stereo view of siderophore outer membrane receptor FpvA bound to iron(III)-
pyoverdine in Pseudomonas aeruginosa (PDB ID: 2IAH). β-barrel is in dark blue with the 
cork domain in light blue. A: Side view with iron(III)-pyoverdine shown in cylinders 
coloured by atom type. B: Transmembrane view with iron(III)-pyoverdine shown in spheres 
coloured by atom type. Figure produced using CCP4mg. 
Once the iron(III)-complex is transported into the periplasm, a periplasmic binding protein 
(with structural similarities to the Gram-positive ‘substrate binding protein’) acts to carry 
the iron source to the inner membrane ATP-binding cassette transporter, where the complex 
is delivered into the cytoplasm (Figure 11).20 Siderophore periplasmic binding proteins 
generally have a bilobate structure, with a shallow binding cleft between the two main 
domains where the iron(III)-siderophore complex is bound.20 This is demonstrated in the 
crystal structure of FhuD, a periplasmic binding protein from E. coli, bound to iron(III)-
coprogen (Figure 13). The iron(III)-coprogen is bound in the region between the two lobes 
of the protein.122 There are currently no known crystal structures for a siderophore inner-





Figure 13: Stereo view of periplasmic binding protein FhuD (yellow ribbons) from E. coli 
bound to siderophore iron(III)-coprogen (cylinders coloured by atom type) (PDB ID: 
1ESZ).122 Figure produced using CCP4mg. 
For haem uptake, haem must first be sequestered from a mammalian host, and this can be 
done directly via binding of the bacterial outer membrane receptor to a host 
haemoprotein,123-125 or via the synthesis of additional haemophore proteins that are produced 
and secreted into the extracellular matrix, which then act to scavenge haem and deliver it to 
the outer membrane receptor 20, 25, 123, 126  
Once iron(III)-complexes are transported into the cytoplasm, the iron(III) must be released 
from the complex for storage or use, which can be achieved by degradation of the organic 
ligand, and/or reduction of the iron(III) to iron(II). Although it was once thought that 
siderophore complexes would be too stable for iron(III) release by biological reductants,18 
reductase enzymes have been identified for the reduction of iron(III)-siderophore complexes 
in a number of Gram-negative species, using NADH or NADPH as the reductant.25 These 
reductases may be specific to iron(III)-siderophore reduction, but general flavin reductases 
are also reported to reduce iron(III)-siderophore complexes.32  
Bacterial Iron Regulation via Fur and DxtR 
As discussed in section 1.3 it is important for bacteria to maintain a strict iron concentration 
within their cells to ensure necessary cell function without generation of damaging reactive 
oxygen species. In most Gram-negative bacterial species, and a large proportion of Gram-
positive species with low genetic guanine-cytosine content, iron levels are controlled by the 
ferric uptake regulator (Fur).127 When genetic guanine-cytosine content is high in Gram-
positive species, iron levels are often regulated in a similar manner by the diphtheria toxin 
regulator (DtxR).30 In the Fur system, the 17 kDa ferric uptake regulator protein (Figure 14) 
acts as a sensor for iron, and represses the expression of genes that code for the proteins 





Figure 14: Stereo view of the crystal structure of the Fur regulator protein from C. jejuni. 
(Zn2+ ions shown as grey spheres) (PDB ID: 4ETS).129 Figure produced using CCP4mg. 
This means that when iron concentrations are high, Fur is iron(II)-bound, and represses the 
upregulation of iron uptake machinery, limiting further iron-uptake into the cell. When 
cellular iron concentrations decrease, iron is released from the Fur protein, and the genes for 
expression of iron-uptake machinery are no longer repressed. Iron concentrations can then 
be replenished as the iron-uptake capacity of the cell is increased. 
In many bacteria, including E. coli,127 C. jejuni130, 131 and V. cholerae,132 there is a fur gene 
and a ‘fur box’ region, with the consensus sequence GATAATGATAATCATTATC located 
in the promoter sequence of a gene or operon that is iron-regulated. When the Fur protein is 
iron-loaded, a conformational change is induced, allowing the binding of two dimers of the 
protein to the Fur Box sequence, preventing access to RNA polymerase.133 Fur has also been 
shown to act as a transcriptional activator for the genes responsible for essential iron-
containing enzymes, and is involved in the regulation of the bacterial ferritin iron-storage 
proteins. This proves that Fur acts as a global iron regulator protein, prioritising only vital 
iron consumption when under deficiency.133 In addition to Fur, efflux pumps are known to 
exist for the rapid export of iron(III) outside of the cell, to prevent cell death by iron(III) 
overload and generation of reactive oxygen species. In S. typhimurium, an iron citrate efflux 
transporter was found to export iron(III)-citrate when under stress conditions. These systems 
are however not regulated by Fur, but a two component regulator thought to be linked to the 
disruption of normal iron concentrations.21 
Iron Uptake in Escherichia coli  
E. coli, the most widely studied bacterial species, is Gram-negative and exists in the gut flora 
of a wide range of animal species, including mammals. E. coli is largely aerobic when in the 
mammalian gut, where the species is able to protect the host from pathogenic colonisation, 




coli, including Shiga Toxin-producing E. coli (STEC), are a significant threat to human 
health, with more than 2.8 million cases of intra and extra-intestinal E. coli infections per 
year.134-136 Iron uptake is of vital importance to successful host colonisation and E. coli 
employs a range of strategies for iron acquisition, including the use of haem as well as a 
variety of siderophore complexes.20, 126, 137 The widely-studied E. coli K-12 strain 
synthesises and secretes enterobactin as its only siderophore. Pathogenic strains of E. coli 
have been found to synthesise salmochelin S4, aerobactin, yersiniabactin as well as 
enterobactin, and it is likely that these siderophores are involved in virulence (Figure 15).138 
The ability to produce and utilise a range of structurally-diverse siderophores allows for iron 
uptake over a broader pH range, and the use of a range of starting materials for siderophore 
synthesis means growth of the species is possible with a broader range of nutrients, 
increasing the chances of survival. 
 
Figure 15: Siderophores synthesised and secreted by pathogenic strains of E. coli.138 
The catecholate siderophores enterobactin and salmochelin S4 are of most interest for this 
thesis, and their role in E. coli will be discussed further. As salmochelin S4 is the bis-C5-
glucosylated analogue of enterobactin, the biosynthesis of both siderophores is identical, 
with a final glucosylation transforming enterobactin into salmochelin S4. Enterobactin 
biosynthesis is favoured at a lower pH of 5.6, while salmochelin S4 production predominates 




22-kb cluster as follows: entD-fepA-fes-entF-fepE-fepC-fepG-fepD-fepB-entC-entE-entB-
entA-ybdA. Within the cluster there are 6 operons with three promoter regions and a fur-
box.139 The genes termed ‘ent’ code for six enzymes (EntA-F) that catalyse the production 
of enterobactin. Catecholate siderophore uptake in E. coli is summarised in Figure 16. The 
‘fep’ genes in the gene cluster code for the proteins FepABCDEG, which are dedicated to 
the import of ferric enterobactin. FepA is the TonB coupled outer membrane receptor (Figure 
17).140, 141  
 
Figure 16: Proposed functions of proteins involved in catecholate siderophore synthesis, 
secretion and uptake in pathogenic E. coli. Ent is an abbreviation for Enterobactin, S4, S2, 





Figure 17: Stereo view of the crystal structure of FepA, the enterobactin outer-membrane 
receptor in E. coli.142 A: Side view B: Transmembrane view. (PDB ID: 1FEP) Figure 
produced using CCP4mg. 
FepB (Figure 18) is the periplasmic binding protein that delivers iron(III)-enterobactin to the 
ABC transporter in the cytoplasmic membrane, made up of FepC2D2.
20, 143-146 The function 
of FepG is less well documented, but is also thought to play a role in uptake at the 
cytoplasmic membrane.3, 20, 147-149 There are no published structures for FepC2D2 or FepG. 
The ‘fepE’ gene codes for the protein FepE that is bound to the cytoplasmic membrane, but 
is in fact an unrelated polysaccharide co-polymerase, involved in the synthesis of 
polysaccharide chains for cell surface antigens.150, 151 The ‘fes’ gene codes for the Fes 
protein, an esterase located in the cytoplasm that causes the hydrolysis of the enterobactin 
trilactone backbone. The ‘ybdA’ gene codes for the EntS protein, which acts as a cytoplasmic 
enterobactin export protein, and has similarities to efflux pumps of the major facilitator 





Figure 18: Stereo view of FepB, the enterobactin periplasmic binding protein in complex 
with iron (III)-enterobactin (PDB ID: 3TLK).146 Figure produced using CCP4mg. 
Salmochelin S4 is synthesised via the transfer of a glucose functional group onto the C5 
position of two of the catecholamide units of enterobactin via the C-glucosyltransferase 
IroB.154 IroB is derived from the iroNEDCB gene cluster. The cluster also contains the genes 
for a further four proteins involved in siderophore uptake. The function of IroC is disputed 
as it is commonly reported as a cytoplasmic salmochelin exporter. 153, 155, 156 A contrasting 
study suggests that IroC may be the cytoplasmic iron(III)-salmochelin S2 transporter, which 
is also reported to uptake iron(III)-enterobactin linear hydrolysis product iron(III)-
trisDHBS.157 The confusion is likely to arise from the same naming system being used for 
similar proteins from S. typhimurium.158 IroC may have a different function in this species 
when compared to the IroC in E. coli, and further studies are required to establish whether 
this protein really possesses a dual function as both an exporter and importer.155, 156 IroD is 
a cytoplasmic esterase known to break down both salmochelin S4 and enterobactin to their 
linear hydrolysis products. IroE is a periplasmic esterase that linearises both salmochelin S4 
and iron(III)-salmochelin S4 to salmochelin S2. IroE has also been shown capable of the 
slow linearisation of both enterobactin and iron(III)-enterobactin to trisDHBS and 
bisDHBS.159 Finally, IroN is the outer membrane iron(III)-salmochelin S4 importer.154, 157 
Interestingly there is no known periplasmic binding protein associated with the Iro 
salmochelin uptake system, meaning there are no known interactions of a periplasmic 
binding protein with the salmochelins, or indeed the enterobactin hydrolysis products. 
Fiu and Cir are outer membrane receptors employed in the uptake of linear hydrolysis 
products of enterobactin,152 and it is known that trisDHBS, bisDHBS and DHBS can 
transport iron into E. coli. 95, 160 The FepBDGC system is proposed to be involved in the 
transport of the linear enterobactin hydrolysis products, but this requires more rigorous 




products.157 Once inside the cytoplasm, iron is released from enterobactin via hydrolysis by 
the esterases Fes and IroD to trisDHBS, then bisDHBS and finally to the bidentate DHBS. 
These hydrolysis events are much more efficient than those of periplasmic IroE.159 Iron(II) 
is then released from enterobactin and the lower denticity hydrolysis products by reduction 
via the NADPH dependent reductase YqjH.161-163 YqjH is fur regulated, but is also linked to 
nickel homeostasis.164 The reductase reduces iron(III) bound to enterobactin to iron(II), but 
works most efficiently on iron(III)-trisDHBS, after prior hydrolysis of the cyclic trilactone 
backbone by Fes.163 YqjH can reduce iron(III)-citrate, but is not active on hydroxamate 
siderophores.163 The growth of E coli with iron(III)-MECAM is directly dependent on the 
action of YqjH.165  
 
Iron Uptake in Campylobacter jejuni 
Campylobacter jejuni is a Gram-negative species responsible for gastroenteritis in humans, 
causing more cases of infection than the sum of both Salmonella spp. and E. coli and is 
commonly transmitted through under-cooked poultry.166-169 It is thought to be particularly 
good at co-operative survival with other species,170 and requires a high degree of metabolic 
flexibility to enable survival in a number of environments upon migration from avian host, 
to pathogenic colonisation of the human intestinal tract.168, 171  
C. jejuni possesses an array of iron(III) uptake machinery to ensure the necessary iron(III) 
concentration inside the cell for survival and growth,131 and is able to acquire iron(III) from 
its environment via a number of known sources, including catecholate siderophore 
complexes, rhodotorulic acid complexes, haem, transferrin and lactoferrin.168,172, 173 C. jejuni 




174 Although some strains are thought to produce siderophores in small amounts, the 
siderophore type has never been classified.175, 176  
The full genome of C. jejuni has been sequenced, but the complete iron transport system is 
not yet fully characterised, with several proteins of currently unknown function likely to be 
involved in iron transport.115, 177 Six gene clusters were identified as iron regulated, 
indicating that these genes may code for proteins involved in iron homeostasis.115 C. jejuni 
possesses typical Gram-negative transport machinery which is regulated by fur in a similar 
manner as discussed for E. coli.131 Fur regulation has shown to be involved in prevention of 
oxidative stress and for allowing the species to survive in acidic environments.130 Iron(II)-
uptake is known in C. jejuni by the Feo system, with FeoB, the outer membrane receptor 
essential for iron(II) uptake.118, 168 The periplasmic binding protein cFbpA is known to bind 
iron directly, and is selective for iron(II).178 ChuABCD are fur regulated and are involved in 
the uptake of hemin, and haem from haemoglobin.115, 173 The outer-membrane receptor is 
ChuA, ChuB and ChuC are the permease and ABC transporter components for uptake of 
haem into the cytoplasm, and ChuD acts as the periplasmic binding protein.172 Similar 
systems exist for uptake of iron(III) via ferrichrome, rhodotorulic acid and transferrins.172 
All known strains of C. jejuni can employ exogenous enterobactin for iron uptake.115, 175 For 
catecholate enterobactin-derived siderophore complexes, the uptake machinery consists of 
the outer membrane transporters CfrA and CfrB (structures currently unknown),179 with 
three TonB systems which provide active transport of complexes into the periplasm. 
CeuBCDE (Campylobacter enterobactin uptake) proteins transport enterobactin-derived 





Figure 19: Proposed functions of proteins involved in catecholate siderophore uptake in C. 
jejuni.115, 173, 180 
CeuBCD share high homology with the iron(III)-enterobactin ABC transporter in C. coli.115 
CeuB and CeuC are therefore likely to be cytoplasmic membrane permeases, and CeuD, the 
ATPase that aids the necessary active transport of complexes into the cytoplasm.181 172 
Although CeuBCD are known to be involved in cytoplasmic uptake of enterobactin derived 
iron(III)-complexes,172 it has not been established whether these are complexes of the full 
cyclic trimer or the hydrolysis products, and there is currently no published crystal structure. 
CfrA and TonB3 were shown to be required for use of enterobactin, bisDHBS, trisDHBS 
and salmochelin S4 as iron sources, indicating that CfrA is likely to be involved in the uptake 
of multiple catecholate substrates.182 This is currently the only study showing that an 
iron(III)-salmochelin siderophore supports growth of C. jejuni.182 CfrB, a second iron(III)-
enterobactin outer membrane receptor, is present in fewer C. jejuni strains than CfrA, and 
more commonly only one of the two outer-membrane receptors is present in each strain, 
unlike in C. coli where both are present.183 Strains that contained only CfrB could not always 
use iron(III)-enterobactin as an iron source.183  
CeuE (Figure 20), is a periplasmic lipoprotein, characterised as having siderophore-binding 
properties in 1995.171 Crystal structures revealed it has a typical overall fold of a type III 




containing lobes linked via an α-helix.186 There is a shallow iron(III)-siderophore binding 
cleft located between the two lobe regions (Figure 20).186, 187 The protein is naturally located 
in the periplasm, and acts to deliver catecholate iron(III)-siderophore complexes from the 
outer membrane receptor CfrA to the inner membrane transporter CeuBCD, for uptake of 
the complexes into the cytoplasm.30 CeuE has been proven not to be essential for iron 
acquisition from iron(III)-enterobactin, but without CeuE, growth is significantly 
impaired.115, 159 It has been reported that CeuE along with the cytoplasmic transporter made 
up of CeuBCD are involved in the transport of iron(III)-enterobactin into the cytoplasm.168 
However more recent studies have shown that iron(III)-bisDHBS is a more optimised 
substrate for CeuE than iron(III)-enterobactin, suggesting that the linear hydrolysis products 
may be the main source of delivery of cytoplasmic iron(III).90 It is likely that confusion arises 
over the use of impure enterobactin sources, or the lack of consideration of the potential for 
in situ enterobactin hydrolysis. 
 
Figure 20: Stereo view of CeuE (yellow ribbons) (PDB 1D: 5ADW) has bilobate shape with 
a shallow binding cleft where iron(III)-bisDHBS is bound (cylinders coloured by atom 
type).186 90 Figure produced using CCP4mg. 
It is known that C. jejuni is able to use enterobactin as a sole iron source without a functional 
CeuBCDE ABC transporter system if Cee is present.182 Cee is a periplasmic esterase in C. 
jejuni known to degrade iron(III)-enterobactin to iron(III)-trisDHBS, iron(III)-bisDHBS and 
iron(III)-DHBS, as well as the apo siderophore to trisDHBS, bisDHBS and DHBS.159 Cee 
was shown to be essential for iron(III)-enterobactin utilisation with CfrB, however Cee was 
not required when CfrA was present. As CeuE is optimised for binding of iron(III)-
bisDHBS, this may indicate that CfrB can only transport cyclic iron(III)-enterobactin into 
the periplasm, whereas CfrA is known to transport the linear hydrolysis products as well as 
cyclic enterobactin.182 If this is the case, a system with CrfB but no Cee would cause cyclic 
enterobactin to accumulate in the periplasm, without an esterase capable of hydrolysis of the 




appears to be the only trilactone esterase capable of hydrolysing enterobactin in C. jejuni, 
this supports the theory that the major function of the CeuBCDE system is to transport the 
linear hydrolysis products into the cytoplasm.159 The current scheme for catecholate 
siderophore iron uptake in C. jejuni is shown in Figure 19.  
The iron(III)-linear hydrolysis products are likely to have higher redox potentials than 
iron(III)-enterobactin, meaning they require less powerful reducing agents for release of 
iron(II) from the complex.30, 56, 95 It is thus more likely that iron(II) would be released from 
the linear hydrolysis products with greater efficiency by a cytoplasmic reductase than from 
cyclic enterobactin. No cytoplasmic iron(III)-siderophore reductase has been characterised, 
however riboflavin production is fur regulated and has been linked to iron(III) to iron(II) 
reduction capacity, suggesting that a potential reductase is likely to contain a riboflavin 
derived cofactor such as FAD.188 This suggests that a reductase with a wide range of 
functions may act on the linear hydrolysis products of enterobactin.  
Remaining unanswered questions in the catecholate siderophore uptake of C. jejuni include 
the study of the CeuBCD complex to establish which siderophore complexes are taken up 
into the cytoplasm, as the fact CeuE binds tightly to iron(III)-bisDHBS and not iron(III)-
enterobactin raises the question as to whether CeuBCD is also optimised for the iron(III)-
bound hydrolysis products as suggested by studies with Cee and the lack of an iron(III)-
enterobactin reductase.159 Direct protein-siderophore binding studies are required in 
conjunction with growth studies to confirm this theory. Additionally, since CfrA is able to 
take up iron(III)-salmochelin S4, and supports growth of the species, it is of interest to study 
the role of this siderophore in C. jejuni, and establish the pathway these siderophores take 
for release of iron(III) into the cytoplasm.182  
Iron Uptake in Vibrio cholerae 
Vibrio cholerae is the Gram-negative pathogen that causes cholera in humans, and is 
estimated to cause at least 120,000 annual deaths worldwide, with the greatest prevalence in 
developing countries in Asia and Africa.189, 190 Infections usually arise from the consumption 
of contaminated water, where the species is often found associated with zooplankton.191 
Once the species has colonised the latter portion of the small intestine,192 the production of 
cholera toxin causes severe diarrhoea, meaning rapid rehydration therapy is required 
alongside antibiotic treatment.190 V. cholerae is able to form biofilms, as well as being able 
to switch to a viable but non-culturable state, enhancing the ability of the species to survive 




Iron regulation has been linked to the virulence of V. cholerae,190-193 and like E. coli and C. 
jejuni, V. cholerae possesses a fur system, with a conserved Fur box sequence that controls 
iron homeostasis, and can acquire iron from a number of sources including haem and a range 
of siderophore complexes.132 V. cholerae has a fur regulated Feo system for the uptake of 
iron(II), comprising the FeoA, FeoB and FeoC transporter proteins.132, 194 Under iron limited 
conditions V. cholerae produces haemolysin to lyse host cells and then uptake haem 
compounds liberated from the cellular matrix.3 The haem uptake system comprises of HutA, 
the outer membrane receptor, HutB the periplasmic binding protein, HutCD, the inner 
membrane ABC transporter, and HutZ, a protein thought to be involved in haem shuttling 
or storage, more recently suggested to be a haem degradation enzyme.132, 195-197  
V. cholerae employs two catecholate siderophores, enterobactin (and enterobactin 
derivatives) and vibriobactin. V. cholerae does not produce enterobactin but can poach 
enterobactin and linear derivatives from the surrounding environment.  
  
Vibriobactin is however synthesised by the species, in a very similar manner to the synthesis 
of enterobactin by E. coli. Once synthesised, vibriobactin is known to be exported from the 
cytoplasm by the fur regulated resistance-nodulation-cell division transporter VexGH, 
however there is currently no known outer membrane exporter for the siderophore.198 
There is crossover between the uptake machinery for iron(III)-vibriobactin and iron(III)-
enterobactin in V. cholerae so the two must be described together. The study of the use of 
iron(III)-enterobactin in V. cholerae has suffered from the lack of consideration of the 
presence of potential hydrolysis products such as trisDHBS, bisDHBS and DHBS. Growth 
studies involving the use of enterobactin or even crude E. coli extracts have often assumed 
that enterobactin was the only siderophore species present without additional 




cyclic trilactone for iron(III) uptake by V. cholerae was suggested in 1984, when growth of 
the species on enterobactin was delayed.202 The most recent studies have considered linear 
enterobactin derivatives, and the possible presence of these derivatives can be used to 
explain previously conflicting results.161 It is likely that enterobactin derivative utilisation is 
important when in aquatic environments where E. coli is abundant, and less so in the host 
intestine as E. coli predominantly resides in the colon.161 Fur regulated systems for the 
uptake of iron(III)-siderophores enterobactin and vibriobactin include VctAPDGC (Vibrio 
catechol transport APDGC) and ViuAPDGC (Vibrio iron uptake APDGC) (Figure 21).200 
  
Figure 21: Known functions of proteins involved in catecholate siderophore synthesis and 
uptake in V. cholerae. 
V. cholerae produces two TonB systems that provide the energy for transport of iron(III)-
siderophore complexes across the outer membrane for the two outer membrane receptors 
VctA and IrgA (iron regulated gene A) for linear enterobactin derivatives,203 and the receptor 
for vibriobactin ViuA.192, 204, 205 It was first thought that VctA and IrgA were receptors for 
iron(III)-enterobactin, but it has since been shown that these receptors are optimised for 




ViuA may also be capable of uptake of iron(III)-trisDHBS. All three receptors can also be 
used in the uptake of iron(III)-fluvibactin, a siderophore similar to vibriobactin that could be 
poached from Vibrio fluvialis.161, 204 It remains unclear whether cyclic enterobactin can be 
used to support growth of V. cholerae at all, but it is now accepted that iron(III)-trisDHBS 
and iron(III)-bisDHBS provide the most efficient iron(III) delivery.161, 202, 206 
Once inside the periplasm, the periplasmic binding proteins and ABC transporters for uptake 
of iron(III)-vibriobactin and linear derivatives of iron(III)-enterobactin into the cytoplasm 
are less specific than outer membrane receptors. Both VctPDGC and ViuPDGC have been 
shown to transport iron(III)-vibriobactin and iron(III)-enterobactin derivatives as well as the 
hexadentate catecholate siderophore mimic MECAM into the cytoplasm (Figure 21).161, 192, 
200, 207 VctPDGC transplanted into E. coli deficient in FepB was said to be able transport 
iron(III)-enterobactin into the cytoplasm, but with the FepC2D2-FepG ABC transporter 
intact, it is difficult to establish whether this was the case, or whether the FepC2D2-FepG 
was simply operating without its periplasmic binding protein.161 As a result, it is unclear 
which enterobactin-derived species are transported by VctPDGC, but it would be logical to 
suggest that VctPDGC may be involved in uptake of iron(III)-trisDHBS and iron(III)-
bisDHBS if these species are more readily transported into the periplasm than iron(III)-
enterobactin.161 Both VctP and ViuP have been crystallised and their structures solved: VctP 





Figure 22: Stereo view of catecholate siderophore periplasmic binding proteins VctP (A) 
(PDB ID: 3TEF) and ViuP bound to iron(III)-vibriobactin (B) (PDB ID:3R5T). Protein 
shown in yellow ribbons with vibriobactin in cylinders coloured by atom type.208, 209 Figure 
produced using CCP4mg. 
ViuB, with homology to the E. coli cytoplasmic reductase YqjH acts as a reductase for iron 
release from vibriobactin in the cytoplasm of V. cholerae. ViuB is needed for iron release 
from vibriobactin but not for enterobactin, enterobactin derivatives or MECAM.192 V. 
cholerae can use MECAM and linear enterobactin derivatives for growth, which suggests 
there is likely to be another uncharacterised reductase present that allows iron release from 
these siderophores and siderophore mimic.161 There is no known cytoplasmic enterobactin 
esterase in V. cholerae that has homology with the cytoplasmic esterase Fes in E. coli.204 
Siderophore-free uptake of iron(III) has been reported for V. cholerae. The studies suggest 
that VctP may be able to bind iron(III) without the presence of a catecholate siderophore. 
However, the specific interaction was not studied directly, but relied on growth studies, so 
it is not clear whether the system was truly siderophore-free, or whether an alternative 
uncharacterised iron-uptake pathway was present.201 Direct iron(III)-binding studies with 
VctP are required to establish whether VctP can indeed bind siderophore-free iron(III). FbpA 
is reported as the periplasmic binding protein for FbpBC, a ferric iron uptake ABC 




aid of siderophores.199-201, 204 In addition, there may be some remaining undiscovered iron 
uptake proteins in  V. cholerae.200 
Areas still to be addressed in the catecholate siderophores use in iron uptake in V. cholerae 
include the examination of the exact role of VctPDGC and ViuPDGC in the uptake of 
enterobactin and linear derivatives. To confirm the action of these systems in greater detail, 
direct protein-siderophore interactions must be studied. A new area of study would involve 
the potential role of salmochelin siderophores in V. cholerae iron uptake. It would be 
interesting to study whether the Vct or Viu systems can use this siderophore class for iron 
uptake and growth. 
1.6 Iron Regulation in the Mammalian Host and Stealth Siderophores 
As bacterial species E. coli, C. jejuni and V. cholerae can colonise the mammalian gut and 
act as pathogens, it is important to understand the iron availability for these bacteria in this 
host environment. Macrophages are vital for systemic and cellular iron homeostasis, and 
limit the iron available to pathogens- known as nutritional immunity.1, 210, 211 E. coli is known 
to produce siderophores in the mammalian gut.32, 212 Iron regulatory proteins (IRP) produced 
by host macrophages are essential for preventing colonisation of the gut with such 
pathogenic species.211 The proteins cause interference with bacterial iron uptake machinery 
including the iron(II) uptake systems, and the siderophore production machinery, as well as 
inducing the production of siderocalins, and limiting the amount of available ferritin: the 
mammalian iron storage protein.211 
Lipophilic siderophores such as enterobactin are sequestered by immunoproteins such as 
serum albumin,154, 213 however a specific binding protein exists to specifically sequester 
bacterial siderophores. Siderocalins, also known as Scn or Lipocalin 2, are host 
immunoproteins that cannot bind free iron(III), but bind iron(III)-bound siderophores, 
limiting the availability for bacterial iron uptake (Figure 23). 214-218 The structures of 
siderocalins are thought to be optimised for binding the siderophores of bacterial species of 
particular pathogenic threat.37, 218 The human siderocalin protein is a β-barrel with a 
positively charged binding pocket that promotes the binding of negatively charged iron(III)-
siderophore complexes, and a tyrosine that provides direct coordination to the iron(III) 
centre.219-221 Siderocalin can bind a number of iron(III)-bound siderophores including 
enterobactin, bacillibactin, vibriobactin, fluvibactin, carboxymycobactins and pyochelin, as 
well as a number of siderophore mimic complexes, bidentate catechols, and actinide 
complexes.219-224 Enterobactin binding is predominantly electrostatic, (Figure 23), and has a 




to the specificity of the siderocalin binding pocket, some functionalised enterobactin 
derivatives, and siderophores with vast structural differences cannot be captured by 
siderocalin.215, 218, 219 
 
Figure 23: Stereo view of crystal structure of human siderocalin in complex with iron(III)-
enterobactin (cylinders coloured by atom type) (PDB ID: 3CMP) Siderocalin is shown in 
surface view, with blue representing positively charged regions, red representing negatively 
charged regions and white representing neutral or hydrophobic regions.219, 220 Figure 
produced using CCP4mg. 
Bacteria that employ a range of structurally diverse siderophores can survive over a wide pH 
range, and adapt to a range of environments. For example, while the majority of E. coli 
strains produce enterobactin, as described in section 1.5, the additional production of 
aerobactin, yersiniabactin and salmochelins is more prevalent in pathogenic strains.138, 155 
Stealth siderophores are so-called because they are able to evade immunoproteins such as 
siderocalin.215, 218 214, 225 These siderophores are thought to be used by bacteria to more 
effectively acquire iron from their mammalian host. 
Aerobactin (Figure 15) does not to bind to siderocalin due to lack of aromatic groups capable 
of cation-π interactions, causing structural incompatibility of the siderophore with the 
siderocalin binding cleft. Yersiniabactin (Figure 15) also possesses structural 
incompatibilities comprising one aromatic ring and three thiazolidine rings so is not bound 
by siderocalin.226-228 Although these siderophores bind iron(III) less effectively than 
enterobactin, their production provides a selective advantage for survival of E. coli under 




Petrobactin is a mixed-type stealth siderophore with two catecholate groups, and one α-
hydroxycarboxylate, produced by Bacillus anthracis. 215, 218, 230 The siderophore evades 
siderocalin by the use of 3,4-catecholates that are sterically incompatible with the siderocalin 
binding cleft, rather than the 2,3-arrangement that is present in enterobactin and 
bacillibactin.230, 231 
 
Salmochelin siderophores are C5-glucosylated analogues of enterobactin and the 
enterobactin hydrolysis products produced under neutral to alkaline conditions by 
pathogenic strains of E. coli (Figure 15).138, 157, 232, 233 They incorporate the enterobactin 
backbone with extremely high iron(III) affinity, but have increased hydrophilicity when 
compared to enterobactin, and the appended glucose moieties confer steric bulk.154, 234 These 
two properties allow the siderophores to avoid sequestration by immunoproteins.235, 236 In 
addition, salmochelin siderophores were proven to be more effective at iron(III) acquisition 
in the presence of lipids, when compared to enterobactin, due to the decreased membrane 
partition coefficient of the hydrophilic siderophore.234 
Salmochelins are derivatised into a number of microcins.73 Siderophore-microcins are short 
peptides (5-10 kDa) linked to siderophores via the C-terminus, used by bacteria to target and 
kill iron-starved competitors - commonly by forming cytoplasmic membrane pores.237-240 
Microcin immunity proteins are expressed in conjunction with microcins to protect the 
exporter species from its own microcin. For example, microcins secreted under iron limited 
conditions by E. coli are effective against Salmonella typhimurium.238 MccE492 is a 
microcin produced in Klebsiella pneumoniae known to be linked to the linear trimer 
salmochelin MGE.73, 241 This microcin targets E. coli via the FepA, Fiu, and Cir outer-
membrane receptors.237, 239, 242-244 Microcins not only evade the host immunoproteins as 
stealth siderophores, but have a Trojan-horse type antimicrobial effect on competitors to 





In addition, natural inhibitors for siderophore production are known as a tool for a bacterial 
species to limit the iron(III)-uptake of neighbouring species. Baulamycin A is produced by 
Streptomyces tempisquensis to block siderophore synthesis in Staphylococcus aureus and 
Bacillus anthracis.246 This strategy is particularly effective when siderophore piracy 
between species is low. 
1.7 Siderophore Mimics 
Natural siderophores often require complex syntheses, due to their structures containing 
specific stereochemistries. In addition, they often contain hydrolytically labile linker 
regions, that are required in biological iron-uptake for hydrolysis of the siderophore for 
iron(III) release.76, 247 This instability can cause challenges for in vitro studies, so producing 
a similar but more stable mimic compound allows for more versatile investigations than may 
be possible with the natural moiety. In addition, mimic designs can be simplified, allowing 
individual siderophore features to be investigated. Many mimics have been well studied and 
their iron(III)-binding properties investigated, but they are also useful for study of biological 
function, or for development of novel applications.2,108 To investigate how siderophores have 
such high affinity and specificity for iron(III), denticity and conformational rigidity have 
been explored with the use of mimics. Computational modelling tools have been employed 
to establish how siderophore structure influences iron(III)-binding affinity.63 
MECAM (Figure 24) is a well-established mimic for enterobactin, and is a triscatecholate 
with an aromatic backbone that confers rigidity and structural stability over a wide pH 
range.248, 249 Although MECAM binds iron(III) with lower affinity than enterobactin,  




salicylate binding mode in enterobactin.29, 68, 248, 250 Sulfonation of MECAM in the C5 
position increased the aqueous solubility and resistance to oxidation. In addition, C5-
trisulfonated-MECAM (MECAMS) had a slightly higher pFe(III) than MECAM (Table 
2).248 Functionalisation of the MECAM backbone with methyl and ethyl groups proved that 
backbone rigidity is important for ligand pre-organisation, and enhances iron(III) binding 
(Table 2).251 3,3,4-CYCAM (Figure 24) was a poorer iron(III) chelating ligand than 
MECAM due to the conformational demands of the flexible ring backbone, that does not 
have the hydrogen bonding capacity of the triserine backbone in enterobactin.2, 249, 252 
TRENCAM (Figure 24) has also been used extensively as an enterobactin mimic. The 
tertiary amine backbone provides a more flexible structure that results in a lower pFe(III) 
(Table 2).253 Alongside a bidentate 2,3-dihydroxyterephthalamide siderophore mimic (S)-
(PhMe)2TAM (Figure 24),
254 studies proved the importance of the amide nitrogen, and 
resulting hydrogen bonding, for the stability of enterobactin, and helped to confirm the Δ-
configured preference of the iron(III)-enterobactin complex.16, 65 Capping the triscatecholate 
siderophore to create a macrobicyclic structure was explored as a strategy to impart further 
rigidity on the iron(III) coordination sphere, with the aim to increase the iron(III) binding 
affinity and kinetic stability by pre-organisation of the ligand. Several analogues, including 
bicapped TRENCAM (Figure 24) were synthesised, for which a pFe(III) of 30.7 was 
achieved.253 The iron binding affinity did not exceed that of enterobactin, likely due to the 
fact that the rigid structure imparted trigonal prismatic coordination geometry around the 
iron(III) centre. Trigonal prismatic geometry is usually of higher energy, and therefore 
disfavoured when compared to octahedral geometry due to ligand repulsion. The large 
pFe(III) was therefore more likely due to the ease of deprotonation of the catechol units of 
this ligand rather than from the benefits of a preorganised structure.253, 255 Such bicapped 
structures have been shown to be tuneable for selective encapsulation of different transition 
metals, by variation of the linker length resulting in different sized cavities.255 The 
importance of backbone pre-organisation for high affinity iron binding was demonstrated by 
the design and synthesis of a biscatecholate-hydroxamate siderophore mimic, with a flexible 
lysine-glutamic acid backbone (H6L) (Figure 24). This mimic had a low pFe(III) of 18.3, 
which did not significantly improve with change in pH, this pFe(III) was even lower than 
linear trishydroxamate ferrioxamine B (Table 2).256 Interestingly, a mimic with higher 
iron(III) affinity than enterobactin at neutral pH has never been achieved, however at low 
pH, the mimic hopobactin (Figure 24), with three 3-hydroxy-1-methyl-2(1H)-pyridinonate 
iron-binding units, has been shown to have a higher pFe(III). This is because iron(III)-




type binding mode as is the case for enterobactin.257 The use of carbohydrates in siderophore 
mimic backbones increase the hydrophilicity of iron(III) complexes.111, 258, 259 
Table 2: pFe(III) values for a selection of siderophore mimics. 
























Growth studies showed that several catecholate siderophore mimics could support growth 
of E. coli under iron-limited conditions. MECAM and TRICAM (Figure 25) were shown to 
support growth, but their sulfonated derivatives MECAMS and TRICAMS (Figure 25) could 
not. Interestingly, the linear sulfonated triscatecholate, 3,4-LICAMS supported growth. This 
gave an insight into the specificity of the iron(III)-siderophore uptake machinery in E. coli.165 
Mimics of ferrichrome have proven useful in the study of hydrogen bonding in iron(III) 
chelation, and the specificity of hydroxamate outer membrane receptors.263 Enterobactin 
receptor recognition of the E. coli outer-receptor FepA was probed using siderophore mimics 
bound to rhodium(III). These kinetically inert complexes allowed the isolation of the 
individual properties of key functional units of enterobactin, the iron-binding unit, the amide 
linkage and the triserine backbone. It was successfully shown that the iron-binding catechol 
unit and carbonyl were essential for receptor recognition, but the compounds could still be 
taken up if there was variation at the amide nitrogen and backbone.264 These studies of the 
properties of triscatecholate siderophores have since be used to inspire high affinity benzene-
o-dithiolato donor ligands for titanium(IV) and molybdenum(IV) complexes.265 
 
Figure 25: Tetradentate and bidentate catecholate siderophore mimics.94, 266, 267 
As well as hexadentate siderophore mimics, catecholate siderophore mimics have been 
synthesised to mimic tetradentate siderophores such as bisDHBS and azotochelin. n-LICAM 
and n-LICAMS mimics include an aliphatic backbone linking two catecholamide units, and 
are more hydrolytically stable than the ester-based backbone of bisDHBS.266 L3 (Figure 25) 
is a more rigid mimic, with a xylene spacer. L3 and 5-LICAM were synthesised to probe the 
molybdenum binding ability of tetradentate siderophores.94, 268 2-,4- and 6-LICAMS were 
synthesised for applications in actinide sequestration.266 In addition, simple bidentate 




267 The highest affinity of which is TAMmeg (Figure 25), and when prepared in a 3:1 iron 
complexes has a pFe(III) of 24.7.267 
1.8 Applications of Siderophores 
Iron Chelation Therapy 
Patients that are diagnosed with blood disorders such as sickle cell anaemia and thalassemia 
commonly require multiple blood transfusions. As iron excretion mechanisms are limited 
within the body, iron overload is a common side effect.267 Excess iron is toxic to mammalian 
cells, causing problems for the heart, liver and endocrine system, as well as promoting 
unwanted bacterial infections.269, 270 Siderophores and siderophore mimic compounds are 
therefore in clinical use to enable the excretion of excess iron.256, 271 The first approved 
medical iron chelator was ferrioxamine B, which had to be administered via subcutaneous 
infusion. More recently, the orally active chelator deferasirox (Figure 26) has become a 
preferred choice, due to higher patient compliance.256, 272 Iron overload is still a high cause 
of death in transfusion-dependent patients, with over 70% of deaths in thalassemia patients 
due to heart problems, so further work is required to improve the properties of medical 
iron(III) chelators.269, 270, 273, 274 Enterobactin analogues 3,4-LICAMS (Figure 26) and 
MECAM (Figure 24) have been explored for their ability to remove iron(III) from 
transferrin. MECAM was shown to outperform enterobactin over a 30 minutes period and 
3,4-LICAMS outperforms ferrioxamine B (Figure 26) at high ligand: transferrin ratios.275 It 
was suggested that enterobactin forms complexes that are too kinetically labile for this 
application, and thermodynamics as well as kinetics must be considered for design of an 
efficient therapeutic agent.275 With this in mind, the 2,3-hydroxypyridinone unit, found not 
to suffer from the proton competition that is characteristic of catechol ligands, may have the 
necessary thermodynamic stability for design of new therapeutic iron chelators.267 
More recently, orally administered iron chelating polymers with a hexadentate 3-
hydroxypyridin-4-one based structure have been developed, that tackle iron overload by 
reducing dietary iron uptake.276, 277 Such polymers have the advantage that the chelating 
agents are not absorbed through the intestine, so carry fewer side effects, and do not promote 
undesirable bacterial infections.278 Chelation therapy using siderophore mimics can also be 




cleared from mammalian kidneys by tetradentate catecholate 5-LICAMS (Figure 25) and 5-
LIO(Me-3,2-HOPO) (Figure 26).279-282 
 
Figure 26: Siderophore mimics involved in iron(III)-chelation therapy.279-283 
Bacterial Detection and Molecular Imaging 
Incorporation of radioisotopes into siderophore complexes has potential application in 
positron emission tomography imaging, and as imaging agents with more broad 
functions.284-286 Initial studies have involved the use of gallium-68 and zirconium-89 
complexes of ferrioxamine B and E (Figure 9).284 In addition, attachment of a fluorescent 
moiety to a siderophore can be useful in applications of tracking iron(III), siderophore 
uptake, or identification of particular bacterial species.239, 287, 288 This could prove useful for 
better diagnosis and more selective treatment of bacterial infections, resulting in more rapid 
patient recovery.285 Fluorescent analogues of ferrichrome (Figure 3) were successfully 
tracked in uptake studies of  Pseudomonas species, and fluorescent catecholate derivatives 
have been used to track and image P. aeruginosa infection in mice.289, 290 
Antibiotics by Iron Starvation 
It has been shown that high affinity iron chelators that are not recognised by bacterial outer 




proven using 3-hydroxypyridin-4-ones based siderophore mimics for disruption of 
staphyloferrin-driven iron(III)-uptake in methicillin resistant Staphylococcus aureus. As 
these systems can be incorporated into polymers, the most promising applications are in 
external wound infections.277, 291 
Trojan Horse Antibiotics 
A strategy in the development of novel antibiotics is to exploit the absolute requirement for 
iron of bacteria. By attaching antibiotics to siderophores, the approach relies on the bacterial 
outer-membrane receptors recognising the iron(III)-loaded siderophore component when 
under iron-limiting conditions, and importing the whole conjugate into the cell, where the 
antibiotic can then exert its toxic effects.292 This antibiotic smuggling method may be useful 
in combating problems of antimicrobial resistance that arises from adaptations in membrane 
permeability, and drug efflux.293 Sideromycins are natural antimicrobial conjugated 
siderophores that inspire this application.246, 293 
The focus of this work has involved the incorporation of β-lactam or fluoroquinolone 
antibiotics onto a siderophore scaffold (Figure 27).294-298 Studies have often suffered from 
reduced activity of the antimicrobial due to the attachment of the siderophore component, 
and further efforts are required to produce an optimised conjugate.299, 300 Progress into 
increasing potency has been made where the linker region is bio-labile, and the antibiotic 
can be released from the conjugate.294, 301 In addition, hydrophilic salmochelin siderophores 
that have a reduced mammalian host immune response have been incorporated, for enhanced 





Figure 27: Examples of siderophore-antibiotic Trojan horse conjugates.296, 301 
For antibiotics that are active on Gram-positive but not Gram-negative bacteria, the Trojan 
horse strategy may improve access of current antibiotics into a wider range of bacterial 
species. For example, oxazolidinones were proven to be much more potent in Pseudomonas 
aeruginosa when conjugated to a catecholate siderophore mimic.302 Complexation of a DNA 
intercalator with an iron(III)-hydroxamate siderophore mimic enhanced selectivity of the 
drug towards bacterial cells over mammalian cells.303 The Trojan horse strategy is of 
particular interest for the development of antifungal treatments which commonly encounter 
selectivity issues due to the fact that mammalian and fungal cells are both eukaryotic. 
Targeting siderophore uptake machinery which is not present in mammalian cells may 
enable the reduction of adverse side effects of antifungal drugs.286 
1.9 Project History 
As described in section 1.5, CeuE is a periplasmic lipoprotein involved in catecholate 






The first crystal structure of CeuE was obtained from a co-crystal with iron(III)-MECAM.187 
The crystal contained 2:2:2 dimeric complexes, with two MECAM ligands bridging between 
two CeuE binding clefts, with two iron(III) centres, shared by both MECAM ligands (PDB 
ID: 2CHU) (Figure 28).187 This was a surprising ligand arrangement, as it is much more 
common for similar periplasmic binding proteins to adopt 1:1:1 complexes when bound to 
iron(III)-siderophore complexes. Known 1:1:1 complexes include FhuD from V. cholerae 
bound to desferrioxamine B (PDB ID: 5GGX), FepB from  E. coli bound to iron(III)-
enterobactin (PDB ID: 3TLK), FeuA from B. subtilis bound to iron(III)-enterobactin (PDB 
ID: 2XUZ) and even the iron(III)-MECAM complex of FeuA from B. subtilis (PDB ID: 
2XV1).122, 146, 304, 305 It was reasoned that the formation of the unusual dimeric complex of 
[CeuE-iron(III)-MECAM]2
 was favourable due to the stabilisation provided by hydrophobic 
interactions of the mesitylene backbones. 
 
Figure 28: A: Crystal structure of CeuE-iron(III)-MECAM in the 2:2:2 dimer (PDB ID: 
2CHU).187 CeuE is shown in sea green ribbons, and iron(III)-MECAM in ball and stick 
coloured by atom type. B: Stereo view of the 2:2 Fe:  MECAM arrangement across two 




for the maximum likelihood map was contoured at the 2 level. Figure produced using 
CCP4mg. 
The complex was arranged in the Λ-configuration in both binding pockets, and this 
configuration was also present in CeuE-iron(III)-MECAM complexes in solution, as 
confirmed by circular dichroism.11, 13, 187 It was not established whether the 2:2:2 dimer was 
present in solution phase or indeed in a biologically relevant environment. The CeuE 
concentration in the periplasm, of somewhere between 0.1 and 1 mM, is a lot lower than in 
crystal screening and so it is possible that the 2:2:2 dimer is favourable at high concentrations 
but not at lower biological concentrations.306 It may be that favourable hydrophobic 
interactions between MECAM backbones causes protein dimerisation at biologically-
relevant concentration, rendering the binding clefts inaccessible for interaction with the 
necessary inner membrane transporter CeuBCD.115, 172, 187 Although these findings may 
render MECAM a poor enterobactin mimic for the CeuE system, it has been postulated that 
these properties may prove advantageous for future applications such as in the development 
of antimicrobials.20 
CeuE-iron(III)-4-LICAM 
CeuE binds the tetradentate siderophore mimic iron(III)-4-LICAM in a 1:1:1 binding ratio 
and this ligand served as a mimic of the enterobactin hydrolysis product bisDHBS.86, 95, 186 
 
This was the first reported crystal structure for a periplasmic binding protein crystallised 
with an iron(III)-bound tetradentate ligand (PDB 1D: 5A1J) (Figure 29).186 Studies with 
bidentate and tetradentate siderophores previously showed that lower denticity siderophores 
are able to support growth of a number of bacterial species.307, 308 There are however few 
protein crystal structures of bacterial uptake machinery in complex with low denticity 
siderophores.309 This study established the importance of the investigation of tetradentate 
siderophores, and their direct role in iron(III) uptake via interaction with ferric siderophore 






Figure 29: Crystal structure of CeuE-iron(III)-4-LICAM.186 A: CeuE depicted in lawn green 
ribbons, iron(III)-4-LICAM shown as ball and stick coloured by atom type with coordinating 
His 227 and Tyr 288 shown as cylinders coloured by atom type. B: Stereo view of iron(III)-
4-LICAM shown as ball and stick coloured by atom type with coordinating His 227 and Tyr 
288 shown as cylinders coloured by atom type. iron(III) bond distances are labelled in Å. 
The electron density for the maximum likelihood map was contoured at the 2 level. Figure 
produced using CCP4mg. 
A key finding was the discovery of His 227 and Tyr 288 residues from CeuE that donated N 
and O chelating atoms respectively to directly coordinate the iron(III) centre, completing the 
hexadentate octahedral coordination (Figure 29). The resulting complex retained Λ-
configuration, as seen for [CeuE-iron(III)-MECAM]2 and circular dichroism was employed 
to prove the Λ-configuration was also dominant in solution phase.186, 187 Fluorescence 
quenching titration studies proved that iron(III)-4-LICAM bound tightly to CeuE, with a 
dissociation constant of 21 ± 6 nM.186 It was suggested that CeuE is somewhat promiscuous, 




siderophores, the protein could employ His 227 and Tyr 288 to aid full iron(III) coordination 
for lower denticity siderophores.186 
A Linker Length of Five Atoms 
A natural tetradentate siderophore, bisDHBS, was synthesised and studied with CeuE.90 This 
study was fundamental for proving the biological relevance of tetradentate siderophores in 
C. jejuni, and for testing the hypothesis that n-LICAM compounds make good mimics for 
tetradentate catecholate siderophores. Interestingly, iron(III)-bisDHBS bound tightly to 
CeuE with a low dissociation constant of 10 ± 4 nM. Circular dichroism proved that the Λ-
configuration was adopted upon introduction of CeuE to iron(III)-bisDHBS in solution.90 
 
Crystal structure solutions showed that the CeuE-iron(III)-bisDHBS complex (PDB ID: 
5ADW) does indeed adopt a similar ligand binding arrangement to that of CeuE-iron(III)-4-
LICAM, with His 227 and Tyr 288 completing the octahedral iron(III) coordination. 
Interestingly, CeuE exhibits high enantioselectivity, with the asymmetric chiral serine-
derived linker between the catecholate binding units always incorporated into the binding 
pocket in the same orientation. This is demonstrated by the good electron density observed 
for the free alcohol and acid in fixed orientation in the crystal structure (Figure 30).90 Next, 
CeuE was studied with iron(III)-5-LICAM, a siderophore mimic of iron(III)-bisDHBS with 
the same number of atoms in the linker region between the two catecholate iron(III) binding 
units. Iron(III)-5-LICAM binds to CeuE in a very similar manner to that of iron(III)-
bisDHBS with r.m.s.d of 0.63 over 286 Cα positions upon superposition of the structures 
with the SSM algorithm (Figure 31).310 Iron(III)-5-LICAM binds to CeuE with a very high 
affinity, <10 nM via fluorescence quenching titration.310 As such, n-LICAM compounds 
were chosen as good mimics for tetradentate siderophores such as bisDHBS, and these 
studies provided a good foundation for further investigation of the CeuE binding pocket via 





Figure 30: Top: CeuE depicted in gold green ribbons, iron(III)-bisDHBS shown as ball and 
stick coloured by atom type with coordinating His 227 and Tyr 288 shown as cylinders 
coloured by atom type. Bottom: Stereo view of iron(III)-bisDHBS shown as ball and stick. 
The electron density for the maximum likelihood map contoured at the 1.5 level.90 Figure 
produced using CCP4mg. 
 
Figure 31: Stereo view of the crystal structure overlay of CeuE-iron(III)-5-LICAM 
(cylinders coloured by atom type with carbon in light crimson) with CeuE-iron(III)-
bisDHBS (cylinders coloured by atom type with carbon in light gold) superimposed by SSM 
algorithm based on Cα positions. The iron(III)-binding ligands display a very similar binding 




1.10 Project Aims 
The overall aim was to investigate the interactions between selected bacterial periplasmic 
binding proteins and iron(III)-siderophore and siderophore mimic complexes. The project 
was designed to increase knowledge of bacterial iron uptake strategies, which could itself 
inform the development of novel antimicrobials or artificial metalloenzymes. The 
investigations are divided into four key areas of study. The first covers how siderophore 
linker length affects binding of tetradentate siderophores to CeuE. Linker lengths of six and 
eight atoms were employed in iron(III)-n-LICAM siderophore mimics and studied via 
fluorescence quenching titration, circular dichroism and protein crystallography to probe the 
protein-ligand interactions and binding affinities (Chapter 2). The second area of study uses 
CeuE variant proteins to investigate key residues His 227 and Tyr 288, and their importance 
in iron(III)-siderophore binding via the same above techniques (Chapter 3). The third area 
covers the design and synthesis and iron(III)-binding of tetradentate salmochelin siderophore 
mimics and their interaction with CeuE (Chapter 4). The fourth area of study aims to tie all 
three previous areas together, with comparison of three periplasmic binding proteins CeuE, 
FepB and VctP, and investigation of their binding preferences for hexadentate or tetradentate 
iron(III)-siderophore complexes, with additional insight into whether these proteins may 




2 Investigation of the Binding of Tetradentate Siderophore 
Mimics to CeuE 
2.1 Introduction 
CeuE, the periplasmic catecholate-siderophore binding protein from C. jejuni, described in 
detail in Chapter 1, has been reported to bind the tetradentate siderophore, iron(III)-bis(2,3-
dihydroxybenzoyl-L-Ser: a hydrolysis product of enterobactin, and the tetradentate 
siderophore mimics iron(III)-4-LICAM and iron(III)-5-LICAM with high affinity.90, 186, 311 
It is known that C. jejuni does not produce its own siderophores, but is able to scavenge 
iron(III)-bound siderophores, produced by other microorganisms, from its environment.115, 
131, 168, 172, 175, 312  It is therefore of interest to investigate whether C. jejuni would be able to 
scavenge tetradentate siderophores of different linker lengths if they were present in the 
environment, and potentially utilise them via the CeuE transport system to uptake iron(III).95, 
172 Tetradentate siderophores of interest include serratiochelin and the amonabactins, with 
extended linker lengths, produced by the enteric pathogens Serratia marcescens and 









The aim of the present work is to explore a family of iron(III)-siderophore mimic complexes 
that can be bound in the CeuE binding cleft, and to establish the binding modes and binding 
affinities. To further knowledge of the tolerance of CeuE to a range of tetradentate 
siderophores, siderophore mimics with longer linker lengths were investigated, using n-
LICAM siderophore mimics where n = 6 and n = 8 (Figure 32).94 n-LICAM n = 6, 8 ligands 
were synthesised and provided by Anne K. Duhme-Klair. Such mimics, are useful tools, 
since the natural siderophores are often unstable in aqueous media or are very challenging 
to synthesise in large enough quantities.77, 253, 256, 315, 316 Mimics are generally simplified in 
their chemical structures when compared to natural siderophores, allowing for 
uncomplicated model studies of natural systems. 
 
Figure 32: n-LICAM siderophore mimic compounds with extended linker lengths from 4 to 
8 carbon atoms. 
Protein crystallography was employed to determine the structure of siderophore mimic 
complexes, while fluorescence quenching titrations were used to quantify binding affinities, 
and circular dichroism to probe binding arrangement in solution. All three techniques were 
used to assess trends in binding affinity across a range of linker lengths, and to establish the 





Wild-type CeuE was expressed from an overexpression system in BL21 E. coli and purified, 
and characterised in several batches by Daniel J. Raines, Adam Hughes and Elena Blagova 
via the standard purification procedure detailed for FepB in Chapter 6. The correct construct, 
containing a C3 cleavable N-terminal hexahistidine tag, was confirmed by DNA sequencing.  
Purification involved nickel column chromatography, followed by cleavage of the 
hexahistidine tag, further nickel column chromatography and gel filtration chromatography, 
with validation via SDS PAGE. The pure protein was characterised with electrospray 
ionisation mass spectrometry. Circular dichroism spectroscopy was used to confirm that all 
proteins were folded correctly.90, 186, 310 
2.3 Crystal Structure of CeuE-iron(III)-6-LICAM 
Protein crystallography revealed how CeuE binds to iron(III)-6-LICAM. This work was 
analogous to previous co-crystallisation studies carried out for CeuE-iron(III)-4-LICAM.186 
Crystals were obtained via co-crystallisation of iron(III)-6-LICAM with CeuE, the 
procedure for which is detailed in Chapter 6. The crystal was in space group P212121, 
containing a single protein monomer in the asymmetric unit. The electron density was well 
defined for the full CeuE protein backbone, and the overall fold was very similar to 
previously reported structures.90, 186 CeuE adopts a bilobate structure, with the iron(III)-
ligand binding cleft situated between two protein domains. 
 
Figure 33: Crystal structure of CeuE-iron(III)-6-LICAM (PDB ID: 5A5V). CeuE is depicted 




type. Iron(III)-coordinating His 227 and Tyr 288 are depicted as cylinders coloured by atom 
type. Figure produced using CCP4mg. 
The CeuE-iron(III)-6-LICAM (PDB ID: 5A5V) structure has a root mean square deviation 
(r.m.s.d.) of 0.48 Å (287 C positions) from that of CeuE-iron(III)-4-LICAM (PDB ID: 
5A1J) upon superposition of the structures calculated using the SSM (secondary structure 
matching) algorithm,317 indicating a very high similarity of the protein fold. There is also a 
close similarity to the apo-CeuE structure (PDB ID: 3ZKW) with r.m.s.d of 0.94 Å (283 C 
positions), indicating that the protein does not significantly rearrange upon ligand binding. 
This is a common feature of type III periplasmic binding proteins. Bilobate periplasmic 
binding proteins are known to have a hinge region between the two domains. Type III 
periplasmic binding proteins have the longest α-helical hinge region, which imparts 
structural rigidity.184, 185 
The positioning of the iron(III)-6-LICAM ligand in the CeuE binding pocket is very similar 
to that of CeuE-iron(III)-4-LICAM and CeuE-iron(III)-5-LICAM (PDB ID: 5A5D), and 
there is good electron density for all ligand atoms, with B-values close to the average for the 
whole structure. This indicates that the ligand had a fixed orientation in the crystal. The 
iron(III)-centre is coordinated in an octahedral arrangement. The 6-LICAM ligand provides 
four oxygen donor atoms from the deprotonated catecholate groups. To complete the 
hexadentate iron(III) coordination, CeuE provides two donor atoms, an oxygen donor from 
a deprotonated tyrosine residue, Tyr 288, and a nitrogen donor atom from a histidine, His 
227 (Figure 34). These are the same donor atoms observed in the CeuE-iron(III)-n-LICAM 
(n =4, 5) and CeuE-iron(III)-bisDHBS structures. The complex is further stabilised by three 
arginine residues, Arg 118, Arg 205 and Arg 249, that form hydrogen bonds with the 
catechol oxygen atoms, and a lysine residue Lys 121 that forms a hydrogen bond with a 
catecholamide carbonyl oxygen atom (Figure 34). The only other direct hydrogen bonds to 
the linker region are with water molecules. This suggests that there are few unfavourable 
interactions between CeuE and the linker region of 6-LICAM, which should allow the 
protein to accommodate linkers of longer length than the natural linker of five atoms: 






Figure 34: Crystal structure of CeuE-iron(III)-6-LICAM in stereo view. A: iron(III)-6-
LICAM as ball and stick. The electron density for the maximum likelihood difference map 
was calculated before introduction of the iron(III)-ligand into the model to avoid phase bias 
and contoured at the 2 level (green chicken wire). B: iron(III)-6-LICAM ball and stick, 
coordinating His 227 and Tyr 288 in cylinders. Iron(III) bond distances are labelled in Å. 
The electron-density for the maximum likelihood map was contoured at the 2 level in blue 
chicken wire. C: iron(III)-6-LICAM in the CeuE binding pocket, with all significant contacts 




2.4 Crystal Structure of CeuE-iron(III)-8-LICAM 
Crystals of CeuE-iron(III)-8-LICAM were grown by co-crystallisation methods, for which 
the procedure is detailed in Chapter 6. The high resolution for the structure of 1.32Å allowed 
for anisotropic refinement of the model (Figure 36). CeuE bound iron(III)-8-LICAM in a 
similar manner to iron(III)-6-LICAM. As there are few protein contacts with the n-LICAM 
backbone, it appears that the longer backbone in 8-LICAM does not cause any unfavourable 
clashes, but is able to point away from the protein out of the binding cleft into a more solvent 
exposed region (Figure 35). Interestingly, the iron(III)-8-LICAM ligand is well ordered in 
the CeuE binding cleft, with clear electron density for fixed atom positions along the whole 
backbone (Figure 36).  
Although all CeuE-iron(III)-n-LICAM (n= 4, 5, 6, 8) crystal structures are in the same space 
group of P212121, the unit cell for CeuE-iron(III)-8-LICAM has a quite different packing 
arrangement. CeuE-iron(III)-8-LICAM has unit cell parameters of a= 42.98 Å, b= 55.98 Å 
c= 140.08Å, while for iron(III)-6-LICAM, the cell parameters are a= 61.37 Å, b= 66.08 Å 
c= 68.96 Å- close to those of iron(III)-n-LICAM (n= 4, 5).186 This suggests that the solvent 
exposed longer backbone of iron(III)-8-LICAM results in different crystal contacts. This 
change in packing arrangement is likely to be the reason for the higher resolution achieved 
for this structure. 
 
Figure 35: Crystal structure of CeuE-iron(III)-8-LICAM (PDB ID: 5AD1). CeuE is depicted 
as orange ribbons. Iron(III)-6-LICAM is depicted as ball and stick coloured by atom type. 
Iron(III)-coordinating His 227 and Tyr 288 are depicted as cylinders coloured by atom type. 




His 227 and Tyr 288 act to complete the hexadentate octahedral coordination of the iron(III) 
centre as seen for previous structures.90, 186 As for the CeuE-iron(III)-6-LICAM structure, 
the longest iron(III) bond is 2.3 Å, for that of the iron(III)-nitrogen from His 227. This is 
likely due to the iron(III) being a small, highly-charged cation, with hard Lewis acidity.318 
The negatively charged oxygen atoms from the 8-LICAM ligand and the deprotonated Tyr 
288 have hard Lewis base character and make a good match, forming strong  iron(III)-O 
bonds of between 2.0 and 2.2 Å. As the histidine nitrogen is a weaker Lewis base than the 
donor oxygens, it is a weaker electron donor, and forms a longer bond to the iron(III) of 2.3 
Å (Figure 36). In addition to the iron(III) binding residues, Arg 118, Lys 121, Arg 205 and 





Figure 36: Crystal structure of CeuE-iron(III)-8-LICAM in stereo view. A: Iron(III)-8-
LICAM shown as ball and stick. The electron density for the maximum likelihood difference 
map was calculated before introduction of the iron(III)-ligand into the model to avoid phase 
bias and contoured at the 2 level in green chicken wire. B: Iron(III)-8-LICAM as ball and 
stick, with coordinating His 227 and Tyr 288 as cylinders. Bond distances are labelled in Å. 




iron(III)-8-LICAM in the CeuE binding pocket, with all significant contacts labelled. Figure 




2.5 Determination of Dissociation Constants 
Dissociation constants were determined for CeuE with iron(III)-6-LICAM and iron(III)-8-
LICAM via fluorescence quenching titration. This was possible due to the close-proximity 
of the only tryptophan residue (Trp 287) to the iron(III)-siderophore binding pocket (Figure 
37). When excited at 280 nm, a broad emission peak is observed between around 310 nm 
and 410 nm.319 
 
Figure 37: Crystal structure of CeuE-iron(III)-6-LICAM showing that the only tryptophan 
residue, Trp 287 (circled in orange), is located adjacent to the iron(III)-siderophore binding 
pocket in CeuE. Figure produced using CCP4mg. 
Addition of iron(III)-bound ligands into the CeuE binding pocket causes quenching of 
tryptophan fluorescence. Subsequently, when CeuE is saturated with iron(III)-bound ligand, 
the addition of further iron(III)-bound ligand does not cause any further fluorescence 
quenching. The fluorescence emission observed was therefore recorded over a series of 
additions of ligand, and the area of the emission band for each ligand concentration 
calculated and plotted against concentration to obtain a binding curve. This is a commonly 
used technique for determination of protein-ligand binding affinities,219, 223, 231, 320, 321 and 
was previously used for the determination of dissociation constants of CeuE with iron(III)-
4-LICAM and iron(III)-5-LICAM.186, 310, 322 It was important to establish that the observed 
fluorescence quenching was indeed from the binding of the iron(III)-complex to CeuE. 
Control experiments were recorded and are described in detail in Chapter 6.  
It was proven that CeuE was adequately stable, with negligible change in intrinsic 




excitation wavelength of 280 nm. Upon dilution of CeuE by 10%, and application of a linear 
dilution correction, decrease in fluorescence was observed to be within an acceptable range. 
This ensured that any fluorescence quenching observed was a direct consequence of the 
addition of iron(III)-n-LICAM (n= 6, 8) and not due to dilution or oxygen exposure during 
mixing. It was decided that for a calculated dissociation constant to be significant, the final 
normalised emission must be below 0.4 to ensure that protein fluorescence was adequately 
quenched. Ligand absorbance limits were set to ensure no significant contributions from 
primary inner filter effects.323-325 The upper permissible concentrations for iron(III)-6-
LICAM and iron(III)-8-LICAM were 37.3 µM and 41.1 µM, respectively.  
Fluorescence quenching titrations for CeuE with iron(III)-6-LICAM and iron(III)-8-LICAM 
were performed according to a published method and so could be directly compared to those 
already published for iron(III)-4-LICAM and iron(III)-5-LICAM.90, 310 The titrations were 
recorded in triplicate, then the fluorescence signal observed was buffer subtracted and the 
area of each peak was calculated between 310 and 410 nm. The data were normalised and 
Kd values and associated error calculated using non-linear regression analysis with Dynafit 
fitting software for a 1:1 binding model.326 A weighted average and uncertainty in average 
calculation were used to calculate the final Kd and error from the three independent titrations. 
The curves for each titration of CeuE with iron(III)-6-LICAM are displayed in Figure 38 
and the Kd values calculated from each curve recorded in Table 3. The curves for each 
titration of CeuE with iron(III)-8-LICAM are displayed in Figure 39 and the Kd values 





Figure 38: Fluorescence quenching titration curves, as a plot of normalised fluorescence 
emission vs ligand concentration in µM for CeuE-iron(III)-6-LICAM and their associated 
non-linear regression fitting data from Dynafit.326 CeuE at a concentration of 240 nM in 40 
mM Tris-HCl pH 7.5, 150 mM NaCl was titrated with aliquots of 12 M iron(III)-6-LICAM 
in 40 mM Tris-HCl pH 7.5, 150 mM NaCl.  
Table 3: Dissociation constants for CeuE titrated with iron(III)-6-LICAM for three 
independent fluorescence titrations, and their associated error. The average was then 
calculated via a weighted average method. 
CeuE-iron(III)-6-LICAM Kd /nM Error /nM 
Run 1 41.1 4.6 
Run 2 23.9 3.4 
Run 3 44.1 5.8 





Figure 39: Fluorescence quenching titration curves as a plot of normalised fluorescence 
emission vs ligand concentration in µM for CeuE-iron(III)-8-LICAM and their associated 
non-linear regression fitting data from Dynafit.326 CeuE at a concentration of 240 nM in 40 
mM Tris-HCl pH 7.5, 150 mM NaCl was titrated with aliquots of 12 M iron(III)-8-LICAM 
in 40 mM Tris-HCl pH 7.5, 150 mM NaCl. 
Table 4: Dissociation constants for CeuE titrated with iron(III)-8-LICAM for three 
independent fluorescence titrations, and their associated error. The average was then 
calculated via a weighted average method. 
CeuE-iron(III)-8-LICAM Kd/nM Error /nM 
Run 1 62.8 5.0 
Run 2 47.2 7.5 
Run 3 59.7 6.7 
Average 58 8 
The dissociation constants could then be compared to the literature values for iron(III)-4-
LICAM and iron(III)-5-LICAM (Table 5). All titrations were carried out with 240 nM CeuE 
in 40 mM Tris-HCl pH 7.5, 150 mM NaCl with aliquots of 12 M iron(III)-n-LICAM in 40 




Table 5: Dissociation constants for CeuE with iron(III)-n-LICAM (n = 4, 5, 6, 8) each 
calculated as a weighted average from three independent fluorescence titrations. Errors for 
each are calculated as an uncertainty in average.310, 322 
Iron(III)-n-LICAM CeuE Kd /nM Error /nM 
4 21 6 
5 < 10 - 
6 33 8 
8 58 8 
 
It is clear that iron(III)-5-LICAM binds most tightly to CeuE, with a Kd of <10 nM. However, 
the dissociation constant could not be accurately determined from the recorded data, with 
the binding being too tight to provide an adequate curve for satisfactory fitting.310  
Iron(III)-4-LICAM and iron(III)-6-LICAM bind less strongly than iron(III)-5-LICAM, with 
comparable affinity to each other, given the associated error values, with a Kd of 21 ± 6 nM 
and 33 ± 8 nM respectively.310, 322 Iron(III)-8-LICAM has the weakest affinity of the four, 
with a Kd of 58 ± 8 nM. The binding curves display the differences in binding affinity, with 
the steepest curve arising from CeuE-iron(III)-5-LICAM and the shallowest from CeuE-






Figure 40: Overlay of selected binding curves for fluorescence quenching titrations of CeuE 
titrated with of iron(III)-n-LICAM (n = 4, 5, 6, 8) and their associated non-linear regression 
fitting data calculated using Dynafit (n= 4, 5 are taken from the literature).186, 326 
The binding affinities of CeuE to the iron(III)-n-LICAM (n = 4, 5, 6, 8) siderophore mimics 
are comparable to the binding affinity of iron(III)-bisDHBS reported as 10.1 ± 3.8 nM.90 All 
dissociation constants lie within the nanomolar range, with iron(III)-bisDHBS and iron(III)-
5-LICAM, both with a 5 atom linker, binding to CeuE with the highest affinities. 
Isothermal titration calorimetry was trialled as an alternative method to attempt to validate 
the fluorescence quenching titration method for dissociation constant calculation but 
unfortunately proved unsuitable.327, 328 The additional  equilibria between iron(III) and n-
LICAM ligands in 1:1 and 2:3 ratio, and the necessary addition of iron(III) complexed with 
NTA to inhibit Fe(OH)3 precipitation represented a complicated array of equilibria.
90, 186 As 
such it was not possible to isolate the specific CeuE to iron(III)-n-LICAM binding event 
from the thermal effects of all other binding processes.327 Microscale thermophoresis also 
gave inconclusive results, likely due to a similar complications of multiple equilibria.329 
The fluorescence quenching titration method overcomes these complications by having the 
CeuE-based tryptophan as the sole reporter. As such the iron(III) binding equilibria are 
fluorescence silent, and the CeuE to iron(III)-n-LICAM binding event is the only observable 




2.6 Circular Dichroism  
The crystal structures of CeuE-iron(III)-6-LICAM and CeuE-iron(III)-8-LICAM show that 
the siderophore analogues are bound in the Λ-configuration, as previously reported for 
CeuE-iron(III)-4-LICAM, CeuE-iron(III)-bisDHBS and CeuE-iron(III)-MECAM (Figure 
41).186,90,11, 187  
 
Figure 41: Λ and Δ configurations depicted for a general octahedral metal complex, and the 
Λ-configuration as is present in a schematic of CeuE-iron(III)-n-LICAM and the crystal 
structure of CeuE-iron(III)-6-LICAM.11, 14 Figure produced using CCP4mg. 
Circular dichroism spectroscopy was used to confirm whether the Λ-configuration is also 
present in solution for CeuE-iron(III)-n-LICAM (n= 5, 6, 8). This was possible as the ligand 
to metal charge transfer band (LMCT) can be monitored in the visible region from 300 to 
700 nm, and the observed signal compared to similar but enantiomerically pure kinetically 
inert Λ or Δ-configured complexes.13, 95, 330 
If a lack of signal is observed in the circular dichroism spectrum from 300 to 700 nm, this 
indicates no preference for Λ or Δ-configured complexes. When CeuE is analysed with no 
iron(III) bound ligand, there is no significant observed signal, and the same is true when the 
iron(III)-n-LICAM (n= 5, 6, 8) is analysed with no protein (Figure 42). This confirms that 
the protein does not absorb over this wavelength range without iron(III)-n-LICAM (n= 5, 6, 




and is a racemic mixture of both Λ and Δ-configured complexes. Upon introduction of CeuE 
to iron(III)-n-LICAM (n= 5, 6, 8), a substantial preference for the Λ-configuration is 
observed (Figure 42). This confirms that the protein selectively binds the Λ-configuration 
and drives the equilibrium of free Λ and Δ-configured complexes to a Λ-configured majority. 
  
Figure 42: Circular dichroism spectra for CeuE plotted as ellipticity in mdeg vs wavelength 
from 300 to 700 nm. The spectra are run for 50 µM CeuE in 0.11M Tris-HCl pH 7.5, 150 
mM NaCl buffer with and without 50 µM iron(III)-n-LICAM (n = 5, 6, 8) ligands as well as 
the ligands at 50 µM in 0.11M Tris-HCl pH 7.5, 150 mM NaCl buffer without CeuE. The 
spectra show the induction of Λ-configuration upon introduction of CeuE to each iron(III)-
n-LICAM (n = 5, 6, 8). 
All CeuE-iron(III)-n-LICAM (n= 5, 6, 8) circular dichroism spectra were run at the same 
concentration of 50 µM so spectra could be directly compared to each other. The amplitude 
of the signal is largest for CeuE-iron(III)-5-LICAM and decreases as the number of spacer 
atoms increases (Figure 42). This suggests that the binding observed by fluorescence titration 
can be correlated to the amount of induced Λ-configured complex. The tighter the binding, 
the more Λ-CeuE-iron(III)-n-LICAM (n= 5, 6, 8) protein-ligand complex is present in 





2.7 The Optimum Linker Length of n= 5 
Overall, the CeuE-iron(III)-n-LICAM (n= 4, 5, 6, 8) crystal structures are all very similar, 
with only subtle differences in overall protein fold and ligand-binding arrangement. The 
global similarities between structures were quantified by comparing the r.m.s.d in C 
positions upon superposition of the structures (Table 6). 317 The most similar structures are 
CeuE-iron(III)-4-LICAM and CeuE-iron(III)-5-LICAM with r.m.s.d of 0.38 over 288 C 
positions, and all structures containing ligands were more similar to one another than to apo-
CeuE, confirming there is very limited structural rearrangement of the protein upon ligand 
binding. 
Table 6: R.m.s.d in Å over number of C positions for superpositions calculated using the 
SSM algorithm of CeuE and CeuE-iron(III)-n-LICAM crystal structures showing the 
similarity in atom positions for all structures.317 
Crystal 
Structure 
Apo- CeuE 4-LICAM 5-LICAM 6-LICAM 8-LICAM 
Apo- CeuE 
(chain A) 
 0.68 /286 0.62 /286 0.70 /285 0.63 /286 
4-LICAM   0.38 /288 0.48 /287 0.45 /288 
5-LICAM    0.58 /254 0.43 /289 
6-LICAM     0.54 /288 
8-LICAM      
 
To explain the differences in binding affinity for iron(III)-n-LICAM (n= 4, 5, 6, 8) to CeuE, 
the crystal structures were overlaid and analysed. Although all four ligands bind in a very 
similar Λ-configured orientation, there are small differences in precise binding mode. When 
the structures are viewed with His 227 oriented towards the back, the catecholate units 
viewed on the right-hand side have atom positions that are almost identical for all four 
structures. However, differences in the structures arise for the left hand catecholate units. 
Although the catecholate oxygen atoms are all in very similar positions, the catecholate 
aromatic ring in the CeuE-iron(III)-4-LICAM structure is displaced upwards relative to the 





Figure 43: Stereo view overlay of CeuE-iron(III)-n-LICAM crystal structures showing atom 
positions of the iron(III)-n-LICAM ligands in the CeuE binding pocket and the iron(III) 
binding residues His 227 and Tyr 288 for each structure. CeuE-iron(III)-4-LICAM (lawn 
green), CeuE-iron(III)-5-LICAM (light crimson), CeuE-iron(III)-6-LICAM (dark purple) 
and CeuE-iron(III)-8-LICAM (orange). CeuE-iron(III)-4-LICAM has catecholate ring (left) 
displaced out of the optimum plane due to linker strain. Figure produced using CCP4mg. 
It is likely that this displacement in the catecholate ring seen for iron(III)-4-LICAM is 
present due to the iron(III)-4-LICAM linker being shorter than is optimum for the ideal 
binding arrangement.  Although the octahedral iron(III) coordination is possible, there is 
strain in the linker of 4-LICAM. This difference can be quantified by measuring the 
interplanar angle between the catecholate aromatic rings. Using the atom positions of each 
ligand in each crystal structure, planes for each ring were generated and the angle between 






Figure 44: Planes constructed for the six carbon atoms of each catecholate aromatic ring 
displayed in red (left) and yellow (right). Atom coordinates from CeuE-iron(III)-n-LICAM 
(n = 4, 5, 6, 8) crystal structures for each ligand are displayed in cylinders coloured by atom 
type. Interplanar angles are calculated between catecholate aromatic rings for each structure. 
Images created in Mercury.331 
For CeuE-iron(III)-4-LICAM, the angle is 97°, but for iron(III)-n-LICAM (n= 5, 6, 8) the 
angles are 111°, 110° and 110°, respectively. It appears that the ideal angle is around 110°, 
and a smaller angle is forced when the linker is too short to achieve the optimum. This helps 
to explain why iron(III)-4-LICAM binds more weakly to CeuE than does iron(III)-5-
LICAM. Iron(III)-5-LICAM is better suited for enthalpic and geometric requirements of the 




Although iron(III)-n-LICAM (n=6, 8) are able to satisfy the enthalpic requirements, and 
allow for the optimum catecholate interplanar angle, when the linker region is extended, the 
binding affinity for CeuE weakens. This is likely due to the entropic cost of fixing a longer 
linker with an increased number of degrees of freedom. Protein-ligand binding entropy can 
be estimated using computational calculations.332-334 For the purpose of calculations, the 
overall entropic cost of ligand binding is often separated into conformational and vibrational 
entropy. The entropic cost of ligand binding is likely due to fewer possible ligand rotamers, 
and is therefore principally conformational entropy. There will however also be 
contributions from the changes in vibrational entropy.332 The calculations are however very 
complicated when also taking the flexibility and motion of the protein into account.332, 334 
For the CeuE system, the protein does not have a large conformational change upon ligand 
binding, and the protein conformation is very similar when each iron(III)-n-LICAM (n=4, 5, 
6, 8) are bound. This is shown by the high similarity in atom position upon superposition of 
the crystal structures (Table 6). It is therefore likely that the majority of the difference in 
conformational entropy of the system is caused by the ligand rather than the protein, and a 
longer linker comes with a larger entropic cost. 
It seems that the shortest linker of five atoms in iron(III)-5-LICAM that achieves the ideal 
interplanar angle without strain is the tightest binder due to a balance of enthalpic and 
entropic optimisation. Unsurprisingly, the known natural ligand, iron(III)-bisDHBS, has a 
linker region containing five atoms.90 The binding affinities of the longer linkers are however 
within an acceptable biological range: periplasmic chaperone proteins are commonly known 
to have submicromolar binding affinities for their natural substrate.335 These findings 
therefore may indicate that it is possible for CeuE to bind natural iron(III)-bound 
siderophores of longer linker length. This means there is a good chance that C. jejuni is able 
to acquire iron(III) from a more structurally diverse set of tetradentate catecholate 
siderophores, other than just the enterobactin hydrolysis product bisDHBS. This could give 
C. jejuni a competitive advantage over a wide number of  tetradentate siderophore producing 
species, or conversely may allow for wider cooperative virulence of C. jejuni with a larger 




2.8 Summary and Conclusion 
It was shown that CeuE can bind iron(III)-n-LICAM siderophore mimic complexes with 
linker lengths of n= 6 and n= 8, which adds to findings already published in the literature 
that it can bind a range of linker lengths including n= 4 and n= 5.186, 310 The CeuE iron(III)-
n-LICAM complexes adopt the Λ-configuration in both crystal and solution phase, proven 
by protein crystallography and solution phase circular dichroism. Fluorescence quenching 
titrations with CeuE showed that the tightest binding complex is iron(III)-5-LICAM with a 
Kd of <10 nM. Iron(III)-4-LICAM and iron(III)-6-LICAM bind more weakly than iron(III)-
5-LICAM with Kd values of 21 ± 6 nM and 33 ± 8 nM, respectively. The weakest binder is 
iron(III)-8-LICAM with a Kd of 58 ± 8 nM. The interplanar angles obtained from the crystal 
structures show that CeuE-iron(III)-4-LICAM does not possess the optimum geometry 
around the iron(III) centre, and this is suggested to be caused by strain from having the 
shortest linker length. Iron(III)-6-LICAM and iron(III)-8-LICAM are suggested to bind less 
tightly than iron(III)-5-LICAM due to the entropic cost of fixing a longer linker in the CeuE 
binding pocket. Iron(III)-5-LICAM with the highest binding affinity to CeuE is the closest 




2.9 Future Work 
To complete the study, a good starting point would be to test the limits of linker lengths that 
CeuE is able to bind. To do this, the n-LICAM series should be pushed to extreme linker 
lengths. To test the shortest linker, it would be necessary to synthesise and repeat studies 
with 3-LICAM. It is likely that this linker length would either be too short to establish the 
necessary octahedral binding arrangement in the CeuE binding pocket, or the formation of 
2:3 Fe: ligand complexes would be much more stable than the 1:1 complexes required for 
CeuE binding. As such, it is likely that the binding affinity of iron(III)-3-LICAM to CeuE 
would be dramatically diminished. It would be interesting to test this hypothesis. 
It would then be of interest to try a series of longer linkers. As the amonabactins can contain 
a linker length of 16 atoms, 16-LICAM would be an key choice of ligand to establish the 
upper limit of linker length tolerance of CeuE.109 
CeuE is now known to bind tetradentate catecholate siderophore mimics of increased 
backbone length, and this poses the question as to whether CeuE is able to bind analogous 
natural tetradentate siderophores such as serratiochelin and the amonabactins. The above 
studies could be repeated with these natural siderophores to investigate whether the binding 
affinities are comparable by fluorescence quenching titration. It would then be of interest, if 
these siderophores did have a biologically relevant binding affinity, to study whether they 
were able to bind to CeuE with the observed Λ-configured binding arrangement both in 
crystal and solution phase. Protein crystallography with these ligands would establish the 
role of His 227 and Tyr 288 and other neighbouring residues in the binding configuration 
with these new natural siderophores. 
It would then be of interest to determine whether any natural tetradentate siderophores 
promote growth of C. jejuni under iron limited conditions. This study would validate whether 
any interactions of CeuE with the iron(III) bound siderophores were of biological relevance. 
Studies could be extended to the use of C. jejuni mutants that are unable to produce CeuE, 
to confirm whether CeuE is essential for the uptake of the iron(III) bound siderophores for 
effective growth of the species under iron limited conditions. 
This study could be extended to the n-LICAM siderophores, to probe whether these 
siderophore mimics are able to be used in the full CeuBCDE iron(III)-siderophore uptake 
system for delivery of iron(III) to the cytoplasm. 
The high binding affinity of iron(III)-siderophore complexes to CeuE make this system an 





Figure 45: Schematic diagram of CeuE as a potential scaffold for an artificial 
metalloenzyme. CeuE is shown in green ribbons. The iron(III) siderophore complex is 
shown in the binding cleft in purple, with a linked inorganic catalyst labelled ‘cat’ in orange. 
Figure produced using CCP4mg. 
The knowledge that CeuE is able to bind a range of linker lengths allows for a range of 
catalyst-siderophore anchor designs that do not need to be limited to a 5-atom linker. This 
knowledge may prove important for the successful attachment of an inorganic catalyst to a 
siderophore backbone for anchorage in the CeuE binding cleft, or to optimising function of 






3 The study of CeuE Variant Proteins for Investigation of 
Structure-Function Relationships in the CeuE Binding Cleft  
3.1 Introduction 
Residues that contribute to iron(III)-siderophore binding include a basic triad of arginine 
residues, Arg 118, Arg 205 and Arg 249, that form hydrogen bonds with the deprotonated 
catecholate oxygens, and a lysine, Lys 121, that provides a hydrogen bond to the carbonyl 
oxygen of the catecholamide backbone as detailed in the literature and in Chapter 2.90, 186, 
187, 310  Crucially, for tetradentate iron(III)-siderophore binding (iron(III)-n-LICAM and 
iron(III)-bisDHBS), a histidine, His 227, and tyrosine, Tyr 288 coordinate directly to the 
iron(III) centre (Figure 46).90, 186, 310 To better understand the binding of iron(III)-complexes 
in the CeuE binding cleft, the structure-function relationships of these key residues must be 
studied in greater detail.  
 
Figure 46: Structure of CeuE-iron(III)-8-LICAM in stereo view (PDB: 5AD1) showing 
residues involved in iron(III)-n-LICAM binding Arg118, Arg205, Arg 249, Lys 121, His 
227 and Tyr 288. Residues involved in binding are shown in cylinders coloured by atom 
type. Iron(III) is shown as a grey sphere. 8-LICAM is shown in circles coloured by atom 
type. Figure produced using CCP4mg. 
Residues involved in iron(III) binding in CeuE are conserved across a range of iron(III)-
siderophore periplasmic binding proteins from other bacterial species.90, 186, 337 Previously, 
the Dali server was used to identify periplasmic binding proteins that are structurally similar 
to CeuE.90, 338 To follow up this study and provide an up-to-date assessment, a structural 




CeuE crystal structure (PDB ID: 3ZKW) were used in a search model against structures 
deposited in the PDB with 70% or greater secondary structural similarity. 21 distinct proteins 
were found, and the most homologous structures, at above 85% secondary structure 
similarity, included YclQ (PDB ID: 3GFV) from Bacillus subtilis,231 an unnamed PBP (PDB 
ID: 4MX8) from Xylanimonas cellulosilytica, PiuA (PBD ID: 4JCC) from Streptococcus 
pneumoniae and VctP (PDB ID: 3TEF) from Vibrio cholerae.209 These four proteins were 
previously identified, suggesting no crystal structures of very closely matching (above 85% 
SSE match) proteins to CeuE have been solved in the last two years.90 The structures of 
CeuE and the four identified proteins were superposed using the SSM algorithm (Figure 
47).317 All structures had the characteristic type III periplasmic binding protein extended α-
helix hinge region, and an overall bilobate shape.184, 185 
 
Figure 47: Overlay of crystal structures of CeuE (ice blue) (PDB ID: 3ZKW), YclQ (sea 
green) (PDB ID: 3GFV), PiuA (light crimson) (PBD ID: 4JCC), VctP (lilac) (PDB ID: 
3TEF) and an unnamed PBP (dark grey) (PDB ID: 4MX8) by the SSM algorithm.317 Protein 
backbones are shown in ribbons. Figure produced using CCP4mg. 
Sequence alignments revealed that there were a number of conserved residues across these 
structurally similar proteins, including the His and Tyr involved in iron(III) binding in CeuE, 
as well as two of the Arg residues involved in hydrogen bonding in CeuE-iron(III)-





Figure 48: Sequence alignment of amino acid sequences for proteins superposed in Figure 
47. Red blocks are totally conserved, red text indicates close matches or residues of similar 
properties. Black text shows non-matching residues. Conserved arginine residues are shown 
with a blue triangle, conserved histidine with a pink star, conserved tyrosine with a green 
star. 
Using CCP4mg, the binding cleft regions were superposed with the apo CeuE crystal 
structure (PDB ID: 3ZKW) via the SSM algorithm, to identify whether the potential iron(III) 
binding histidine and tyrosine residues were in similar positions in all structures.317 The four 
structures, their structural similarity by secondary structure elements in % to CeuE, and the 
numbering of their conserved histidine and tyrosine residues are detailed in Table 7. The 
position of the conserved histidine and tyrosine residues in the crystal structures are all very 
similar to each other for CeuE YclQ, PiuA and VctP (Figure 49). The greater variation in 
histidine position, relative to the tyrosine position, is likely due to the histidine residue being 
located on a more mobile loop region of each protein. For the unnamed PBP (PDB ID: 




Table 7: Proteins identified with high structural similarity to CeuE via secondary structure 








SSM match to 
CeuE in Å / 
residues matched 
His Tyr 




4JCC 88 1.53 /266 H238 Y300 




4MX8 85 1.64 /258 H228 Y291 
 
 
Figure 49: Overlay of crystal structures of CeuE (ice blue) (PDB ID: 3ZKW), YclQ (sea 
green) (PDB ID: 3GFV), PiuA (light crimson) (PBD ID: 4JCC) and VctP (lilac) (PDB ID: 
3TEF) by the SSM algorithm in stereo view.317 Protein backbones are shown in ribbons. 
Conserved Tyr and His residues that are expected to be involved in iron(III)-coordination 





Figure 50: Overlay of crystal structures of CeuE (ice blue) (PDB ID: 3ZKW) with unnamed 
PBP (grey) (PDB ID: 4MX8) in stereo view. Selected regions of protein backbone are shown 
as ribbons with the conserved His and Tyr shown in cylinders. The His of the unnamed PBP 
is folded away from the binding cleft. Figure produced using CCP4mg. 
Interestingly, three out of the four identified proteins were from Gram-positive bacteria, with 
only VctP from a Gram-negative species V. cholerae. As Gram-positive species have a single 
cell membrane, the periplasmic binding protein equivalent, termed the substrate-binding 
protein, is often anchored in the cytoplasmic membrane, in close proximity to the ABC-
transporter to which it delivers iron(III)-siderophore complexes.231 This is also the case for 
CeuE, as although the protein is located in the periplasmic space, it is a lipoprotein that is 
tethered to the cytoplasmic membrane. Lipoprotein character was confirmed by a 
characteristic signal sequence as well as post-translational modification with palmitic acid 
when expressed in E. coli.171, 342 It is thought that similar post-translational modification 
allows anchorage of the protein to the cytoplasmic membrane in C. jejuni.171 The structural 
similarity of CeuE to Gram-positive analogues may be explained by this similarity in 
function -with the need for membrane anchorage. 
Many more putative periplasmic binding proteins, containing the conserved histidine and 
tyrosine residues, were found by protein sequence alignment, but the 3D structures of these 
are yet to be solved. Many were from Gram-positive species, and many of these were from 
the Bacillaceae family. In addition, there were a number of species of medical relevance that 
are likely to have a tetradentate catecholate siderophore binding protein with conserved His 
and Tyr residues (Figure 51). Species included Haemophilus influenzae, commonly known 
as bacterial influenza, Chlamydia trachomatis, the species responsible for human chlamydia 
infection, and Akkermansia muciniphilia, a species thought linked to obesity and diabetes.343-
346 Staphylococcus aureus, Enterococcus faecium and Enterococcus raffinosus were also 
identified to express a protein with sequence similarities for CeuE. These are all species that 





Figure 51: Sequence alignment for proteins similar to CeuE from a range of bacterial species. 
Residues 235-345 are shown, with conserved His and Tyr shown as residue 260 and 320 as 
a pink star and green star, respectively. The structures of these proteins are currently 
unsolved. Red blocks are totally conserved across all proteins, red text indicates close 
matches or residues of similar properties. Black text shows non-matching residues. 
It is of interest to study the role of His 227 and Tyr 288 residues in CeuE, as the results may 
reveal a general siderophore-binding mode for this identified range of similar putative 
periplasmic binding proteins from different pathogenic bacterial species. CeuE thus provides 
a model for understanding this whole subfamily of periplasmic binding proteins. It may then 
be of medical interest to use these proteins as a tool to gain a better understanding of the iron 
uptake capacities of the above species, and understanding the iron uptake pathways of 
pathogenic species may lead to more effective design of new antibiotics.295, 299, 301 In some 
cases, these proteins may even prove suitable in the development of vaccines.351 
A number of thermophilic species including Geobacillus thermoglucosidasius were 
identified in the sequence alignment. Geobacillus thermoglucosidasius is a thermophilic 
Gram-positive species that is capable of growth up to around 70 ºC, with an optimum range 
of 61-63 ºC.352-354 A protein analogous to CeuE from a thermophilic species may prove to 
be more thermostable than CeuE. Thermostable proteins are desirable candidates for the 
protein scaffold of potential artificial metalloenzymes, as this would allow for catalysis over 
a wider temperature range, and therefore have potential for greater catalytic turnover 
frequencies than those possible at lower temperatures.355-357 These species are already known 
for their applications in thermostable biocatalysis, such as in the production of bioethanol at 




The worked detailed in this chapter aims to investigate the individual roles of key residues 
His 227 and Tyr 288 in the CeuE binding cleft. The objective was to study CeuE variant 
proteins, deficient in each of these residues, with tetradentate siderophore mimics iron(III)-
n-LICAM (n =4, 5, 6, 8). Using the same experimental techniques that were used in the 
studies in Chapter 2, including protein crystallography, fluorescence titration, and circular 
dichroism, it was possible to directly compare variant CeuE proteins and wild-type CeuE. 
Differences in iron(III)-n-LICAM (n =4, 5, 6, 8) binding could then be used to infer the 
individual structure-function relationships of His 227 and Tyr 288. This information may 
provide a model for understanding a whole subfamily of periplasmic binding proteins, and 




3.2 CeuE Variant Proteins 
CeuE variants were designed without the functional regions of residues His 227 and Tyr 288, 
replacing them with amino acids with no iron(III)-coordinating atoms in their side chains. 
Histidine was replaced with alanine and leucine, and tyrosine replaced with phenylalanine 
(Scheme 2). Alanine, with a CH3 sidechain was a non-coordinating alternative to histidine. 
Leucine, with a bulkier aliphatic sidechain was a closer match to histidine in terms of steric 
bulk, so it was decided the two mutations would be compared to investigate any influence 
of sterics on iron(III)-n-LICAM binding. Phenylalanine provided similar steric bulk and 
aromatic rigidity to tyrosine, but without the hydroxy group this residue was rendered unable 
to participate in iron(III)-coordination. 
 
Scheme 2: Chemical structures of the amino acids used in mutations of His 227 and Tyr 288 
in CeuE variants. Atoms that coordinate to iron(III) after deprotonation are shown in red. 
Site-directed mutagenesis is a common technique used for determining structure-function 
relationships of significant residues in proteins. Systematic methods can be employed when 
functional residues are not already known, and this is particularly helpful when structural 
information cannot easily be obtained.360-363 Database-derived software SIFT can even be 
used to predict whether a mutation might affect protein function.364 
CeuE variant proteins were expressed, purified, and characterised by Dr E. V. Blagova. The 
necessary mutations were made by PCR-based site directed mutagenesis. Firstly, three 
mutant proteins were produced with the mutations: H227L, H227A and Y288F. A second 
cycle of PCR produced the double mutants H227L/Y288F and H227A/Y288F. All mutations 
were confirmed by DNA sequencing. The mutations were then confirmed in the expressed 
proteins by electrospray ionisation mass spectrometry. Circular dichroism spectroscopy was 




3.3 Crystal Structures of Apo CeuE Variant Proteins 
CeuE variants were crystallised in their apo form and cryoprotected by Dr E. V. Blagova. 
Crystallisation procedures are detailed in Chapter 6. Data for the following structure solution 
were collected at the Diamond Light Source and structure solution and refinement 
procedures are detailed in Chapter 6. All variants, with the exception of CeuE-Y288F, 
crystallised in space group P1, and were isomorphous with the wild-type, with three 
independent molecules in the asymmetric unit (Table 8). As might be expected, the mutants 
adopted an essentially identical fold to that of apo wild-type CeuE (Figure 52) and residues 
227 and 288 were located in very similar locations in all mutants, with an open binding cleft 
in the absence of ligands (Figure 53). 
Table 8: Comparison of CeuE variant crystal structures to that of wild-type CeuE. R.m.s.d 
is given for superposition with the wild-type structure via the SSM algorithm and the number 
of Cα positions matched is given in parentheses.  





Wild-type P1 a= 56.95 b= 62.74 c= 67.98 
α= 82.19 β= 76.74 γ= 75.96 
- 3ZKW186 
H227L P1 a= 56.92 b= 62.56 c= 67.79 




H227A P1 a= 56.90 b= 62.61 c=67.79 




Y288F P3221 a= 65.52 b= 65.52 c= 145.66 




H227L/Y288F P1 a= 56.72 b=62.36 c= 67.71 




H227A/Y288F P1 a= 56.90 b= 62.61 c= 67.79 









Figure 52: Overlay of the A chain of all mutant structures, showing high similarity in overall 
fold. H227L is shown in lemon ribbons, H227A in light brown, Y288F in light green with 
Zinc(II) ions shown as grey spheres, H227L/Y288F in light blue and H227A/Y288F in lilac. 
Figure produced using CCP4mg. 
 
Figure 53: Stereo view of overlay of the A chain of all mutant structures with that of wild-
type CeuE bound to iron(III)-5-LICAM, showing residues 227 and 288 in cylinders. There 
is little change in the arrangement of the 227-loop region for any of the mutants, but when 
iron(III)-5-LICAM is bound, the loop region is shifted towards the iron(III) centre. H227L 
is shown in lemon ribbons, H227A in light brown, Y288F in light green with zinc(II) ions 




iron(III)-5-LICAM is shown in light crimson, with the ligand shown in translucent cylinders. 
Figure produced using CCP4mg. 
Structure Solution for CeuE-H227L 
The structure of CeuE-H227L was well ordered with an average B value of 25.7 Å2 for the 
protein. The most similar chain to apo wild-type CeuE was chain B with r.m.s.d of 0.14 Å 
over 287 Cα positions. The CeuE-H227L binding cleft contained good electron density for 
iron(III)-chelating residue Tyr 288 and for Arg 205. There was some electron density for the 
sidechains of Arg 118 and Arg 249 which act as stabilising residues (Figure 54).90, 186 The 
mutated H227L was on a moveable loop, and while there was good electron density for the 
Cα backbone of the loop region, the electron density for side chains in this region was weak, 
indicating that they were flexible and disordered. There was a no significant electron density 
for the side chain of Leu 227 (Figure 55). 
 
Figure 54: Stereo view of iron(III)-siderophore binding residues Tyr 228, Arg 118, Arg 205 
and Arg 249 in the binding cleft of chain A of CeuE-H227L. The electron density for the 






Figure 55: Stereo view of loop region in chain A of CeuE-H227L from residues 222 to 230. 
Residues 222-226, 288-230 shown in lemon cylinders. Leu 227 is shown in cylinders 
coloured by atom type. The electron density for the maximum likelihood weighted map was 
contoured at the 1.5 level. There is poor electron density for the Leu 227 sidechain. Figure 
produced using CCP4mg. 
Structure Solution for CeuE-H227A  
The structure of CeuE-H227A was solved as for CeuE-H227L, and the average B value for 
the whole structure was 25.2 Å2. Some flexible loop regions of the protein (detailed in 
Chapter 6) could not be modelled, as there was not sufficient electron density present in 
these regions, indicating that these residues were mobile in the crystal. Residues Tyr 288, 
Arg 205 and Arg 249 were well ordered in the iron(III)-siderophore binding cleft (Figure 
56). As in CeuE-H227L, the Ala 227 residue located on the moveable loop region of the 
CeuE binding cleft possessed good electron density for the Cα protein backbone, but the 





Figure 56: Stereo view of the CeuE-H227A binding cleft (chain B). Protein backbone shown 
in pale brown ribbons with key sidechains of Arg 118, Arg 205, Arg 249 and Tyr 288 shown 
as pale brown cylinders. The electron density for the maximum likelihood weighted map 
was contoured at the 1.5 level. Figure produced using CCP4mg. 
 
Figure 57: Stereo view of loop region of CeuE-H227A residues 222-226 and 228-230 shown 
in pale brown cylinders. Ala 227 shown in cylinders coloured by atom type. The electron 
density for the maximum likelihood weighted map weighted was contoured at the 1.5 level. 
Figure produced using CCP4mg. 
Structure solution for CeuE-Y288F 
CeuE-Y288F was in P3221, a spacegroup not previously observed for CeuE crystals. The 
cell parameters gave one particularly long cell length, in the c dimension of 145.65 Å, and 
two equal cell lengths of 65.52 Å for a and b. There was one protein monomer in the 
asymmetric unit, and there was clear electron density for all residues in the protein backbone 




zinc(II) ions coordinated by residues His 210 and His 227, a result of the crystal being grown 
in conditions containing ZnCl2. An intramolecular zinc(II) complex arose from chelation of 
the zinc(II) by His 210 and a neighbouring residue Glu 220 (Figure 58).  
 
Figure 58: Stereo view of zinc(II) chelated by His 210 and Glu 220 in CeuE-Y288F. Protein 
backbone is depicted in light green ribbons. His 210 and Glu 220 sidechains are displayed 
as cylinders coloured by atom type. Zinc(II) is shown as a grey sphere with protein contacts 
as black dashed lines with bond distances annotated in Å. The electron density for the 
maximum likelihood weighted map was contoured at the 1.5 level. Figure produced using 
CCP4mg. 
The second set of zinc(II) interactions were intermolecular, formed from two protein 
monomers, one providing a nitrogen donor atom from His 227, and the other oxygen donor 
atoms from Glu 183. Water molecules completed the zinc(II) coordination sphere (Figure 
59). This zinc(II) complex between protein monomers is likely an important factor in the 
crystal packing arrangement of CeuE-Y288F, which is a probable cause of the different 
spacegroup of P3221 for this variant protein, instead of the more common P1. The mutation 
of the iron(III) binding tyrosine to a phenylalanine was clearly visible in the binding cleft, 





Figure 59: Stereo view of zinc(II) chelated by His 227 and Glu 183 from a neighbouring 
protein monomer in CeuE-Y288F. Protein backbones are depicted in light green ribbons. 
His 227 and Glu 183 sidechains are displayed as cylinders coloured by atom type. Zinc(II) 
is shown as a grey sphere with protein contacts as black dashed lines with bond distances 
annotated in Å. The electron density for the maximum likelihood weighted map was 
contoured at the 1.5 level. Figure produced using CCP4mg. 
 
Figure 60: There is clear electron density for the Y288F mutation in the single mutant variant 
protein. Protein backbone is shown in light green ribbons in stereo view. Phe 288 is shown 
in light green cylinders. The electron density for the maximum likelihood weighted map was 
contoured at the 1.5 level. Figure produced using CCP4mg. 
This mutation was very clear when modelling in a tyrosine or phenylalanine in COOT.365 




negative electron density map over the oxygen atom. When this atom was removed, and the 
residue was a phenylalanine, the model provided a much better match for the observed 
electron density (Figure 61). 
 
Figure 61: Modelling of residue 288 in COOT.365 The model is shown in dark blue sticks. 
Weighted electron density map shown in light blue chicken wire, set at 1.5σ. The weighted 
difference map is shown in red and green chicken wire for negative and positive electron 
density respectively, set at 1.5σ. A: Tyrosine modelled, with observed negative electron 
difference density around the tyrosinated oxygen atom. B: Phenylalanine modelled. 
Structure Solution for CeuE-H227L/Y288F and CeuE-H227A/Y288F 
The double mutant CeuE-H227L/Y288F and CeuE-H227A/Y288F structures were well 
ordered, with overall B values of 30.0 Å2 and 35.9 Å2, respectively. Both variants contained 
a number of disordered regions that could not be modelled due to a lack of electron density, 
detailed in Chapter 6. Features present in the binding clefts of both variants were equivalent 
to those in the single mutant structures, with the H227(L/A) mutation not well resolved, but 
Y288F clearly present in all cases, with a lack of electron density for the tyrosinate oxygen 





Figure 62: Stereo view of crystal structure of CeuE-H227L/Y288F showing residues Leu 
227 and Phe 288 in the binding cleft region of chain B. Protein backbone is shown as ice 
blue ribbons with residues Leu 227 and Phe 288 shown as ice blue cylinders. The electron 
density for the maximum likelihood weighted map was contoured at the 1.5 level. Figure 
produced using CCP4mg. 
 
Figure 63: Stereo view of crystal structure of CeuE-H227A/Y288F showing residues Ala 
227 and Phe 288 in the binding cleft region of chain B. Protein backbone is shown as lilac 
ribbons with residues Ala 227 and Phe 288 shown as lilac cylinders. The electron density for 





Apo-Variant-CeuE Crystal Structures Summary 
The crystal structures of all apo-CeuE variants were used to validate the results from DNA 
sequencing and ESI-MS that the confirmed mutation was present for variants containing the 
Tyr 288, and although the H227(L/A) sidechains are not resolved with complete certainty, 
there is a lack of electron density for a histidine sidechain in this position. The Tyr 288 
mutation was well resolved due to its location in a rigid α-helical region, whereas the poorly-
resolved His 227 mutations in a flexible loop region, that had less conformational order. In 
addition, the structures of all apo-CeuE variants confirmed that the mutations left the overall 
fold of CeuE unchanged, demonstrated by only minor differences in Cα positions when the 
structures are superposed.317 This allowed further study via fluorescence quenching titration 
and circular dichroism spectroscopic titrations of binding of ligands that were known to bind 
to wild-type CeuE.186, 310 If there were differences in binding between wild-type CeuE and a 
variant protein with an iron(III)-siderophore complex, then this could be related to the 






3.4 Dissociation Constants with Iron(III)-n-LICAM 
All five variants were studied via fluorescence quenching titration with iron (III)-5-LICAM, 
the siderophore mimic with the highest binding affinity with wild-type CeuE (as discussed 
in Chapter 2),310 to assess whether the mutations to the key iron(III)-binding residues 
affected the binding affinity. This was possible as all variants retained Trp 287 in a very 
similar position to that of wild-type CeuE. The fluorescence quenching of Trp 287 in all 
variants upon addition of iron(III)-siderophore was therefore monitored by the standard 
fluorescence quenching titration method as detailed in Chapter 6. 
The double variants CeuE-H227L/Y288F and CeuE-H227A/Y288F showed very poor 
iron(III)-5-LICAM binding. This was not surprising, as without an oxygen donor atom from 
Phe 288, or a nitrogen donor atom from Leu/Ala 227, the hexadentate coordination required 
by iron(III) could not be fulfilled in the binding cleft of these proteins. The fluorescence 
quenching data for CeuE-H227L/Y288F titrated with iron(III)-5-LICAM and fitted curves 
are plotted in Figure 64. The decrease in fluorescence observed when the protein is titrated 
with an equal volume of 40 mM Tris-HCl pH 7.5, 150 mM NaCl buffer is also displayed to 
demonstrate the significance of the binding curves. As the normalised fluorescence does not 
decrease below 0.4 and quenching appears to be only slightly greater than is observed for 







Figure 64: Fluorescence quenching titration curves, as a plot of normalised fluorescence 
emission vs ligand concentration in µM for CeuE-H227L/Y288F titrated with iron(III)-5-
LICAM. CeuE at a concentration of 240 nM in 40 mM Tris-HCl pH 7.5, 150 mM NaCl was 
titrated with aliquots of 12 M iron(III)-6-LICAM in 40 mM Tris-HCl pH 7.5, 150 mM 
NaCl The titration was performed in triplicate, and a binding curve calculated using 
Dynafit.326 The data were plotted alongside the normalised fluorescence quenching observed 
when CeuE-H227L/Y288F is diluted with the same amount of 40 mM Tris-HCl pH 7.5, 150 
mM NaCl buffer. 
The calculated Kd values and their weighted average and error are displayed in Table 9. 
Although the errors appear within an acceptable range, the calculated Kd values are not 
calculated from a true binding curve, as the end-point is not reached, and so these values 
must be interpreted with caution. It is more likely that the true Kd is a lot higher, probably in 
excess of 1 µM. To calculate this accurately, the protein and ligand concentrations were 
increased in an attempt to drive the equilibrium towards complex formation. This method 
should produce more pronounced fluorescence quenching with a definite end-point, and a 
better curve for more accurate fitting with Dynafit.326 In practice this was not possible due 
to the large concentration of iron(III)-5-LICAM required for full quenching, and the 




Table 9: Calculated Kd values from fluorescence quenching data for CeuE-H227L/Y288F 
titrated with iron(III)-5-LICAM. 
CeuE-H227L/Y288F-iron(III)-5-LICAM Kd /nM Error /nM 
Run 1 233 49 
Run 2 270 58 
Run 3 219 45 
Average 236 44 
 
It was decided that at 280 nm a ligand absorbance under 0.1 was acceptable, but exceeding 
0.1 was likely to be too large an absorbance for estimation of an accurate Kd value. This is 
due to the primary inner filter effect caused by the ligand absorbing at the excitation 
wavelength, and ‘artificially’ decreasing the emission intensity due to inadequate excitation 
of the protein. The maximum iron(III)-5-LICAM concentration was calculated by UV-
visible spectroscopic methods detailed in Chapter 6 as 67.3 µM. To obtain a suitable binding 
curve, it was necessary to introduce at least five equivalents of ligand to protein to ensure 
saturation of the protein. As such, the maximum protein concentration possible was 13.4 
µM. Given the maximum protein concentration of 13.4 µM, a titration with 12 µM for CeuE-
H227L/Y288F was trialled, to be sure not to exceed the maximum permissible ligand 
concentration. This titration gave a shallow titration curve, without a significant amount of 
fluorescence quenching upon addition of iron(III)-5-LICAM. The data could not be fitted 
with an adequate curve. The binding affinity could therefore not be accurately quantified by 





Figure 65: Fluorescence quenching titration curves, as a plot of normalised fluorescence 
emission vs ligand concentration in µM for CeuE-H227L/Y288F titrated with iron(III)-5-
LICAM. CeuE-H227L/Y288F at a concentration of 12 µM in 40 mM Tris-HCl pH 7.5, 150 
mM NaCl was titrated with aliquots of 60 M iron(III)-6-LICAM in 40 mM Tris-HCl pH 
7.5, 150 mM NaCl. A binding curve was calculated using Dynafit.326 The quenching was 
not sufficient for determination of a dissociation constant. 
Based on the limitation of the method described above, a variation was attempted for titration 
of CeuE-Y288F with iron(III)-5-LICAM. A 6 µM solution of CeuE-Y288F was titrated with 
10 equivalents of iron(III)-5-LICAM, and the binding curve observed was shallow, giving a 
dissociation constant of 19.4 µM ± 1.9 µM (Figure 66). As there was no well-defined end-
point, this dissociation constant was not accurate. As the limit of the method was reached at 
this protein concentration, further ligand cannot be added before primary inner filter effects 
become a significant problem. As such, the dissociation constant was estimated as above 1 
µM. Although His 227 was still present in this variant, and capable of iron(III) chelation, 






Figure 66: Fluorescence quenching titration curves, as a plot of normalised fluorescence 
emission vs ligand concentration in µM for CeuE-Y288F titrated with iron(III)-5-LICAM. 
CeuE-Y288F at a concentration of 12 µM in 40 mM Tris-HCl pH 7.5, 150 mM NaCl was 
titrated with aliquots of 60 M iron(III)-6-LICAM in 40 mM Tris-HCl pH 7.5, 150 mM 
NaCl. A binding curve was calculated using Dynafit.326 The quenching was not sufficient 
for determination of a dissociation constant. 
In contrast, iron(III)-5-LICAM did bind to the variants CeuE-H227L and CeuE-H227A. The 
fluorescence quenching titrations, at the standard protein concentration of 0.24 µM,90 were 
recorded in triplicate and the binding curves displayed in Figure 67 and Figure 68. All 







Figure 67: Fluorescence quenching titration curves, as a plot of normalised fluorescence 
emission vs ligand concentration in µM for CeuE-H227L-iron(III)-5-LICAM and their 
associated non-linear regression fitting data from Dynafit.326 CeuE-H227L at a concentration 
of 240 nM in 40 mM Tris-HCl pH 7.5, 150 mM NaCl was titrated with aliquots of 12 M 





Figure 68: Fluorescence quenching titration curves, as a plot of normalised fluorescence 
emission vs ligand concentration in µM for CeuE-H227A-iron(III)-5-LICAM and their 
associated non-linear regression fitting data from Dynafit.326 CeuE-H227A at a 
concentration of 240 nM in 40 mM Tris-HCl pH 7.5, 150 mM NaCl was titrated with aliquots 
of 12 M iron(III)-5-LICAM in 40 mM Tris-HCl pH 7.5, 150 mM NaCl. 
The dissociation constants, calculated via non-linear regression of the binding curves in 
Dynafit, are reported in Table 10 for CeuE-H227L titrated with iron(III)-5-LICAM and in 
Table 11 for CeuE-H227A titrated with iron(III)-5-LICAM.326 The dissociation constants 
were within the nanomolar range previously observed for wild-type CeuE binding to 
iron(III)-n-LICAM (n= 4, 5, 6, 8). CeuE-H227L bound iron(III)-5-LICAM slightly more 
tightly than CeuE-H227A with a dissociation constant of 22.0 nM ± 10.0 nM for CeuE-
H227L and 35.2 nM ± 13.8 nM for CeuE-H227A. With the associated errors of the method, 
it was concluded that the binding affinities for iron(III)-5-LICAM were broadly similar for 
both CeuE-H227L/A variants. Both variants had weaker binding affinities than that of wild-




Table 10: Dissociation constants for triplicate runs of CeuE-H227L titrated with iron(III)-5-
LICAM. The average was calculated using a weighted average method. 
CeuE-H227L-iron(III)-5-LICAM Kd /nM Error /nM 
Run 1 36.6 8.3 
Run 2 32.9 7.7 
Run 3 14.6 4.3 
Average 22 10 
Table 11: Dissociation constants for triplicate runs of CeuE-H227A titrated with iron(III)-5-
LICAM. The average was calculated using a weighted average method. 
CeuE-H227A-iron(III)-5-LICAM Kd /nM Error /nM 
Run 1 58.4 7.4 
Run 2 23.2 5.2 
Run 3 36.7 0.8 
Average 35 14 
These findings indicate that Tyr 288 is essential for CeuE to bind iron(III)-5-LICAM. While 
His 227 is not essential, it does enhance the binding affinity for CeuE to iron(III)-5-LICAM.  
Next, the effect of linker length was explored with the variants to probe whether His 227 had 
an influence on the binding affinities of shorter or longer linkers compared to the optimum 
5-linker. CeuE-H227L and CeuE-H227A were titrated with iron(III)-n-LICAM (n = 4, 5, 6, 
8) via the standard fluorescence quenching method,90 and their associated dissociation 
constants calculated. The binding curves with associated fitting data for selected runs for 
each protein and each iron(III)-n-LICAM (n = 4, 5, 6, 8) are shown in Figure 69 for CeuE-





Figure 69: Selected binding curves for the fluorescence quenching titration of iron(III)-n-
LICAM (n = 4, 5, 6, 8) with CeuE-H227L, as a plot of normalised fluorescence emission vs 
ligand concentration in µM for CeuE-H227L-iron(III)-n-LICAM (n = 4, 5, 6, 8) and their 
associated non-linear regression fitting data from Dynafit. CeuE-H227L at a concentration 
of 240 nM in 40 mM Tris-HCl pH 7.5, 150 mM NaCl was titrated with aliquots of 12 M 






Figure 70: Selected binding curves for the fluorescence quenching titration of iron(III)-n-
LICAM (n = 4, 5, 6, 8) with CeuE-H227A, as a plot of normalised fluorescence emission vs 
ligand concentration in µM for CeuE-H227A-iron(III)-n-LICAM (n = 4, 5, 6, 8) and their 
associated non-linear regression fitting data from Dynafit. CeuE-H227A at a concentration 
of 240 nM in 40 mM Tris-HCl pH 7.5, 150 mM NaCl was titrated with aliquots of 12 M 
iron(III)-n-LICAM in 40 mM Tris-HCl pH 7.5, 150 mM NaCl. 
The binding data from triplicate runs were used to calculate three independent dissociation 
constants using Dynafit.326 The average dissociation constant is reported in Table 12. Wild-
type CeuE dissociation constants are included for comparison.310 
Iron(III)-n-LICAM binding was weaker across all linker lengths for both variants compared 
to wild-type CeuE. It is likely that although His 227 does not appear to be essential to 
iron(III)-n-LICAM binding, that it does provide a stabilising effect that enhances the binding 





Table 12: Dissociation constants for wild-type CeuE, and variants CeuE-H227L and CeuE-
H227A with iron(III)-n-LICAM (n= 4, 5, 6, 8) siderophore mimic compounds. CeuE-




For the iron(III)-n-LICAM (n = 4, 5, 6, 8) ligand series, a similar trend in binding affinities 
is observed for the CeuE-H227L/A variants as was reported for wild-type CeuE. A linker 
length of 5 carbon atoms provides the iron(III)-n-LICAM with the highest binding affinity, 
while longer linkers of 6 and 8 carbon atoms provide a weaker binding affinity, as linker 
length is increased. iron(III)-4-LICAM binds more weakly than iron(III)-5-LICAM, 
probably due to linker strain as reported for wild-type CeuE as discussed in Chapter 2.310 It 
appears that this effect of a linker shorter than 5 atoms providing a weaker binding affinity 
is more pronounced in the CeuE-H227L/A variants than in wild-type CeuE. The dissociation 
constants for iron(III)-4-LICAM are larger than those of iron(III)-6-LICAM, whereas with 
wild-type CeuE, iron(III)-4-LICAM was observed to bind more tightly than iron(III)-6-
LICAM. This is also observed with shallower binding curves for iron(III)-4-LICAM than 
the curves for iron(III)-6-LICAM for the titrations with both CeuE-H227L and CeuE-H227A 
variant proteins. 
It may be that the CeuE-H227L/A variants are slightly more tolerant of longer linker lengths, 
with the flexible loop with H227L/A located away from the binding pocket. It could be that 
His 227 somehow provides a particularly stabilising effect for the binding of iron(III)-4-
LICAM in wild-type CeuE. Given the significant errors in a number of dissociation 
constants, it was not possible to draw firm conclusions on the reasons for differences in 
observed binding affinities. It was concluded that the CeuE-H227L and CeuE-H227A 
variants bind the iron(III)-n-LICAM (n = 4, 5, 6, 8) siderophore mimics with a similar trend 
in binding affinities to wild-type CeuE, but with overall weaker binding for all ligands.  
Iron(III)-n-LICAM CeuE Kd /nM CeuE-H227L Kd /nM CeuE-H227A Kd /nM 
n= 4 21 ± 6 90 ± 30 131 ± 28 
n= 5 < 10 22 ± 10 35 ± 14 
n= 6 33 ± 8 65 ± 21 41 ± 7 




3.5 Crystal Structure of CeuE-H227L-iron(III)-5-LICAM 
Variant CeuE-H227L was co-crystallised with iron(III)-5-LICAM and data were collected 
at the Diamond Light Source. Details of crystallisation and structure solution are detailed in 
Chapter 6. The data were indexed in space group P1 with three CeuE-H227L monomers in 
the asymmetric unit. All three binding clefts contained electron density that allowed 
iron(III)-5-LICAM to be modelled (Figure 71).  
 
Figure 71: CeuE-H227L co-crystallised with iron(III)-5-LICAM. Three protein monomers 
are present in the asymmetric unit, with an iron(III)-5-LICAM in each binding cleft. Chain 
A is shown in sea green ribbons, chain B in lawn green ribbons, and chain C in navy ribbons. 






Figure 72: Crystal structure of CeuE-H227L-iron(III)-5-LICAM showing just chain A. 
iron(III)-5-LICAM is shown as ball and stick coloured by atom type. The aqua (or hydroxo) 
ligand is shown as a red sphere. Iron(III) contacts are shown as black lines. Figure produced 
using CCP4mg. 
The iron(III) centres in all three chains are coordinated by four oxygen donor atoms from 
the 5-LICAM ligand scaffold, and by the oxygen donor atom of Tyr 288 (Figure 72). In 






Figure 73: Co-crystal structure of CeuE-H227L-iron(III)-5-LICAM, showing the binding 
cleft of Chain A (A) and Chain B (B) in stereo view. An aqua (or hydroxo) ligand the 
octahedral coordination of iron(III). Tyr 288 is shown in cylinders coloured by atom type. 
iron(III)-5-LICAM is shown in ball and stick coloured by atom type. The aqua (or hydroxo) 
ligand is shown as a red sphere. Iron(III) bond distances in Å are labelled. The electron 
density for the maximum likelihood weighted map was contoured at the 1.5 level. Figure 
produced using CCP4mg. 
The loop region of the protein, where the H227L mutation is contained, is disordered, with 
poor electron density for the Leu 227 sidechain (Figure 74). The loop is located away from 
the binding cleft, probably since there are no available donor atoms for iron(III) chelation. 
Overlaying the structure with that of wild-type CeuE-iron(III)-5-LICAM shows that there 
are only subtle differences in the binding arrangement of the iron(III)-5-LICAM ligand in 
the binding cleft, and the Λ-configuration is adopted around the iron(III) centre (Figure 75). 
The co-crystal structure therefore confirms that iron(III)-5-LICAM can still be bound in the 






Figure 74: Stereo view of the crystal structure of CeuE-H227L-iron(III)-5-LICAM. CeuE-
H227L-iron(III)-5-LICAM is shown in sea green ribbons, with key residues coloured by 
atom type. The iron(III)-coordinating aqua/hydroxo ligand is shown as a red sphere. The 
electron density for the maximum likelihood weighted map was contoured at the 1.5 level. 
Electron density for the flexible loop region is poor for the L227 sidechain. Figure produced 
using CCP4mg. 
 
Figure 75: Stereo view of the overlay of crystal structure of CeuE-H227L-iron(III)-5-
LICAM with that of CeuE-iron(III)-5-LICAM and CeuE-H227L via secondary structure 
matching.317 CeuE-H227L-iron(III)-5-LICAM is shown in sea green cylinders, with key 
residues coloured by atom type. CeuE-iron(III)-5-LICAM is shown in light crimson 
cylinders, with key residues coloured by atom type. The water/hydroxide molecule in the 
CeuE-H227L-iron(III)-5-LICAM structure is shown as a pale blue sphere. CeuE-H227L 




located is folded away from the iron(III) centre when the H227L mutation is present. Figure 




3.6 Circular Dichroism 
Circular dichroism spectroscopy was employed to probe the interaction of the CeuE variant 
proteins with iron(III)-n-LICAM (n = 4, 5, 6, 8) siderophore mimics. Iron(III)-5-LICAM 
was mixed with each CeuE variant, and the circular dichroism spectra recorded. All five 
spectra were overlaid in Figure 76. 
 
Figure 76: Circular Dichroism spectra for all five CeuE variant proteins upon the addition of 
iron(III)-5-LICAM. Ellipticity in mdeg was plotted vs wavelength from 300 to 700 nm. The 
spectra were run for 50 µM CeuE-variant in 0.11M Tris-HCl pH 7.5, 150 mM NaCl buffer 
with 50 µM iron(III)-5-LICAM.  
As fluorescence quenching titration suggested very weak binding affinity for iron(III)-5-
LICAM to the proteins containing the Y288F mutation (section 3.4), it was of interest to see 
whether variants CeuE-Y288F, CeuE- H227L/Y288F and CeuE- H227A/Y288F exerted any 
chiral preference on the Λ/Δ equilibrium of iron(III)-5-LICAM in solution. As the signal 
remained very close to zero for all three of these variants, it was confirmed that the observed 
weak binding by fluorescence quenching titration was either very weak, completely non-




The variants containing His 227 mutations, but with an intact Tyr 288, bound iron(III)-5-
LICAM with nanomolar affinity as shown by fluorescence quenching titration in section 3.4. 
The circular dichroism spectra showed a significant Λ signal for both variants when mixed 
with iron(III)-5-LICAM (Figure 76),11, 14 as seen for CeuE-H227L-iron(III)-5-LICAM in the 
crystal structure. This proved that the Λ-configuration is indeed retained in the solution 
phase, and that His 227 is not required to induce the Λ-configuration binding mode in CeuE. 
Circular dichroism spectra were then recorded with the full iron(III)-n-LICAM (n= 4, 5, 6, 
8) series for CeuE-H227L to investigate whether the Λ-configuration was induced for all 
four linker lengths, and whether the amplitudes of the signal correlated with the observed 
binding constants from fluorescence quenching studies. All iron(III)-n-LICAM (n= 4, 5, 6, 
8) ligands showed a signal for Λ-configured complexes. The strongest signal was observed 
when iron(III)-5-LICAM was bound, which was not surprising as this ligand had the lowest 
dissociation constant of the four. Iron(III)-6-LICAM gave the next strongest signal, with 
iron(III)-4-LICAM and iron(III)-8-LICAM giving the weakest (Figure 77). These spectra 
correlated well with the dissociation constants recorded for these complexes with CeuE-
H227L, and backed up the finding that iron(III)-4-LICAM has a particularly weak interaction 





Figure 77: Circular Dichroism spectra for CeuE-H227L with each iron(III)-n-LICAM (n= 4, 
5, 6, 8) complex. Ellipticity in mdeg was plotted vs wavelength from 300 to 700 nm. The 
spectra were run for 50 µM CeuE-H227L in 0.11M Tris-HCl pH 7.5, 150 mM NaCl buffer 
with 50 µM iron(III)-n-LICAM (n = 5, 6, 8) ligands. The spectra show the induction of Λ-
configuration. 
The magnitudes of the circular dichroism spectra for variant CeuE-H227L were compared 
with those of wild-type CeuE in Chapter 2. The magnitudes for each protein when in 
complex with iron(III)-5-LICAM are quite similar, as might be expected for dissociation 
constants of <10 nM and 20 ± 10 nM for wild-type CeuE and CeuE-H227L respectively, 
that are within the associated error. For iron(III)-6-LICAM and iron(III)-8-LICAM, the 
magnitude of the circular dichroism signal is significantly reduced for CeuE-H227L 
compared to wild-type CeuE, in keeping with the observed binding affinities. Iron(III)-6-
LICAM and iron(III)-8-LICAM display increased binding constants of 65 ± 21 nM and 112 
± 21 nM respectively with CeuE-H227L, when compared to wild-type CeuE of 33 ± 8 nM 




3.7 Summary and Conclusion 
The study of CeuE variants containing the Y288F mutation by fluorescence quenching 
titration showed that they are unable to bind iron(III)-5-LICAM with any measurable binding 
affinity, with circular dichroism spectra in the presence of iron(III)-5-LICAM showing no 
significant signal for a Λ-configured complex. These findings indicate that CeuE iron(III)-
5-LICAM binding is significantly impaired when Tyr 288 is not available to donate an 
oxygen atom for iron(III) coordination and indicates that Tyr 288 is fundamental to iron(III)-
5-LICAM binding. 
Variants containing both the H227L and H227A mutations retained the ability to bind 
iron(III)-5-LICAM with nanomolar affinity, as was proven by fluorescence quenching 
titrations. Both variants were able to bind the full iron(III)-n-LICAM (n= 4, 5, 6, 8) series, 
with larger dissociation constants for all linker lengths when compared to the dissociation 
constants with wild-type CeuE. This indicates that His 227 is not essential for CeuE to bind 
iron(III)-n-LICAM (n= 4, 5, 6, 8), but its presence does enhance the binding affinity. As the 
dissociation constant for iron(III)-4-LICAM was significantly larger for the binding with 
H227L and H227A variants when compared to the wild-type CeuE, it may be that His 227 
provides a particularly stabilising effect for such strained complexes. The crystal structure 
of CeuE-H227L-iron(III)-5-LICAM backs up the above findings, showing that iron(III)-5-
LICAM is able to adopt a very similar binding mode in the binding cleft of CeuE-H227L as 
that in wild-type CeuE. The vacant coordination site, where His 227 would usually provide 
a nitrogen donor atom, is filled by a water or hydroxide molecule. The observed Λ-
configuration in the CeuE-H227L-iron(III)-5-LICAM co-crystal structure is retained in 
solution phase, as circular dichroism confirms that CeuE-H227L exerts a preference for the 
Λ-configuration upon introduction to iron(III)-n-LICAM (n= 4, 5, 6, 8). The crystal structure 
and circular dichroism spectroscopic results therefore prove that His 227 is not required for 
the complexes to adopt the Λ-configuration in the CeuE binding cleft. 
These findings that Tyr 288 is essential for iron(III)-n-LICAM (n= 4, 5, 6, 8) binding, but 
His 227 is not, can be rationalised by the positioning of these residues in the tertiary fold of 
CeuE and chemical properties of these residues. Tyr 288 is located on a rigid α-helical region 
of CeuE, and so its position and conformational flexibility are limited. His 227 in contrast is 
located on a flexible loop region, and so from the unbound to the bound state, the protein 
must undergo a conformational rearrangement in this region to bring the chelating His 227 




fixing of His 227 into the bound position. As Tyr 288 is more conformationally rigid, it is 
likely already in the optimum position for iron(III) coordination. 
 
Figure 78: Stereo view of the overlay of crystal structures of apo wild-type CeuE (PDB ID: 
3ZKW) with CeuE-iron(III)-5-LICAM (PDB ID: 5A5D) showing the conformational shift 
of the His 227-loop region for iron(III) binding. Figure produced using CCP4mg. 
Additionally, it is likely that the Tyr O-iron(III) bond is stronger than the His N-iron(III) 
bond, due to nitrogen being less electronegative than oxygen, which means that nitrogen is 
a more intermediate-type donor, and a softer Lewis base. Oxygen is a hard Lewis base, which 
is more able to complement the hard Lewis acid character of the small and highly charged 
iron(III) centre. Combining these factors along with the experimental findings make a clear 
conclusion that Tyr 288 is much better optimised for iron(III)-n-LICAM coordination in the 
CeuE binding pocket than His 227. 
This study provides a general model of the binding arrangement of iron(III)-tetradentate 
catecholate siderophores and the key binding residues in a family of periplasmic binding 
proteins, as were identified by sequence alignments in section 3.1. These results should 
prove useful for the further study of PBPs from pathogenic species, for the development of 




3.8 Future Work 
To extend this study, further mutations could be made to CeuE to explore the wider binding 
pocket and uncover the contribution of other amino acids that are involved in iron(III)-
siderophore binding. For example, the arginine residues Arg 118, Arg 205 and Arg 249 that 
are known to provide stabilising hydrogen bonds could be replaced with non-hydrogen 
bonding residues and the iron(III)-siderophore binding to be quantified. This would be of 
interest for gaining information about the wider family of periplasmic binding proteins 
identified in section 3.1 and may be useful in understanding iron uptake pathways in a 
number of pathogenic bacteria. It may then be of interest to extend the study to analogous 
proteins from such species, to identify whether iron(III)-siderophore binding mode is in fact 
similar to CeuE, which could lead to identification of new antimicrobial targets.299, 301, 303 
A wider variety of ligands could be explored with CeuE variant proteins. It would be 
interesting to validate the study by investigating whether the natural substrate iron(III)-
bisDHBS gives a similar binding profile with the CeuE-H227A/L and CeuE-Y288F variant 
proteins as the n-LICAM siderophore mimics do.90 This would prove whether the n-LICAM 
series are adequate mimics for the natural substrate in these studies. As CeuE is known to 
only bind iron(III)-enterobactin with weak affinity,90 it may be of interest to study whether 
CeuE variant proteins missing the residues needed for optimum tetradentate siderophore 
binding are able to bind this hexadentate siderophore with a significant difference in affinity. 
This work could further inform site-directed mutagenesis of CeuE for applications in 
biotechnology. For example, if the binding affinity for a siderophore-catalyst conjugate 
could be increased, then this would be useful for the development of artificial 
metalloenzymes. If the siderophore component could be tightly anchored into the binding 
cleft, then this would enhance efficiency and potentially the enantioselectivity of the 
system.336, 355-357 To enhance the binding affinity, one strategy might be to replace His 227 
with a residue that could provide an oxygen donor atom, such as tyrosine, aspartic acid or 
glutamic acid, which could be a better match for iron(III) chelation in terms of Lewis acidity. 
Another approach could be to provide more hydrogen-bonding residues in the Arg 118, Arg 
205, Arg 249 coordination sphere, for increased specificity and fixation of the overall ligand. 
There is also scope to introduce unnatural amino acids into the protein backbone, to 
functionalise CeuE for a range of applications.368-370 This could be extended further by 
investigating analogues of CeuE from thermophilic species such as Geobacillus 
thermoglucosidasius, with the aim to develop an artificial metalloenzyme capable of 




4 Synthesis and Study of Salmochelin S1 Siderophore Mimics 
and their Interactions with CeuE 
4.1 Introduction 
The salmochelin family of siderophores are enzymatically C-glucosylated analogues of 
enterobactin and the resulting hydrolysis products, produced by bacterial species including 
E. coli and S. enterica.154, 235, 371 As discussed previously in Chapter 1, salmochelins are 
thought to exist in nature as stealth siderophores that are able to evade capture by the 
mammalian immunoprotein siderocalin.218, 230, 243, 372 Because enterobactin is captured by 
siderocalin, the use of salmochelin siderophores allows bacterial species to more effectively 





It was postulated that as CeuE readily binds iron(III)-bisDHBS, it may also be able to bind 
the iron(III) complex of the glucosylated analogue of bisDHBS, salmochelin S1.90, 154 It is 
known that C. jejuni is able to survive and grow using salmochelin S4 as an iron source 
under otherwise iron-limited conditions.182 However, the stability and hydrolysis of 
salmochelin S4 was not explored in the growth study, and commercially-sourced 
salmochelin S4 was used as supplied without additional characterisation.182 It is therefore 
likely that some salmochelin S1 was present in the sample, or salmochelin S4 was 
hydrolysed during the assay to its tetradentate and bidentate hydrolysis products by the 
periplasmic trilactone esterase Cee.159 It appeared possible that if CeuE binds iron(III)-
salmochelin S1 in the periplasm, iron delivery to the cytoplasm with the CeuBCDE iron(III)-
uptake system may be possible via this siderophore.172, 342 
Computational Modelling of the Binding of CeuE with Iron(III)-Salmochelin 
S1 
To test the hypothesis that CeuE may be able to bind iron(III)-salmochelin S1, computational 
modelling of the CeuE binding cleft was conducted by a collaborator, P. S. Bond, details for 
which are listed in Chapter 6. Interestingly, the modelling indicated that there was a potential 
secondary binding pocket (Cavity 2, Figure 79) adjacent to the known iron(III)-siderophore 
binding cleft (Cavity 1, Figure 79).  
 
Figure 79: CeuE (PDB ID: 3ZKW) shown with surface view, with three identified binding 
cleft regions. Cavity 1 is the known iron(III)-siderophore binding cleft. Cavity 2 is a 




smaller pocket that is unlikely to accommodate a glucose unit. Figure provided by P. S. 
Bond. 
Using the coordinates from the CeuE-iron(III)-4-LICAM crystal structure (PDB ID:5A1J), 
a glucose moiety was attached via a carbon-carbon bond at the C5 position of an iron(III)-
bound catecholate siderophore that was modelled into the CeuE binding cleft, in the 
previously known tetradentate siderophore-binding arrangement.186 The glucose was 
positioned towards the secondary binding cleft. It was observed upon energy minimisation, 
via a standard dynamics cascade method, that it was possible for this glucose to be 
accommodated in the secondary binding pocket.332, 374 The glucose was able to adopt a 
number of chair conformations that did not cause unfavourable interactions with the 
surrounding protein (Figure 80). 
 
Figure 80: Molecular modelling of chair conformations of the C5 appended glucose in the 
CeuE secondary binding pocket. Each conformation arose from different simulation 
parameters. All four conformations provided possible glucose orientations in the binding 
cleft without unfavourable clashes. Figure provided by P. S. Bond. 
The energy upon addition of the glucose into the secondary binding pocket was calculated 
to decrease from -4.284 × 104 ± 25 kJ mol-1 to -4.324 × 104 ± 10 kJ mol-1, indicating a lack 




glucose unit was shown to be predominantly solvent based, and simulations included a 
number of potential hydrogen bonds to water molecules (Figure 81).  
 
Figure 81: Potential hydrogen bonds between glucose and water molecules when modelled 
in the secondary binding cleft of CeuE. Figure provided by P. S. Bond. 
The results of the simulations indicated that there was a good probability that CeuE would 
be able to bind iron(III)-salmochelin S1. Although an additional third smaller potential 
binding cleft was studied (Cavity 3, Figure 79) it was established that it was less likely that 
salmochelin S4, with two glucose units, would be readily accommodated by all three 
potential binding pockets.  
Methods for Synthesis of Aryl-β-C-glycosides 
To establish experimentally whether iron(III)-salmochelin S1could be bound by CeuE, it 
was necessary to design a salmochelin S1 mimic. A key step in the synthesis involved the 
installation of a carbon-carbon bond in the C5 position of a catechol aromatic ring to generate 





Figure 82: Necessary C-C bond formation between the C5 position of a catecholamide and 
a glucose unit for the generation of an aryl-β-C-glycoside salmochelin mimic compound. 
The new C-C bond is shown in red. 
Interest in aryl-C-glycosides in the literature is predominantly focussed on the synthesis of 
natural products, for study into their biological importance or medicinal properties.375-377 There 
are a number of synthetic methods for the generation of aryl-C-glycosides known, including 
arylation, alkylation and C-C cross coupling, and the area of chemistry has been thoroughly 
reviewed.295, 377-384 Each strategy generally involves the production of an electrophilic centre at 
the anomeric carbon of the glucose unit, that can be reacted with the desired nucleophile, such 
as an appropriately functionalised aryl ring (Scheme 3).  
 
Scheme 3: General strategy for production of aryl-C-glycosides via generation of an 
electrophilic centre at the anomeric carbon. 
Early approaches for aryl-C-glycoside formation included a Friedel-Crafts type reaction via the 
generation of acetate protected glucosyl chlorides (Scheme 3 R =Ac, R1 = Cl) that reacted with 
aromatic compounds when heated with aluminium chloride.385 However, these initial studies 
lacked stereoselective control in the production of the β-anomer, which is required to mimic the 
salmochelins. In an attempt to achieve stereocontrol, the Friedel-Crafts method was adapted with 
an oxidation, followed by an intramolecular migration of a benzyl group to the anomeric carbon, 
exclusively producing the α-anomeric product.386 However, this synthesis involved multiple 






Scheme 4: Intramolecular Friedel-Crafts reaction, resulting in pure α-anomeric product.386 
By carefully selecting protecting groups for the hydroxy units (Scheme 3 shown as R) and 
with the correct choice of leaving group (Scheme 3 shown as R1) it was possible to influence 
the production of the β anomeric product via reaction with a Grignard reagent.387, 388 Full 
conversion to the β-anomer was achieved with the use of benzyl protecting groups and a 
bromide leaving group (Scheme 5).388 Numerous studies reported in the literature expand on 
the use of Grignard reagents for the selective generation of both α and β-aryl-C-glycosides 
with the use of comparable organometallic reagents such as aryllithium species, 
organoindium halides and organocuprates. 380, 381, 389-392 
 
Scheme 5: A Grignard reagent method for selective generation of a β-anomeric product.388 
More recent studies into selective generation of aryl-β-C-glycosides include the use of C-C 
cross coupling reactions.378, 380, 383 The Heck reaction was employed for synthesis of β-
anomeric products of pyrimidine nucleosides, for applications in DNA base biotechnology 
(Scheme 6).378, 393 The method relied on the use of a suitably bulky protecting group on the 
3-hydroxy group of the sugar unit, ensuring exclusive attack on the less sterically hindered 
face by the organopalladium reagent.378 In addition, Suzuki coupling of palladium-catalysed 
aryl boronic acids with exo-glycals proved successful for the generation of β-C-glycosides 





Scheme 6: The use of the Heck reaction to generate a β-anomeric product.393 
 
Scheme 7: Suzuki coupling reaction to generate a β-anomeric product.383, 394 
Key to this project were the studies by Gong and co-workers into the use of Negishi coupling 
reactions in the synthesis of the salmochelins.395-397 The group first published a number of 
different substrates in Negishi coupling reactions of glucose analogues, with resulting α- and 
β-selectivity dependent on the reaction conditions.395, 396 The most β-selective conditions (10 
mol % Ni(COD)2, 15 mol % 
tBu-Terpy, 150 mol % ArZnI.LiCl in DMF) were then applied 
to synthesise a key β-C5-glucosyl protected catechol species in a 20:1 β:α ratio (Scheme 
8).396 This species was then adapted for coupling to a di-serine, tri-serine and cyclic tri-serine 
backbone for syntheses of salmochelin S1, salmochelin S2 and salmochelin S4 
respectively.397 Logically, this study was used as a starting point for the synthesis of the 
salmochelin mimics detailed in section 4.2. 
 
Scheme 8: Negishi coupling reaction utilised for the synthesis  of β-C5-glucosyl catechol 




The research presented in this chapter aimed to identify whether salmochelin S1 or related 
mimics could be accommodated in the known binding cleft, and the adjacent pocket (Cavity 
2, Figure 79) of CeuE. The aim was to further knowledge into the iron(III)-uptake capacity 
of C. jejuni, and give an explanation of the role of stealth siderophores in the growth and 
survival of the bacterial species. The work focussed on the synthesis of salmochelin S1 
mimics and establishing iron-binding properties of these compounds via a Job Plot method. 
The complexes were then studied for CeuE binding via fluorescence quenching titration and 
circular dichroism. The use of these mimics enabled an insight into the potential ability of 




4.2 Design and Synthesis of Salmochelin S1 Mimic Compounds 
Salmochelin S1 
Salmochelin S1 was purchased from EMC Microcollections and the sample was 
characterised by ESI-MS and analytical HPLC, as detailed in Chapter 6. Both methods 
indicated that salmochelin S1 was present. The HPLC trace gave a single peak with strong 
absorbance at 254 nm, with a retention time of 10 minutes (Figure 83). As the analytical 
HPLC parameters were set as close to those described in the literature as possible, the 
retention time when compared with the literature value of around 12 minutes, was deemed 
within the expected range.235 ESI-MS gave a molecular ion peak with m/z of 625.1510, 
corresponding to the [M-H]- species. 
 
Figure 83: HPLC trace for Salmochelin S1. The sample in water containing 0.1% formic 
acid was injected with a 6-40% gradient of acetonitrile in water with 0.1% formic acid over 
25 minutes. 
Upon addition of one equivalent of iron(III) to the salmochelin S1 sample at a concentration 
of 0.5 mM at pH 7 in 0.40 mM Tris-HCl 150 mM NaCl, no typical red or purple colouration 
was observed. This was confirmed by UV-visible spectroscopy, with no absorbance for the 




complexes.66, 90, 254, 398, 399 Considering that the pKa values for the catechol hydroxy groups 
were around 9 and 13,28 the spectra were run across a range of neutral to basic pH values to 
promote deprotonation of the catechol units to facilitate iron(III) binding, but no metal to 
ligand charge transfer band was observed. For reference, a spectrum of the same 
concentration of iron(III)-5-LICAM was recorded, to show the intensity of absorbance bands 
that might be expected for iron(III)-Salmochelin S1. For iron(III)-5-LICAM a broad 
absorbance band was observed between 450 and 650 nm, a very similar absorbance band to 
those documented in the literature for iron(III)-4-LICAM and iron(III)-bisDHBS.90, 322 
 
Figure 84: UV spectra of 0.5 mM iron(III)-5-LICAM at pH 7.0 40 mM Tris-HCl 150 mM 
NaCl overlaid with UV spectra of 0.5 mM iron(III)-S1 sample over a pH range of 7.0-9.1 
in 40 mM Tris-HCl 150 mM NaCl.  
These findings suggested that the sample either contained only a trace amount of salmochelin 
S1, detectable by ESI-MS and HPLC, or the sample contained a form of salmochelin S1 that 
is incapable of iron(III) chelation. As the sample supplied was unable to bind iron(III) in the 




Design of a Sulfonamide Linked Salmochelin Mimic 
With no other commercial suppliers of salmochelin S1, it was necessary to design and 
synthesise a compound that could effectively mimic salmochelin S1, and could therefore be 
used to explore whether a glucose unit could be accommodated in the secondary binding 
pocket of CeuE. A logical design based on work detailed in Chapters 2 and 3, involved the 
use of a LICAM-type backbone, with a link to the anomeric carbon of a glucose moiety from 
the C5 position of one catechol aromatic ring. The first design (sulfonamide salmochelin 
mimic) involved a sulfonamide linkage between the aromatic catechol and the glucose unit.  
 
Upon modelling of this mimic into the secondary binding cleft of CeuE, it was clear that the 
linker region was bulky, and the glucose unit was not in an optimum position in the 
secondary binding pocket. It appeared that an energetically disfavoured axial conformation 
would provide a better fit in the binding pocket than a more favourable equatorial 
conformation. With some doubt as to whether this mimic may allow for a good fit in the 
secondary binding pocket, as well as issues with initial synthetic reproducibility, this design 
was not pursued. 
 
Figure 85: Simple modelling of the sulfonamide salmochelin mimic in the secondary binding 




Design of a Carbon-Carbon Bonded Salmochelin Mimic 
The second salmochelin mimic design involved a more synthetically challenging C5 carbon-
carbon bond formation between a LICAM catechol unit and a glucose unit (Figure 82). This 
was already proven as a favourable linkage for optimum glucose arrangement in the 
secondary binding pocket from initial modelling results (section 4.1) and was a closer match 
for salmochelin S1.  
 
The first C-C bonded target compound (Sal-4-LICAM) was based on a 4-LICAM backbone. 
This linker length was chosen as the least synthetically challenging, as the synthesis of the 
intermediate, benzyl protected aminochelin (compound C), was already well documented in 
the literature.85, 106 Compound C was synthesised over two steps in an overall yield of 47% 
(Scheme 9). Firstly, the catechol oxygen atoms of Compound A were benzyl protected, 
followed by an oxidation of the aldehyde to a carboxylic acid. Addition of Compound B and 
CDI to an excess of 1,4-diaminobutane in a dropwise manner yielded Compound C. 
 
Scheme 9: Synthesis of benzyl protected aminochelin (compound C). 
Salmochelin syntheses were documented in the literature, as discussed in section 4.1, the 
reported procedures for installation of the β-ᴅ-glucose unit were adapted for the synthesis of 
Sal-4-LICAM (Scheme 10, Scheme 11 and Scheme 12).395-397 Synthetic design was carried 
out in collaboration with Dr. T. J. Sanderson, who required intermediate compounds detailed 
in Scheme 12 for the production of a salmochelin inspired antibiotic conjugate.295 All 
compounds were synthesised and characterised individually, however synthetic strategy and 




The full synthesis of Sal-4-LICAM was initially designed with the production of the C5 
iodinated benzyl-protected 4-LICAM (compound J) over five steps from commercially 
available starting material (compound D) (Scheme 10). Compound J was designed as the 
starting material for the Negishi coupling to install a C5 C-C bonded acetate-protected β-ᴅ-
glucose unit (compound K) (Scheme 11).396 It was hoped that base deprotection of the 
acetate protecting groups, followed by hydrogenolysis to remove the benzyl groups would 
produce the desired target Sal-4-LICAM over seven synthetic steps. 
 
Scheme 10: Synthetic route for the production of the benzyl protected C5 iodinated 4-





Scheme 11: Proposed Negishi coupling reaction of Compound J to produce Compound K 
and subsequent deprotection reactions to yield Sal-4-LICAM. 
Compound J was successfully produced in an overall yield of 31% in good purity (Scheme 
10), as confirmed by 1H NMR spectroscopy, with a characteristic doublet at 8.07 ppm for 
one of the aromatic protons ortho to the iodine, with a 4JH-H coupling of 1.8 Hz to the other 
ortho proton. 13C NMR spectroscopy gave characteristic peaks for the two amide carbonyls 
at 164.94 and 163.42 ppm. The characterisation of compound J was also validated with ESI-
MS and elemental analysis.  
Unfortunately, the Negishi coupling of compound J with acetobromo-α-ᴅ-glucose proved 
not to be viable. Rigorous moisture and air free techniques were used in an attempt to obtain 
compound K, but only trace amounts were observed with a peak for the [M+Na]+ species 
with m/z of 1073.4122 (calculated 1073.4024, mean error -7.4 ppm) observable by ESI-MS. 
The major product isolated was benzyl protected 4-LICAM, whereby the iodine in the C5 
position had been replaced with a proton. 
 
The presence of this compound was confirmed by ESI-MS with a peak for the [M+Na]+ 
species with m/z of 743.3048 by ESI-MS. 1H NMR showed an absence of four distinct peaks 
for each set of benzyl CH2 protons for an unsymmetrical compound at 5.17 ppm, 5.12 ppm, 




with relative integrations for four protons each, arising from the symmetry that resulted from 
the exchange of the iodine for a proton. It was not clear why compound J was not compatible 
with the Negishi coupling reaction conditions (Scheme 11). Elemental analysis and 1H NMR 
analysis of the starting material ruled out the possibility of contamination of the starting 
material with water, or other solvent. It was however noted in the literature that Negishi 
couplings were slower with bulkier substrates.396, 400 It was necessary for compound J to be 
converted to an activated arylzinc reagent before the coupling reaction, and it is likely that 
either this arylzinc compound was not formed, or its decomposition was faster than the 
desired C-C bond formation. It is unclear why this was the case, but literature studies 
suggested that steric bulk may have been a factor.396, 400 
Due to the synthetic problems encountered, the synthesis of Sal-4-LICAM was redesigned 
with a smaller iodinated substrate for Negishi coupling (compound G) (Scheme 12). The 
Negishi coupling step to yield compound M was planned on a monocatechol substrate 
(compound G), with the amide coupling step to produce the 4-LICAM backbone planned at 
a later stage of the synthesis (Scheme 13), after installation of the glucose-containing unit 
(compound M). This newly designed route required ten synthetic steps, three more than the 
previously designed route, but had the advantage of a reported successful Negishi coupling 
of a substrate known in the literature, and therefore only required small alterations to the 





Scheme 12: Synthetic route for the production of Negishi coupled product, compound P. 
First, a commercially-available mono methyl protected catechol starting material (compound 
D) was iodinated in the C5 position to yield compound E in 73% yield. Methyl protecting 
groups allowed for the necessary functional group directing effects for selective iodination 
in the C5 position.295, 401 The methyl group protecting the catechol was next removed to yield 
compound F in 89% yield, followed by benzyl protection of both the catechol hydroxy 
groups to afford compound G in a 78% yield.  
The benzyl-protected iodinated catechol product (compound G) was then used for a Negishi 
coupling reaction, whereby a carbon-carbon bond formation allowed for the installation of 
an acetate-protected β-ᴅ-glucose unit in the C5 position to yield compound M in a 66% yield. 
The glucose unit was selectively installed as the β-anomer, as confirmed by the coupling 
constant of the anomeric proton observed in the 1H NMR spectrum. Literature 3J H-H coupling 
constants for diaxial protons, as present in the β-configuration, have a large value, typically 
between 7 and 9 Hz. If the α-configuration was present, the coupling constant would be 
much smaller, typically between 2 and 4 Hz, for an equatorial-axial proton coupling.392, 402 
The doublet at 4.39 ppm for the anomeric proton in compound M had a coupling constant 




The acetate protecting groups on the glucose unit were required in the Negishi coupling for 
selective formation of the β-anomer due to their role in neighbouring group participation.295, 
396, 403Acetate protecting groups however proved unsuitable for later synthetic steps, due to 
their instability under basic conditions.404 As such, the acetate protecting groups were 
removed, and benzyl protecting groups installed in their place to yield both the methyl and 
benzyl ester compounds N. The compounds were individually purified by column 
chromatography to allow for their characterisation, however as the following step required 
deprotection to yield the carboxylic acid (compound P), the two products were recombined. 
The percentage yield, in terms of the combined moles of each species was calculated as 59%. 
A base deprotection yielded the free carboxylic acid in a 62% yield (compound P). 
 
Scheme 13: Amide coupling of the glucosylated catechol unit to benzyl-protected 
aminochelin, and the subsequent global benzyl deprotection via hydrogenolysis. 
The free carboxylic acid species (compound P) was combined with benzyl protected 
aminochelin (compound C) in an amide coupling reaction, using the coupling agent HATU, 
to produce the benzyl-protected, mono-glucosylated 4-LICAM, compound Q, in 45% yield. 
After purification, all benzyl protecting groups were removed in one step via hydrogenolysis 
to yield Sal-4-LICAM over 10 synthetic steps in an overall yield of 5%. The specific rotation 
was recorded as +3.2 at 0.245 g/100 mL in methanol, and the signal for the anomeric proton 
in the 1H NMR spectrum was observed as a doublet at 4.02 ppm with a coupling constant of 
J = 9.2 Hz. This proved that the β-anomer was retained in the final product, as required to 
act as a suitable mimic of the β-configured glucose unit in salmochelin S1. 
The fact that the successful Negishi coupling reaction conditions for the conversion of 




attempted  reaction of compound J to compound K (Scheme 11) further suggested that there 
was substrate incompatibility of compound J, rather than the possibility of a contamination. 
Following successful synthesis of Sal-4-LICAM, the 5-LICAM analogue was synthesised. 
This salmochelin mimic was a more desirable synthetic target, as it contains a 5-atom linker  
that  matches  the linker length  of salmochelin S1.154 In addition, previous studies in Chapter 
2 showed that iron(III)-5-LICAM was the tetradentate siderophore mimic, in the n-LICAM 
(n = 4, 5, 6, 8) series, with the highest binding affinity for CeuE.310  
 
Isolation of the benzyl protected aminochelin analogue containing a 5-carbon linker 
(compound S) proved problematic under the same conditions as the synthesis of compound 
C (Scheme 9). This was likely due to the amphiphilic nature of the mono-amine product, 
and incompatibility with the work up procedure. The synthesis of compound S was therefore 
redesigned (Scheme 14). The method was based on literature procedures for synthesis of 4-





Scheme 14: Scheme for the synthesis of a 5-carbon linker analogue of benzyl protected 
aminochelin (compound S). 
This synthesis, carried out by project student R. P. Thomas, although requiring three 
synthetic steps instead of two, afforded compound S in an overall yield of 21%. Compound 
S could then be coupled to the glucose-functionalised catechol product (compound P) in a 
similar manner to that of the Sal-4-LICAM procedure (Scheme 13), yielding a benzyl-
protected 5-LICAM salmochelin mimic in a 55% yield (compound T) (Scheme 15). 
Hydrogenolysis was used to remove all benzyl groups to produce the final 5-LICAM 
salmochelin mimic in a 90% yield. The final product, Sal-5-LICAM was obtained in an 





Scheme 15: Amide coupling of the glucosylated catechol unit to benzyl protected 5-carbon 
analogue of aminochelin, and the subsequent global benzyl deprotection via hydrogenolysis. 
Both salmochelin mimics were characterised by 1H and 13C NMR, ESI-MS, IR and elemental 
analysis, and all intermediates were characterised by 1H and 13C NMR, ESI-MS and IR as a 
minimum. HMQC, COSY and HMBC were used to aid NMR assignments and 
supplemented with HMBC where necessary. All data are presented in Chapter 6. Sal-4-
LICAM was found to be in a form containing 2.1 equivalents of H2O that could not be 
removed with extensive drying methods. Sal-5-LICAM was found to be in a form containing 
0.9 equivalents of EtOH and 1.2 equivalents of H2O that could not be removed with 
extensive drying methods. The present solvents were observed by 1H NMR, and CHN 
elemental analysis data correlated with the calculated equivalents. The solvents were taken 
into account for further calculations and studies. All further studies were carried out with 
portions of each salmochelin mimic that had been analysed via all characterisation 




4.3 Iron Binding  
Each salmochelin mimic, Sal-4-LICAM and Sal-5-LICAM, was studied for iron binding 
stoichiometry using a Job Plot method adapted from a method documented for the iron(III) 
binding stoichiometry of bisDHBS.90 A Job plot, also known as the Continuous Variation 
Method, was used to determine the stoichiometry of a binding event by studying the physical 
properties of the system over a range of ratios.406 UV-visible spectroscopy is a common 
technique for determination of speciation of coloured metal complexes,90, 281, 322, 406, 407 but 
techniques such as NMR can also be employed.408, 409 The method has previously been used 
for monocatecholate substrates epinephrine and norepinephrine for the study of their iron 
binding stoichiometries.410 The absorbance of solutions of iron(III)-Sal-n-LICAM (n= 4,5) 
of varying iron(III) : ligand ratios with a total concentration of 400 nM, were recorded. For 
the iron(III) complexes of Sal-4-LICAM, the λmax was observed to shift across the range of 
ratios, from around 492 nm to around 552 nm as iron(III) to ligand ratio was increased 
(Figure 86). The colour of the range of solutions transitioned from red to purple as the 
iron(III) to ligand ratio was increased, as would be expected from the shift in λmax in the UV-





Figure 86: Selected UV-Visible spectra of Sal-4-LICAM: iron(III) in the ratios as shown, 
with a final concentration of 400 nM. Spectra were recorded after 1 hour of equilibration. 
Vertical lines are shown at the λmax wavelengths. 
 
Figure 87: Photograph of sample vials of Sal-4-LICAM: iron(III) with highest ligand 
concentration to lowest ligand concentration from left to right, and highest iron(III) 
concentration to lowest iron(III) from right to left. 
Plotting the absorbance at 552 nm and 492 nm for each spectrum over the range of Sal-4-
LICAM: iron(III) ratios, gave the Job plot shown in Figure 88. The maximum absorbance at 
552 nm was at a 50:50 Sal-4-LICAM: iron(III) ratio, and at 492 nm was at a 60:40 Sal-4-
LICAM: iron(III) ratio. This indicated an equilibrium between a 1:1 species and a 3:2 species 
in solution. This is a similar set of equilibria to that observed for bisDHBS : iron(III), where 
exact speciation was confirmed by NMR, using gallium(III) as a diamagnetic replacement 





Figure 88: Job plot for Sal-4-LICAM: iron(III), with the x-axis showing the ratio of ligand 
to iron(III) in %. Absorbance data are plotted at 552 nm (purple triangles) and 492 nm (red 
circles) across the ratio range, showing a peak at a 50:50 Sal-4-LICAM: iron(III) ratio for 
absorbance at 552 nm, and a peak at 60:40 Sal-4-LICAM: iron(III) ratio for absorbance at 
492 nm. 
After 7 days, the spectra were recorded again, to establish whether equilibrium had been 
reached after 1 hour, or whether a slower equilibrium was present. For both wavelengths, 
552 nm and 492 nm, the maximum absorbance was achieved at a 60:40 ratio of Sal-4-
LICAM: iron(III) (Figure 89). This indicated that the 3:2 species predominated over time, 





Figure 89: Job plot for Sal-4-LICAM: iron(III) after 7 days, with the x-axis showing the ratio 
of ligand relative to the percentage of iron(III). Absorbance data are plotted at 552 nm 
(purple triangles) and 492 nm (red circles) across the ratio range, showing peaks at 60:40 
Sal-4-LICAM: iron(III) ratio for absorbance at 552 nm and 492 nm. 
The studies were then repeated with Sal-5-LICAM. The λmax, recorded across the same range 
of ratios, was shifted from around 495 nm to around 555 nm as iron(III) to ligand ratio was 
increased (Figure 90). A similar array of coloured solutions was observed across the range 






Figure 90: Selected UV-Visible spectra of Sal-5-LICAM: iron(III) in the ratios as shown, 
with a final concentration of 400 nM. Spectra were recorded after 1 hour of equilibration. 
Vertical lines are shown at the λmax wavelengths. 
 
Figure 91: Photograph of sample vials of Sal-5-LICAM: iron(III) with highest ligand 
concentration to lowest ligand concentration from left to right, and highest iron(III) 
concentration to lowest iron(III) from right to left. 
The Job plot showed a similar result to the iron(III) ligand speciation for Sal-4-LICAM, with 
a 1:1 and 3:2 species, shown by these ratios resulting in the maximum absorbance at each 
λmax wavelength of 555 nm and 495 nm respectively (Figure 92). After 7 days, the maximum 
absorbance at both λmax wavelength resulted from the 60:40 ratio of Sal-5-LICAM: iron(III), 





Figure 92: Job plot for Sal-5-LICAM: iron(III), with the x-axis showing the ratio of ligand 
as a percentage of total Sal-5-LICAM: iron(III). Absorbance data are plotted at 555 nm and 
495 nm, showing a peak at a 50:50 Sal-4-LICAM: iron(III) ratio for absorbance at 555 nm, 
and a peak at 60:40 Sal-4-LICAM: iron(III) ratio at 495 nm. 
 
Figure 93: Job plot for Sal-5-LICAM: iron(III) after 7 days, with the x-axis showing the ratio 
of ligand as a percentage of total Sal-5-LICAM: iron(III). Absorbance data are plotted at 555 
nm and 495 nm, showing a peak at a 50:50 Sal-4-LICAM: iron(III) ratio for absorbance at 




The similar λmax values of 492 nm and 552 nm for iron(III): Sal-4-LICAM and 495 nm and 
555 nm for iron(III): Sal-5-LICAM, with very similar Job plots, indicate that the difference 
in linker length between the two salmochelin mimics has very little effect on the iron(III) 
binding ratios of the species. For both iron(III): Sal-n-LICAM (n = 4, 5), initially there is an 
equilibrium of 1:1 and 3:2 Ligand: iron(III) species that have maximum absorbances at the 
corresponding Ligand: iron(III) ratios. This is similar to the equilibria present for iron(III) : 
bisDHBS and iron(III) : 4-LICAM.90, 322 After 7 days of equilibration, it appears that the 3:2 
becomes the major species, as the maximum absorbance at both wavelengths peaks with the 
3:2 ratio. It is unclear why a 3:2 ratio is favoured over 1:1, as it could be reasoned that the 
steric bulk of the glucose unit would disfavour close arrangement of three ligands around 
two iron(III) centres, when compared to the LICAM siderophores. As the ligands are not 
symmetrical, and have one glucose unit, it is likely that a number of geometric isomers exist 
in the 3:2 ratio, where the glucose units either align at a single iron(III) centre or alternate 
between the two centres.  
Salmochelin siderophores are known to have a reduced membrane partition coefficient when 
compared to their enterobactin equivalents.234 It may be that the hydrophilic nature of the 
glucose units, and their propensity to hydrogen bond in the water based buffer allows the 
ligands to form a favourable 3:2 arrangement with solvent exposed sugars somewhat 
shielding the aligned hydrophobic LICAM backbones. To explore this further it would be 
necessary to study a wider coordination sphere of the iron(III) centres, and particularly the 
role of hydrogen bonding of the glucose-containing ligands, to understand all interactions 
involved in complex assembly.411-413 
4.4 Circular Dichroism 
Co-crystallisation was tried for both iron(III)-Sal-n-LICAM (n = 4, 5) with CeuE, but 
unfortunately no crystals were obtained. It was therefore necessary to employ other methods 
to establish whether iron(III)-Sal-n-LICAM (n= 4, 5) were able to bind to CeuE.  
Sal-n-LICAM (n= 4,5) were studied by circular dichroism to identify whether there was any 
chiral preference of iron(III) complexes in solution. When complexed with iron(III) in a 1:1 
ratio, the circular dichroism signal remained close to the baseline for both Sal-n-LICAM (n= 
4,5) complexes in solution, indicating a lack of chiral preference (Figure 94).13 It is therefore 






Figure 94: Circular dichroism spectra for 50 mM iron(III)-Sal-4-LICAM and iron(III)-Sal-
5-LICAM in 0.11M Tris-HCl pH 7.5, 150 mM NaCl buffer. 
The salmochelin mimics Sal-n-LICAM (n= 4,5) were next studied for their potential 
interactions with CeuE by circular dichroism. CeuE induced a slight preference for the Λ-
configured complex of iron(III)-Sal-4-LICAM (Figure 95), indicating that there must be a 
CeuE-iron(III)-Sal-4-LICAM interaction in solution. Interestingly, CeuE induced a more 
significant preference for the Λ-configured complex of iron(III)-Sal-5-LICAM (Figure 95), 
with the larger magnitude suggesting higher binding affinity of CeuE for iron(III)-Sal-5-





Figure 95: Circular dichroism spectra of 50 mM CeuE, CeuE-iron(III)-Sal-4-LICAM and 
CeuE, iron(III)-Sal-5-LICAM in 0.11M Tris-HCl pH 7.5, 150 mM NaCl buffer. The spectra 
showed a small Λ-configurational preference upon introduction of CeuE to iron(III)-Sal-4-
LICAM, which increases upon introduction of CeuE to iron(III)-Sal-5-LICAM. 
The circular dichroism results suggested that CeuE did indeed interact with the synthesised 
salmochelin mimics iron(III)-Sal-n-LICAM (n= 4,5). To understand the interactions further, 
it was necessary to quantify the binding affinities of iron(III)-Sal-n-LICAM (n= 4, 5) with 
CeuE. 
4.5 Determination of Dissociation Constants 
CeuE-iron(III)-Sal-4-LICAM 
The standard fluorescence quenching titration method, Chapter 6, was employed to identify 
whether iron(III)-Sal-4-LICAM was able to bind to CeuE. The curves obtained were 
shallow, and a defined end-point was not reached, suggesting a weak binding affinity (Figure 
96). As such, any calculated dissociation constants were unlikely to be accurate to the true 





Figure 96: Fluorescence quenching titration curves for binding of iron(III)-Sal-4-LICAM to 
0.24 µM CeuE 40 mM Tris-HCl pH 7.5, 150 mM NaCl.  
 
Figure 97: Fluorescence quenching titration curve for binding of iron(III)-Sal-4-LICAM to 




Fluorescence quenching titrations were attempted at an increased CeuE concentration of 12 
µM (established as the upper permissible CeuE concentration in Chapter 3) to promote 
CeuE-iron(III)-Sal-4-LICAM complex formation, but similar a shallow curve was obtained, 
confirming weak binding. Because the dissociation constant could not be accurately 
quantified from fluorescence quenching titration, a circular dichroism titration method was 
developed. Primary inner filter effect caused by ligand absorbance at the excitation 
wavelength limits the maximum ligand concentration that is possible via fluorescence 
quenching titration (Chapter 3). Circular dichroism can be run at higher concentrations 
without such problems assuming the ligand does not absorb at the wavelength of interest, as 
was demonstrated in the featureless circular dichroism spectrum of iron(III)-Sal-4-LICAM 
in Figure 94. Complex formation is more favourable at higher protein and ligand 
concentrations, so this method allowed for sufficient  complex formation to produce an 
adequate binding curve.414, 415 The increase in signal observed upon additions of aliquots of 
CeuE to iron(III)-Sal-4-LICAM at 50 mM is shown in Figure 98. 330 nm was chosen as the 
wavelength to monitor, as the largest change in signal was observed in this region. Ellipticity 
at 330 nm was plotted against concentration to produce binding curves for triplicate titrations 
(Figure 99). 
 
Figure 98: Circular dichroism spectra for the titration of 50 µM iron(III)-Sal-4-LICAM in 
0.11M Tris-HCl pH 7.5, 150 mM NaCl with aliquots of CeuE in 0.11M Tris-HCl pH 7.5, 





Figure 99: Binding curves for three independent circular dichroism titrations of 50 µM 
iron(III)-Sal-4-LICAM in 0.11M Tris-HCl pH 7.5, 150 mM NaCl titrated with CeuE. 
Ellipticity at 330 nm was plotted against CeuE concentration. Non-linear regression fitting 
data was generated with Dynafit. 
From the three independent titrations, dissociation constants were calculated with their 
associated errors and then averaged using a weighted average calculation that is detailed in 
Chapter 6 (Table 13). The shapes of the obtained curves were more acceptable with a defined 
end-point, suggesting the concentration range used in the titration was more appropriate for 
promotion of complex formation than the lower concentration ranges used in the previous 
fluorescence titrations. This ensured that the data fitting and dissociation constant 
calculations were more likely to be accurate to the true value.414 The average Kd was 
calculated to be 15.6 µM ± 2.3 µM, a weak binding affinity compared to the low nanomolar 
dissociation constants observed for CeuE binding to iron(III)-n-LICAM (n =4, 5, 6, 8) 
siderophore mimics (Chapter 2). The binding affinity of CeuE to iron(III)-Sal-4-LICAM was 






Table 13: Dissociation constants for the binding of CeuE to iron(III)-Sal-4-LICAM 
calculated using Dynafit from circular dichroism titrations. 
CeuE-iron(III)-Sal-4-LICAM Kd /µM Error /µM 
Run 1 14.5 1.0 
Run 2 18.9 2.3 
Run 3 18.8 2.7 
Average 15.6 2.3 
 
CeuE-iron(III)-Sal-5-LICAM 
The dissociation constant for CeuE binding to iron(III)-Sal-5-LICAM was established by 
both fluorescence and circular dichroism titration techniques. First a standard fluorescence 
titration was used to estimate whether the binding was of high or low affinity. It was 
observed that CeuE binding to iron(III)-Sal-5-LICAM was likely not in the low nanomolar 
range seen for iron(III)-n-LICAM (n= 4, 5, 6, 8) siderophore mimics. This was assessed by 
obtaining a shallow binding curve without a defined end-point: suggesting weak binding 
(Figure 100). 
 
Figure 100: Binding curve for 0.24 µM CeuE in 40 mM Tris-HCl pH 7.5, 150 mM NaCl. 




As binding was weaker than the iron(III)-n-LICAM (n= 4, 5, 6, 8) series in Chapter 2, 
circular dichroism titrations were carried out in triplicate as for CeuE with iron(III)-Sal-4-
LICAM. The signal increased in magnitude with the addition of CeuE, as more iron(III)-Sal-
5-LICAM was converted to Λ-configured complex upon CeuE binding (Figure 101). 
 
Figure 101: Circular dichroism spectra for the titration of 50 µM iron(III)-Sal-5-LICAM in 
0.11M Tris-HCl pH 7.5, 150 mM NaCl with aliquots of CeuE. 
Ellipticity at 330 nm was recorded for each addition of CeuE, and binding curves constructed 
(Figure 102). The binding curve was steep, without many data points around the curved 
region, suggesting that binding was in fact tighter than expected. This caused problems upon 





Figure 102: Binding curves for three independent circular dichroism titrations of 50 µM 
iron(III)-Sal-5-LICAM in 0.11M Tris-HCl pH 7.5, 150 mM NaCl titrated with CeuE. 
Ellipticity at 330 nm was plotted against CeuE concentration. non-linear regression fitting 
data was generated with Dynafit. 
Table 14: Dissociation constants for circular dichroism titration of iron(III)-Sal-5-LICAM 
with CeuE. 
CeuE-iron(III)-Sal-5-LICAM Kd /nM Error /nM 
Run 1 340 110 
Run 2 140 130 
Run 3 225 81 
Average 240 127 
 
A fluorescence quenching titration method at lower concentration than that used for the 
circular dichroism titration was used in an attempt to capture a good binding curve with a 
defined end-point as well as an acceptable number of data points around the curved region. 




whereas the circular dichroism titration was run at a concentration of 50 µM. The second 
fluorescence quenching titration method was run at a more intermediate CeuE concentration 
of 2 µM, and gave a better set of binding curves (Figure 103).  
 
Figure 103: Binding curves for three independent fluorescence quenching titrations of 2 µM 
CeuE in 40 mM Tris-HCl pH 7.5, 150 mM NaCl with 100 µM iron(III)-Sal-5-LICAM in 40 
mM Tris-HCl pH 7.5, 150 mM NaCl. Non-linear regression fitting data was generated with 
Dynafit. 
The dissociation constants calculated from the fitted binding curves are given in Table 15. 
The average dissociation constant calculated by this fluorescence method is likely to be the 
better estimate, due to the increased number of data points in the curved region of the binding 




Table 15: Dissociation constants for 2 µM CeuE titrated with iron(III)-Sal-5-LICAM. 
CeuE-iron(III)-Sal-5-LICAM Kd /nM Error /nM 
Run 1 536 59 
Run 2 396 56 
Run 3 563 42 
Average 511 76 
 
The binding constants for the iron(III) bound salmochelin mimics iron(III)-Sal-n-LICAM (n 
= 4,5) to CeuE were quite different to each other depending on linker length of the LICAM 
backbone. The CeuE-iron(III)-Sal-4-LICAM had a binding constant of 15.6 µM ± 2.3 µM 
whereas that for CeuE-iron(III)-Sal-5-LICAM was much smaller, at 511 nM ± 76 nM, 
showing that iron(III)-Sal-5-LICAM bound around 30 times more strongly. Neither 
iron(III)-Sal-4-LICAM nor iron(III)-Sal-5-LICAM bound as tightly as the iron(III)-n-
LICAM siderophore mimics did. Iron(III)-5-LICAM with a Kd value of <10 nM bound at 
least 50 times more strongly than iron(III)-Sal-5-LICAM. This suggests that the appended 
glucose unit hinders binding to CeuE, and may not be well accommodated in the secondary 
binding pocket as predicted by computational modelling in section 4.1. It appears that the 
shorter linker length of iron(III)-Sal-4-LICAM particularly affects the fit of the glucose into 
the secondary binding pocket. As iron(III)-5-LICAM is known to bind most tightly to CeuE 
out of the whole n-LICAM (n= 4, 5, 6, 8) series, it could be that this linker length, closer to 
that of the natural siderophore, salmochelin S1 is predisposed for a more favourable fit of 
the glucosyl unit into the secondary binding pocket. 
Assuming Sal-5-LICAM is a good mimic for salmochelin S1, these findings suggest that 
while CeuE may be able to utilise this salmochelin S1 for iron uptake, it is unlikely that it is 
optimised for the uptake of this stealth siderophore. The affinity of non-functionalised 
iron(III)-n-LICAM siderophore mimics, and iron(III)-bisDHBS is much greater for CeuE 
than the salmochelin siderophore mimics, so it is likely that bisDHBS is the major 
siderophore used in CeuE iron(III) uptake. The fact that co-crystallisations of iron(III)-Sal-
n-LICAM (n= 4, 5) with CeuE were unsuccessful is likely due to the poor binding affinities 




4.6 Summary and Conclusion 
Salmochelin mimics Sal-4-LICAM and Sal-5-LICAM were successfully synthesised in 
overall yields of 5% and 6% respectively over 10 steps for each compound.  
The iron(III) binding ratios of each mimic were measured using a Job Plot. After 1 hour, 
there was an equilibrium of 1:1 and 3:2 ligand: iron(III) complexes in solution, and after 7 
days the 3:2 complex predominated for both linker lengths. These are similar to the iron(III) 
binding stoichiometries of 1:1 and 3:2 found for 4-LICAM and bisDHBS.90, 322 
When mixed with CeuE, each iron(III)-Sal-n-LICAM (n = 4, 5) complex was arranged in a 
majority Λ-configuration- proving that CeuE is able to bind both iron(III)-bound 
salmochelin S1 mimic compounds. This indicates that CeuE may be able to bind to 
salmochelin S1. Dissociation constants determined by both fluorescence quenching titration 
and circular dichroism titration showed that iron(III)-Sal-4-LICAM is bound around 30 
times more weakly than iron(III)-Sal-5-LICAM, while the latter is bound at least 50 times 
more weakly by CeuE than the non-C5-functionalised iron(III)-5-LICAM siderophore 
mimic, and the natural substrate iron(III)-bisDHBS. This probably indicates that although 
CeuE is able to bind the salmochelin mimic compounds, the periplasmic binding protein is 





4.7 Future Work 
Further efforts are needed to obtain crystal structures of the iron(III) bound salmochelin 
mimics in complex with CeuE. These would give information on the binding arrangement 
of the salmochelin mimics in the CeuE binding pocket, and provide insight into the potential 
role of the secondary binding pocket region of CeuE as predicted by computational 
modelling. Studying potential interactions of the salmochelin mimics with new regions of 
the binding cleft would help to further knowledge of CeuE function in C. jejuni iron-uptake. 
Building on the work in Chapter 2, longer linker length salmochelin mimics such as Sal-n-
LICAM (n = 6, 8) could be synthesised. The longer salmochelin compounds could then be 
tested for their iron(III) binding, and subsequent CeuE binding affinities. It would be 
interesting to see whether linker length influences the ability of the salmochelin mimic to 
position the glucosyl unit in the CeuE binding cleft. To prove whether the salmochelin mimic 
compounds iron(III)-Sal-n-LICAM (n = 4, 5) were indeed good mimics of natural 
Salmochelin S1, it would be necessary to repeat all studies with the natural siderophore that 
contains a serine backbone. To acquire salmochelin S1 it would be necessary to find a new 
supplier of the natural siderophore or to synthesise the compound. It may be possible to 
combine the synthetic knowledge gained in the synthesis detailed in section 4.2 with the 
syntheses of bisDHBS and the salmochelins documented in the literature.90, 396, 397 
Salmochelin S4 mimics could be synthesised based on vibriobactin, or the mimic MECAM. 
The proposed synthesis of salmochelin S1 could be extended to the synthesis of salmochelin 
S4. It would be interesting to study whether CeuE may bind hexadentate salmochelins, and 
compare the affinity with that of CeuE to iron(III)-enterobactin. 
With the identification of a family of tetradentate periplasmic binding proteins described in 
Chapter 3, it would be interesting to study other similar periplasmic binding proteins to 
establish whether any periplasmic binding proteins are able to bind the salmochelin mimics 
with higher affinity than CeuE. If periplasmic binding proteins were found that bound the 
salmochelin mimics with biologically relevant binding constants,185 then this would provide 
insight into the iron uptake capacities of range of species that are able to take advantage of 
tetradentate salmochelin siderophores. As iron uptake often has relevance in bacterial 
virulence, this knowledge may be of medical relevance for understanding the host 
colonisation of pathogenic species. This may provide information for the design of 
antibiotics and vaccines to specifically target such periplasmic binding proteins. Chapter 5 
addresses this area of study, and involves the investigation of the interactions of periplasmic 




5 Comparison of Three Enterobactin-Uptake Periplasmic 
Binding Proteins 
5.1 Introduction 
This chapter compares the type III periplasmic binding proteins involved in iron(III)-
enterobactin uptake from three gram-negative bacterial species that are known to cause 
gastric illness in the mammalian gut: CeuE from C. jejuni, FepB from Escherichia coli, and 
VctP from V. cholerae. As described in Chapter 1, all three species are known to have strains 
that cause diarrheal disease by production of enterotoxins.134, 135, 166, 167, 189, 416 Iron uptake is 
commonly known to be related to bacterial virulence,1, 30, 132, 193 so the strategies employed 
by the above pathogenic species may give an insight into their prevalence as infectious 
agents. As both pathogenic strains of E. coli and V. cholerae have been noted as species at 
risk of widespread antibiotic resistance, the resulting knowledge may prove useful for 
development of new design strategies for novel antimicrobials.134, 135, 417 In addition, the 
study aims to increase knowledge of PBP-iron(III)-siderophore combinations as potential 
candidates for the development of novel artificial metalloenzymes, with tight-binding 
siderophore complexes as anchors for attachment of inorganic catalysts.336, 356 
CeuE is named from a family of Ceu (Campylobacter Enterobactin Uptake) proteins, as it is 
generally accepted that these are involved in the direct uptake of iron(III)-enterobactin into 
the cytoplasm (Figure 104).115, 168, 172, 418  
 
Figure 104: Left: Enterobactin Right: iron(III)-enterobactin displayed as a 3-dimensional 
representation of the octahedral coordination.  
As it has been commonly reported that iron(III)-enterobactin is transported by the Ceu 
proteins into the cytoplasm before iron(III) release,159, 168 the CeuE- iron(III)-enterobactin 




(III)-enterobactin were previously reported.90 iron(III)-enterobactin had predominant Δ-
configuration in aqueous solution, but the equilibrium between Δ- and Λ-configured 
complexes was shifted to predominant Λ-configuration in the presence of CeuE. This 
indicated that there must be a CeuE- iron(III)-enterobactin interaction, and the Kd was 
estimated to be around 400 nM.90 Based on the high binding affinity of iron(III)-bisDHBS 
with CeuE, and the iron(III)-n-LICAM series discussed in Chapter 2, CeuE appears rather 
to be optimised for binding of the tetradentate enterobactin hydrolysis product instead of 
iron(III)-enterobactin.90, 310 This theory fits with the lack of an esterase capable of 
hydrolysing enterobactin, or a suitable reductase in the cytoplasm of C. jejuni.159  
FepB, the periplasmic binding protein in the FepABCDG (Ferric Enterobactin-binding 
Proteins) family of iron(III)-enterobactin uptake proteins in E. coli has been extensively 
studied and is known to bind iron(III)-enterobactin with high affinity.143-146 Fluorescence 
quenching titrations gave Kd values of between 30 and 170 nM.
144, 145 Whole cell binding 
assays using radioactive 55Fe(III) proved that FepB is required for delivery of iron(III)-
enterobactin to the inner membrane,143 and proteinase K digest assays showed that FepB is 
stabilised in the presence of iron(III)-enterobactin.145 The structure of FepB was first solved 
by NMR, and chemical shift perturbations were observed with the addition of gallium(III)-
enterobactin.145 The crystal structure of FepB in complex with iron(III)-enterobactin was 
subsequently solved.146 While the interpretation of the results in that study placed a large 
emphasis on the trimeric symmetry of FepB in the crystal structure,146 the trimer does not 
seem likely to be of biological relevance as there were no direct protein-protein contacts that 
would indicate that it is able to hold together at biological concentrations. A 1:1 relationship 
is observed in NMR and binding affinity experiments, and it is widely documented that a 
1:1 complex is required for delivery of iron(III)-siderophore complexes to the uptake 
machinery located in the cytoplasmic membrane,20, 145, 305, 419-422 Inspection of the binding 
pocket of FepB from the co-crystal structure (PDB ID: 3TLK) (Figure 105) reveals a 
complex array of binding interactions between amino acid residues in the FepB binding cleft 
and the iron(III)-enterobactin scaffold (Figure 106).146 These include hydrogen bonding to 
catechol oxygen atoms from Gly 126 (amide nitrogen) Arg 242 and Arg 301, hydrogen 
bonding to the backbone carbonyl oxygens from Arg78 and Thr200, and hydrogen bonding 
to the amide carbonyls from Thr 73 and Asn 77 (Figure 106). In addition, Trp 209 and Phe 
300 at the base of the binding cleft are likely to provide favourable hydrophobic interactions 
with the aromatic rings (Figure 106). The arginine residues, Arg 75, Arg 239 and Arg 298 




shares some similarities to that of CeuE, which contains a similar basic triad as discussed in 
Chapter 2.146, 186, 310 
 
Figure 105: A: Co-crystal structure of FepB (coral ribbons) with iron(III)-enterobactin in the 
binding cleft (cylinders coloured by atom type). B: stereo view of binding cleft of FepB 
(coral cylinders coloured by atom type, carbon in coral), showing all amino acids involved 
in binding of the enterobactin scaffold (cylinders coloured by atom type) (structure from 
PBD ID: 3TLK).146 Figure produced using CCP4mg.




Figure 106: Stereo view of the binding Cleft of FepB (cylinders coloured by atom type, with 
carbons in coral) with iron(III)-enterobactin bound (cylinders coloured by atom type). Top: 
Thr 73, Asn 77, Arg 78 and Thr 200 provide hydrogen bonds with the backbone and amide 
carbonyl oxygens. Middle: Gly 126 (backbone amide nitrogen) Arg 242 and Arg 301 provide 
hydrogen bonds to catechol oxygens. Bottom: Trp 209 and Phe 300 provide hydrophobic 
interactions (PDB ID: 3TLK).146 Figure produced using CCP4mg.  
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E. coli uses the hexadentate catecholate siderophore mimic MECAM for effective delivery 
of iron(III) for growth.423 Growth was hindered in the absence of the fepb gene product, 
indicating that FepB is required for MECAM uptake, and an E. coli reductase was shown to 
reduce iron(III) to iron(II) from iron(III)-MECAM.165, 423 Although many previous studies 
focussed on the iron(III)-enterobactin binding capacity of FepB, the ability of FepB to bind 
tetradentate catecholate siderophores such as iron(III)-bisDHBS remains largely unexplored. 
It was therefore of interest to investigate whether FepB is capable of binding both 
hexadentate (including iron(III)-MECAM) and tetradentate iron(III)-catecholate complexes. 
VctP is the periplasmic binding protein from the VctACDGP (Vibrio cholerae Transport) 
family of iron(III)-uptake proteins in V. cholerae.200, 201 VctP, contains  the conserved 
histidine and tyrosine residues known to be involved in iron(III)-siderophore binding in 
CeuE,186 and is known to interact with the ABC transporter VctDGC in the inner membrane 
of V. cholerae, reported for the transport of both iron(III)-enterobactin and iron(III)-
vibriobactin as discussed in Chapter 1.192 
The use of enterobactin hydrolysis products rather than the full cyclic trilactone for iron(III) 
uptake by V. cholerae is a topic of debate, with mixed results from growth studies of the 
species with enterobactin.202 It has been suggested that there may not be an enterobactin 
outer membrane receptor, due to the inability of the species to accumulate iron(III)-
enterobactin.206 In the studies where enterobactin uptake was reported, crude E. coli extract 
was used as an enterobactin source without purification, and the linear hydrolysis products 
were not discussed, suggesting possible enterobactin hydrolysis was not taken into 
account.192, 201 More recently, pure enterobactin was proven to be a poor iron(III) delivery 
source for growth of V. cholerae due to a lack of an outer-membrane receptor, as well as the 
lack of an esterase to degrade the trilactone backbone for iron(III) release once inside the 
cell.161 In contrast, iron(III)-bisDHBS and iron(III)-trisDHBS supported growth when taken 
up by both outer-membrane receptors VctA and IrgA- those previously reported for 
enterobactin uptake.161, 192 The structure of apo-VctP (PDB ID: 3TEF) was determined by 
protein crystallography, with high structural homology to CeuE as discussed in Chapter 3.209 
While there are no structures of VctP complexed with an iron(III)-bound ligand in the PDB, 
computational modelling of iron(III)-enterobactin into the binding cleft region of VctP has 
been attempted, using the coordinates from the apo crystal structure.161, 209 So far, no 
dissociation constants have been estimated for the binding of any iron(III)-ligands to VctP, 
so it was of interest to establish whether VctP is able to bind hexadentate and/or tetradentate 
iron(III)-catecholate siderophores as suggested in previous uptake studies, and measure 
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binding affinities of each iron(III)-siderophore for the protein. These studies aim to clear up 
the current confusion over the role of VctP in the use of iron(III)-enterobactin as an iron 
source for V. cholerae.161, 200, 201, 424 
Comparing the amino acid sequences of CeuE, FepB and VctP, it is obvious that the 
sequences are quite different (Figure 107). FepB only has 18.6% identity to CeuE, with 
35.1% similarity, and 23.1% identity to VctP with 35.4% similarity, as calculated using 
EMBOSS Needle.425 CeuE and VctP have slightly higher similarity to each other, and share 
25.3% identical and 47.6% similar residues.425 
 
Figure 107: Sequence alignment of FepB, CeuE and VctP using MUSCLE.426 Image 
produced with ESPript.427 Red blocks are totally conserved, red text indicates close matches 
or residues of similar properties.  
The overlaid crystal structures of the three proteins reveal high structural similarity (Figure 
108). CeuE and VctP are most similar, with r.m.s.d of 1.78 Å over 263 Cα positions and a 
100% match for secondary structure elements.317 Both contain conserved histidine and 
tyrosine residues in the binding cleft, as well as two conserved arginines, as discussed in 
Chapter 3. FepB has r.m.s.d of 3.29 Å over 238 Cα positions with CeuE with 80% match for 
secondary structure elements, and r.m.s.d of 3.27 Å over 226 Cα positions with VctP with 
79% match for secondary structure elements. FepB does not contain the conserved histidine 
or tyrosine in the binding cleft, and instead contains a flexible loop where the tyrosine would 
be, and an extended loop where the histidine would be (Figure 108). These differences 
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suggested that FepB may have different preferences in siderophore binding to CeuE and 
VctP, whereas the latter were expected to share a more similar siderophore binding profile. 
 
 
Figure 108: A: Overlay of Chain A of the structures of CeuE in lemon ribbons (PDB ID: 
3ZKW), FepB in coral ribbons (PDB ID: 3TLK) and VctP in lilac ribbons (PDB ID: 3TEF) 
via the SSM algorithm. B: Stereo view of the binding cleft region of CeuE and VctP: the 
conserved His and Tyr in CeuE and VctP are absent in FepB. Figure produced using 
CCP4mg. 




Figure 109: Hexadentate and tetradentate siderophores and mimic siderophores used to 
probe periplasmic binding protein accommodating ability. Protons shown in red are 
deprotonated upon iron(III) binding. 
To examine the binding abilities of each protein, a range of hexadentate and tetradentate 
siderophores and mimics were selected (Figure 109), and fluorescence quenching titration 
were used to quantify the binding affinities. As already described in Chapter 2, this was 
possible for CeuE due to the intrinsic fluorescence of Trp 276 adjacent to the iron(III)-
siderophore binding pocket region, that was quenched upon addition of iron(III)-
siderophore. This Trp residue is conserved in VctP, as seen in position 300 in the sequence 
alignment in Figure 107. This Trp provides a similar fluorescence quenching event upon 
addition of iron(III)-siderophore to VctP. FepB also contains a Trp adjacent to the Fe(III)-
siderophore binding pocket as shown in Figure 106C, providing fluorescence quenching 
upon addition of iron(III)-siderophore to FepB. As all three periplasmic binding proteins 
contained tryptophan adjacent to the iron(III)-siderophore region, all were compatible with 
the standard fluorescence titration method detailed in Chapter 6. 
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Circular dichroism was then used to assess binding modes, and the results were analysed for 
similarities and differences between the proteins based on binding cleft features, overall iron-
uptake strategies and biological roles of the native organism from which each protein was 
derived. Crystal structure determination was attempted via co-crystallisation of proteins and 
ligands.   
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5.2 Hexadentate Iron(III)-Siderophore Binding of CeuE 
A commercial sample was confirmed to be enterobactin by ESI-MS (Chapter 6), and HPLC 
(Figure 110). The maximum concentration of iron(III)-enterobactin that could be used in 
fluorescence quenching titrations was determined as 18.40 µM, as detailed in Chapter 6. 
 
Figure 110: HPLC trace of purchased enterobactin. The sample was analysed with a gradient 
of 10-80% acetonitrile in water over 35 minutes with 0.1% TFA throughout and a flow rate 
of 1 mL/min. The major peak at a retention time of 21 minutes correlates well with literature 
retention times for enterobactin.86, 87 
To test the hypothesis that enterobactin may not be the major substrate for CeuE, 
fluorescence quenching titrations were performed to quantify the binding affinity.90 Circular 
dichroism proved that there must be a CeuE iron(III)-enterobactin interaction, 90 while the 
fluorescence quenching titrations in the literature gave dissociation constants of limited 
accuracy as a true end-point was not achieved.90 The studies were therefore optimised and 
repeated to estimate a more accurate Kd. The first titration at a protein concentration of 240 
nM gave a shallow binding curve that did not reach a clear endpoint with five equivalents of 
iron(III)-enterobactin (Figure 111). The Kd for iron(III)-enterobactin binding to CeuE was 
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much larger than for the tetradentate analogues iron(III)-n-LICAM (n = 4, 5, 6, 8) as 
discussed in Chapter 2, or iron(III)bisDHBS.90  
 
Figure 111: Fluorescence quenching titration curves, as a plot of normalised fluorescence 
emission vs ligand concentration in µM for CeuE-iron(III)-enterobactin and their associated 
non-linear regression from Dynafit.326 CeuE at a concentration of 240 nM in 40 mM Tris-
HCl pH 7.5, 150 mM NaCl was titrated with aliquots of 12 M iron(III)-enterobactin- in 40 
mM Tris-HCl pH 7.5, 150 mM NaCl. 
Higher concentrations of protein and ligand were used in an attempt to drive the equilibrium 
towards protein-ligand complex formation.414 2.4 µM CeuE was titrated in triplicate with a 
total of seven equivalents of iron(III)-enterobactin and with a final ligand concentration of 
16.80 µM, a more pronounced binding curve was achieved (Figure 112), giving a  Kd of 3.5 
µM ± 0.3 µM (Table 16). This high Kd, around 10 times larger than the previous estimate of 
0.4 ± 0.1 µM,90 showed that CeuE bound iron(III)-enterobactin around 1000 times more 
weakly than iron(III)-5-LICAM. The CeuE-iron(III)-enterobactin binding affinity was at 
least 20 times, and probably over 100 times weaker than the literature values between 30 
and 170 nM for iron(III)-enterobactin binding to FepB.144, 145 




Figure 112: Fluorescence quenching titration curves, as a plot of normalised fluorescence 
emission vs ligand concentration in µM for CeuE-iron(III)-enterobactin and the model from 
Dynafit.326 CeuE at a concentration of 2.4 µM in 40 mM Tris-HCl pH 7.5, 150 mM NaCl 
was titrated with aliquots of 120 M iron(III)-enterobactin in 40 mM Tris-HCl pH 7.5, 150 
mM NaCl. 
Table 16: Kd values calculated for CeuE-iron(III)-enterobactin via fluorescence quenching 
titration and associated errors, giving a weighted average as detailed in Chapter 6. 
CeuE-iron(III)-Enterobactin Kd /µM Error /µM 
Run 1 3.79 0.19 
Run 2 3.66 0.12 
Run 3 3.09 0.15 
Average 3.5 0.3 
 
These findings confirm that CeuE is in fact not a dedicated enterobactin binding protein, as 
although it is able to bind this hexadentate siderophore weakly, it is far better adapted to bind 
the linear hydrolysis product iron(III)-bisDHBS.90 No crystal structure of CeuE-iron(III)-
enterobactin could be obtained via either co-crystallisation or soaking of apo CeuE crystals 
with an iron(III)-enterobactin solution which yielded only data for the native apo protein. 
This is probably because the binding affinity was too weak for adequate complex formation. 
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As previously reported, CeuE is able to bind to the enterobactin mimic iron(III)-MECAM in 
a 2:2:2 complex as observed via crystal structure, and observation of a Λ-configured 
complex in solution.187 To complete this study, the binding affinity of CeuE for iron(III)-
MECAM was measured. Fluorescence quenching titrations gave binding curves that yielded 
a Kd of 30 ± 11 nM (Figure 113) (Table 17), more in-keeping with the binding constants 
observed for iron(III)-n-LICAM (n= 4, 5, 6, 8) and iron(III)-bisDHBS than that of iron(III)-
enterobactin.90, 186 
 
Figure 113: Fluorescence quenching titration plots of normalised fluorescence emission vs 
ligand concentration in µM for CeuE-iron(III)-MECAM and the model from Dynafit.326 
CeuE at a concentration of 240 nM in 40 mM Tris-HCl pH 7.5, 150 mM NaCl was titrated 
with aliquots of 12 M iron(III)-MECAM- in 40 mM Tris-HCl pH 7.5, 150 mM NaCl. 
Table 17: Kd values for CeuE-iron(III)-MECAM from fluorescence quenching titration, with 
a weighted average calculated as detailed in Chapter 6. 
CeuE-iron(III)-MECAM Kd /nM Error /nM 
Run 1 44.7 1.8 
Run 2 10.1 2.0 
Run 3 34.7 2.5 
Average 30 11 
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5.3 FepB Expression and Purification 
FepB was produced and purified with the aid of Dr. E. V. Blagova (Chapter 6). The protein 
sequence for FepB was obtained for E. coli K strain MC1061 from Uniprot (code 
C6EKA3).428 Minimal disorder predictions were used to design a gene construct of 873 base 
pairs, spanning amino acids 27-318 of the full protein sequence (Figure 11).429 A similar 
construct of 27-320 was used for FepB in the published crystal structure (PDB ID: 3TLK).146  
 
Figure 114: Protein sequence for FepB from E. coli K strain MC1061 from Uniprot (code 
C6EKA3, residues 1-26 were predicted to be disordered (shown in a black box) and were 
removed to generate the construct 27-318. Image produced with ESPript.427 
Table 18: Primers used for amplification of the FepB gene. 






The desired protein sequence was converted to the necessary DNA sequence, and forward 
and reverse primers designed for amplification of the DNA via PCR (Table 18). The PCR 
product was inserted into the pET-YSBLIC3C vector, and the resulting plasmid was used to 
transform Competent Nova Blue cells for colony PCR. Plasmid DNA was harvested and 
external sequencing gave a 100% match to the target sequence. BL21 expression cells were 
then transformed with the plasmid DNA and cultured in 1% kanamycin LB media. The cells 
were induced with 1% IPTG upon reaching an OD600 of 0.6 and split into two portions for 
incubation for 4 hours at 37ºC or overnight at 16ºC. SDS PAGE analysis showed good 
overexpression of the target protein in both conditions, with a large proportion of soluble 
protein (Figure 115). The cultures were scaled to four portions of 500 mL, were induced 
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with 1% IPTG upon reaching an OD600 of 0.6, and incubated overnight at 16ºC. 
Overexpression of FepB was confirmed by SDS PAGE gel (Figure 116). 
 
Figure 115: SDS PAGE of test overexpression of FepB in BL21 cells. The bands of 
overexpressed protein are shown in a light blue box. FepB was present in both total and 
soluble fractions for cells cultured at both 37 and 16 ºC. 
 
Figure 116: SDS PAGE of overexpression of FepB in 500 mL cultures of BL21 cells. The 
band of overexpressed protein is shown in a light blue box. FepB was present in both total 
and soluble fractions for all four cultures. 
The cell pellet was collected via centrifugation of the cultures, and purified via nickel column 
chromatography. The protein was eluted over an imidazole gradient (Figure 117), and the 
fractions, confirmed to contain FepB by SDS PAGE (Figure 118) were combined for 
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histidine-tag cleavage with C3 protease. The resulting protein was purified via a second 
nickel column. The desired protein was collected in the fractions eluted before the imidazole 
gradient (Figure 118). The presence of FepB with cleaved histidine tag was confirmed via 
SDS PAGE analysis (Figure 120). 
 
Figure 117: UV-visible absorbance trace at 280 nm (black) for elution of FepB from nickel 
column over an imidazole gradient (blue) Elution volume from 114 mL to 170 mL was 
collected for the absorbance band observed at 280 nm. 




Figure 118: SDS PAGE analysis confirming the presence of FepB in fractions collected after 
nickel column chromatography. 4 mL fractions shown in the light blue box were collected 
and loaded in order of total elution volume. Lane 1: 32-36 mL, lane 2: 52-56 mL, lane 3: 
114-118 mL, lane 4: 118-122 mL, lane 5: 122-126 mL, lane 6: 130-134 mL, lane 7: 142-146 
mL, lane 8: 150-154 mL. All fractions were shown to contain FepB. 
 
Figure 119: UV-visible absorbance trace at 280 nm (black) for elution of crude FepB from 
second nickel column over an imidazole gradient (blue). Fractions from 2 mL to 68 mL were 
collected for the absorbance band observed at 280 nm. 




Figure 120: SDS PAGE of fractions after the second nickel column. Lane 1: tagged FepB, 
lane 2: crude untagged FepB. Untagged protein was confirmed in collected fractions of 
elution volume from 14 mL to 66 mL, lane 3: 14-18 mL, lane 4: 26-30 mL, lane 5: 62-66 
mL. There was no FepB present in the fractions after the imidazole gradient as shown in 
lanes 6: 108-112 mL,7: 116-120 mL. FepB fractions are highlighted in the light blue box. 
The fractions containing untagged FepB were pooled and purified by size exclusion 
chromatography. The fractions observed as the major peak in the chromatogram (Figure 
121) contained protein with a molecular weight estimated at around 35,000-40,000 Da, 
expected to be monomeric FepB. These fractions were collected, and the purity of the protein 
confirmed by SDS PAGE (Figure 122). Correct folding of the protein was established by 
circular dichroism (Figure 123).430, 431 The final pure protein, confirmed as monomeric FepB 
by ESI-MS, was estimated to be a total of 450 mg, and was concentrated to 60 mg    mL-1. 
The concentrated protein was stored at -80ºC until required. 




Figure 121: Chromatogram showing absorbance at 280 nm (black) for fractions collected of 
size exclusion chromatography of FepB. Fractions from elution volume 62 mL to 74 mL 
were collected, giving the major absorbance peak. 
 
Figure 122: SDS PAGE analysis of the collected fractions of FepB after size exclusion 
chromatography. Lane 1: crude FepB before size exclusion, pure FepB was confirmed in 
collected fractions by elution volume from 62 mL to 74 mL, lane 2: 46-50 mL, lane 3: 54-
58 mL, lane 4: 58-62 mL, lane 5: 62-66 mL, lane 6: 66-70 mL, lane 7: 70-74 mL, lane 8: 70-
74 (twice concentrated). Collected fractions are highlighted in the light blue box. 




Figure 123: Circular dichroism spectrum of 0.4 mg mL-1 FepB in 5 mM Tris-HCl pH 7.5.to 
confirm correct folding of the protein.   
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5.4 Iron(III)-Siderophore Binding of FepB 
Binding of FepB was assessed for both hexadentate and tetradentate iron(III)-bound 
siderophores. As expected, FepB bound to iron(III)-enterobactin with nanomolar affinity, 
producing three consistent binding curves giving a Kd of 24 ± 2 nM (Figure 124), concordant 
with literature value of ~30 nM (Table 19),144 providing validation of the fluorescence 
quenching titration method. FepB was shown to bind the hexadentate siderophore mimic 
iron(III)-MECAM with comparable affinity to iron(III)-enterobactin with a Kd of 28 ± 6 nM 
(Figure 125) (Table 19). Both hexadentate species were bound to FepB in the Λ-
configuration, as shown by the circular dichroism spectra (Figure 126). 
 
Figure 124: Fluorescence quenching titration curves for FepB iron(III)-enterobactin 
Fluorescence quenching titration curves, as a plot of normalised fluorescence emission vs 
ligand concentration in µM for FepB-iron(III)-enterobactin and the model from Dynafit.326 
FepB at a concentration of 240 nM in 40 mM Tris-HCl pH 7.5, 150 mM NaCl was titrated 
with aliquots of 12 M iron(III)-enterobactin- in 40 mM Tris-HCl pH 7.5, 150 mM NaCl. 




Figure 125: Fluorescence quenching titration curves for FepB-iron(III)-MECAM and the 
model from Dynafit.326 FepB at a concentration of 240 nM in 40 mM Tris-HCl pH 7.5, 150 
mM NaCl was titrated with aliquots of 12 M iron(III)-MECAM in 40 mM Tris-HCl pH 
7.5, 150 mM NaCl. 
Table 19: Kd values calculated for FepB-iron(III)-enterobactin and FepB-iron(III)-MECAM 




Kd /nM Error /nM Kd /nM Error /nM 
Run 1 25.3 1.6 37.5 5.1 
Run 2 23.4 2.0 27.0 2.9 
Run 3 23.5 1.2 24.5 3.2 
Average 24 2 28 6 




Figure 126: Circular dichroism spectra for FepB plotted as ellipticity in mdeg vs wavelength 
from 300 to 650 nm. The spectra were run for 50 µM FepB in 0.11M Tris-HCl pH 7.5, 150 
mM NaCl buffer with 50 µM iron(III)-enterobactin or iron(III)-MECAM as well as iron(III)-
enterobactin or iron(III)-MECAM at 50 µM in 0.11M Tris-HCl pH 7.5, 150 mM NaCl buffer 
without FepB. The spectra show the induction of the Λ-configuration upon introduction of 
FepB to each iron(III)-ligand. 
In contrast, tetradentate iron(III)-siderophores and siderophore mimics did not bind tightly 
to FepB. Circular dichroism proved that there was some weak interaction for iron(III)-4-
LICAM, iron(III)-5-LICAM and iron(III)-bisDHBS, as solutions of each ligand, with no 
preference for either Λ or Δ configured complexes, were converted to a Λ-configured 
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majority in the presence of FepB (Figure 127). The same was true for both salmochelin 
mimics, iron(III)-Sal-4-LICAM and iron(III)-Sal-5-LICAM (Figure 128). 
 
Figure 127: Circular dichroism spectra for FepB plotted as ellipticity in mdeg vs wavelength 
from 300 to 700 nm. The spectra are run for 50 µM FepB in 0.11M Tris-HCl pH 7.5, 150 
mM NaCl buffer with and without 50 µM iron(III)-n-LICAM (n = 4, 5) or iron(III)-bisDHBS 
ligands as well as the ligands at 50 µM in 0.11M Tris-HCl pH 7.5, 150 mM NaCl buffer 
without FepB. The spectra show the induction of Λ-configuration upon introduction of FepB 
to each iron(III)-ligand. 




Figure 128: Circular Dichroism spectra for FepB plotted as ellipticity in mdeg vs wavelength 
from 300 to 700 nm, using 50 µM FepB in 0.11 M Tris-HCl pH 7.5, 150 mM NaCl buffer 
with and without 50 µM iron(III)-Sal-n-LICAM (n = 4, 5) ligands as well as the ligands at 
50 µM in 0.11M Tris-HCl pH 7.5, 150 mM NaCl buffer without FepB. The spectra show 
the induction of the Λ-configuration upon introduction of FepB to each iron(III)-Sal-n-
LICAM (n = 4, 5). 
The standard fluorescence quenching titration method was employed in an attempt to 
quantify the binding affinities of each tetradentate siderophore or siderophore mimic with 
FepB, but shallow incomplete binding curves were obtained for all combinations. A titration 
was carried out with an equal volume of buffer to estabilish the decrease in fluorescence of 
FepB due to dilution and repeated exposure at the excitation wavelength. All five iron(III)-
tetradentate complexes gave a binding curve similar to or more shallow than this curve, 
suggesting that the binding affinities of the tetradentate iron(III)-siderophores were weak, 
and could not be quantified by this method. It was estimated that the Kd values were likely 
to be in excess of 1 µM.  
To extend the study, salmochelin S4 was purchased in an attempt to establish whether FepB 
was capable of binding the iron(III)-bound hexadentate stealth siderophore. Unfortunately, 
the sample was deemed unsuitable for use, as the presence of salmochelin S4 was not 
confirmed by ESI-MS and many different species were identified by analytical HPLC. 
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HPLC was run after 1 hour of equilibration of the sample in water and then again from the 
same sample after 24 hours (Figure 129). The chromatograms were very similar, with almost 
identical peak ratios, suggesting that salmochelin S4 was not slowly hydrolysing in aqueous 
solution, but rather that multiple stable species were already present in the sample. The 
literature suggested that salmochelin S4 was likely to elute after any hydrolysis products, at 
around 18 minutes, however the major peak eluted at around 7 minutes.235 
 
Figure 129: HPLC chromatograms showing multiple species present in the purchased 
salmochelin S4 sample. The sample in water containing 0.1% formic acid was injected with 
a 6-40% gradient of acetonitrile in water with 0.1% formic acid over 25 minutes. 
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5.5 Iron(III)-Siderophore Binding by VctP 
The VctPDGC uptake system was reported, via growth study analysis, to be capable of 
uptake of siderophore-free iron.201 It was decided therefore to assess whether VctP was 
capable of binding iron(III) from iron(III)-NTA the source of iron(III) used to form 
siderophore complexes in the fluorescence assay. The NTA (nitrilotriacetic acid) ligand was 
employed as a weak iron(III) chelating ligand, to prevent the formation of insoluble 
hydroxides, without affecting the results of the titration.95, 186, 432 
 
The binding curve upon titration of VctP with iron(III)-NTA showed a similar profile to that 
of a buffer dilution titration, suggesting that VctP did not bind iron(III) from the iron(III)-
NTA source with any measurable affinity. This suggested that the published growth studies 
may have contained an uncharacterised chelating agent that was able to deliver iron(III) to 
the VctPDGC system, or that an uncharacterised system is involved in free iron(III) transport 
in V. cholerae.201 This implied that any further fluorescence quenching of VctP observed 
upon addition of iron(III)-siderophores would be due to the binding of the whole iron(III)-
siderophore complex, rather than the iron(III)-siderophore complexes merely acting as a 
source of free iron(III). 
A standard binding curve showed quenching of VctP fluorescence by iron(III)-enterobactin, 
but did not reach a defined end-point, suggesting the binding was too weak to be quantified. 
Therefore, the concentration of both VctP and iron(III)-enterobactin were increased 10-fold, 
to promote complex formation.414 The experiment was repeated in triplicate, achieving 
binding curves with well-defined end-points (Figure 130) and gave an overall Kd of 369 ± 
25 nM (Table 20). This indicated weak binding compared to the previously observed low 
nanomolar affinities, and was around 12 times weaker than for FepB of around 30 nM.145 
Circular dichroism showed that Δ-configured iron(III)-enterobactin was however converted 
to an equilibrium containing a majority of Λ-configured complex in the presence of VctP 
(Figure 131). It must be noted that at 50 µM, the circular dichroism spectra were run at a 
concentration well above the recorded dissociation constant. 




Figure 130: Plot of normalised fluorescence emission vs ligand concentration in µM for 
VctP-iron(III)-enterobactin and the model from Dynafit.326 VctP at a concentration of 2.4 
µM in 40 mM Tris-HCl pH 7.5, 150 mM NaCl  titrated with aliquots of 120 M iron(III)-
enterobactin- in 40 mM Tris-HCl pH 7.5, 150 mM NaCl. 
Table 20: Kd values calculated for VctP-iron(III)-enterobactin via fluorescence quenching 
titration and associated errors, with a weighted average, as in Chapter 6. 
VctP 
Iron(III)-Enterobactin 
Kd /nM Error /nM 
Run 1 375 25 
Run 2 350 38 
Run 3 371 23 
Average 369  25 
 
  




Figure 131: Circular dichroism spectra for VctP plotted as ellipticity in mdeg vs wavelength 
from 300 to 700 nm for 50 µM VctP in 0.11M Tris-HCl pH 7.5, 150 mM NaCl buffer with 
50 µM iron(III)-enterobactin as well as iron(III)-enterobactin at 50 µM in 0.11M Tris-HCl 
pH 7.5, 150 mM NaCl buffer without VctP. The spectra show the induction of the Λ-
configuration upon introduction of VctP iron(III)-enterobactin, with a transition from a Δ-
configured ligand complex to a Λ-configured protein-ligand complex. 
Fluorescence quenching titrations were repeated for VctP with iron(III)-MECAM. The 
binding curve obtained was steep, with full quenching achieved at a 1:1 ratio of VctP to 
iron(III)-MECAM (Figure 132). As a result, there were not enough data points around the 
curved region of the plot for the data to provide an accurate Kd, indicating that iron(III)-
MECAM bound very tightly. In an attempt to obtain an adequate curve for fitting, the 
concentration of VctP and iron(III)-MECAM were decreased 5-fold, but this did not improve 
the curve (Figure 133). The concentrations were decreased by 20-fold, and a Dostal DOSY 
auto-titrating system was used to pipette 0.25 µL aliquots of ligand solution, to gain more 
data points around the 1:1 ratio region of the curve. Unfortunately, this method reached the 
limit of the detector of the fluorescence spectrometer, and the signal to noise ratio was too 
low to achieve accurate Kd values. Thus, the binding was estimated to be in the picomolar 
range, but could not be quantified.  
The experiments were repeated for VctP with iron(III)-bisDHBS, iron(III)-4-LICAM and 
iron(III)-5-LICAM and all were estimated to have a Kd in the picomolar range. In addition, 
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circular dichroism confirmed that iron(III)-bisDHBS, iron(III)-5-LICAM and iron(III)-4-
LICAM all bound to VctP with an induced Λ-configuration (Figure 134). 
 
Figure 132: Fluorescence quenching titration curve for VctP-iron(III)-MECAM and the 
model from Dynafit.326 VctP at a concentration of 240 nM in 40 mM Tris-HCl pH 7.5, 150 
mM NaCl was titrated with aliquots of 12 M iron(III)-MECAM- in 40 mM Tris-HCl pH 
7.5, 150 mM NaCl. 




Figure 133: Fluorescence quenching titration curve for VctP-iron(III)-MECAM and the 
model from Dynafit.326 48 nM VctP in 40 mM Tris-HCl pH 7.5, 150 mM NaCl was titrated 
with 2.4 M iron(III)-MECAM- in 40 mM Tris-HCl pH 7.5, 150 mM NaCl. 
 
Figure 134: Circular Dichroism spectra for VctP plotted as ellipticity in mdeg vs wavelength 
from 300 to 700 nm. The spectra were run for 50 µM VctP in 0.11 M Tris-HCl pH 7.5, 150 
mM NaCl buffer with and without 50 µM iron(III)-n-LICAM (n = 4, 5) and iron(III)-
bisDHBS ligands.  
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VctP was titrated with the salmochelin mimics iron(III)-Sal-4-LICAM and iron(III)-Sal-5-
LICAM. The standard method was used for quantification of the binding of iron(III)-Sal-4-
LICAM to VctP, and with a small extension to ensure a defined end-point, was used for 
iron(III)-Sal-5-LICAM. Satisfactory binding curves were achieved in triplicate for both 
ligands (Figure 135 and Figure 136) giving an average Kd of 7 ± 3 nM for VctP-iron(III)-
Sal-4-LICAM and 9 ± 3 nM for VctP- iron(III)-Sal-5-LICAM (Table 21). These results 
suggest that VctP is likely to be able to bind salmochelin S1 with high affinity, and V. 
cholerae is probably able to use the salmochelin stealth siderophores for iron(III)-uptake via 
the VctPDGC system.  
 
Figure 135: Fluorescence quenching titration curve for VctP-iron(III)-Sal-4-LICAM and the 
model from Dynafit.326 VctP at a concentration of 240 nM in 40 mM Tris-HCl pH 7.5, 150 
mM NaCl was titrated with aliquots of 12 M iron(III)-Sal-4-LICAM in 40 mM Tris-HCl 
pH 7.5, 150 mM NaCl. 




Figure 136: Fluorescence quenching titration curve for VctP-iron(III)-Sal-5-LICAM and the 
model from Dynafit.326 VctP at a concentration of 240 nM in 40 mM Tris-HCl pH 7.5, 150 
mM NaCl was titrated with aliquots of 12 µM iron(III)-Sal-5-LICAM in 40 mM Tris-HCl 
pH 7.5, 150 mM NaCl. 
Table 21: Kd values calculated for VctP-iron(III)-Sal-4-LICAM and VctP-iron(III)-Sal-5-
LICAM via fluorescence quenching titration and associated errors, with a weighted average, 
as in Chapter 6. 
VctP 
Iron(III)-Sal-4-LICAM Iron(III)-Sal-5-LICAM 
Kd /nM Error /nM Kd /nM Error /nM 
Run 1 3.4 1.5 10.5 1.7 
Run 2 6.5 1.4 11.7 1.6 
Run 3 10.0 1.3 4.7 1.9 
Average 7 3 9 3 
 
The circular dichroism spectra of both complexes showed an induced Λ-configuration upon 
complexation with VctP (Figure 137). As VctP contains histidine and tyrosine residues 
equivalent to those in CeuE, it is likely that the Λ-configured binding mode between 
iron(III)-bound tetradentate siderophores is similar in VctP and CeuE.90, 310  




Figure 137: Circular Dichroism spectra for VctP plotted as ellipticity in mdeg vs wavelength 
from 300 to 700 nm. The spectra were run for 50 µM VctP in 0.11M Tris-HCl pH 7.5, 150 
mM NaCl buffer with and without 50 µM iron(III)-Sal-n-LICAM (n = 4, 5) ligands. The 
spectra show the induction of Λ-configuration upon introduction of VctP to each iron(III)-
Sal-n-LICAM (n = 4, 5). 
Crystal structure determination of iron(III)-Sal-5-LICAM with VctP was unsuccessful. 
Crystals of apo VctP provided good diffraction data, however as the structure was already 
solved and deposited (PDB ID: 3TEF), it was decided unnecessary to pursue further structure 
solution. Although crystals of apo VctP when soaked with iron(III)-Sal-5-LICAM took on a 
purple colour, indicating uptake of the iron(III)-complex, the crystals did not diffract 
adequately for structure solution. Further screening of crystal conditions is needed if a 3D 
structure with a tetradentate ligand is to be achieved. 




Figure 138: VctP crystals soaked with iron(III)-Sal-5-LICAM.  
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5.6 Comparison of FepB, CeuE and VctP iron(III)-siderophore binding 
Although FepB CeuE and VctP have all been reported to be enterobactin uptake periplasmic 
binding proteins,115, 144, 192 the binding profiles of iron(III)-siderophores and iron(III)-
siderophore mimics, and the associated affinities are quite different (Table 22). Dissociation 
constants range from micromolar affinities for iron(III)-salmochelin mimics binding to 
CeuE, to picomolar affinities for iron(III)-MECAM, iron(III)-n-LICAM (n= 4, 5) and 
iron(III)-bisDHBS binding to VctP. All combinations of ligand and protein do however 
produce Λ-configured complexes as proven by circular dichroism. 
Table 22: Dissociation constants for periplasmic binding proteins with iron(III)-siderophores 
and iron(III)-siderophore mimics. Dissociation constants taken from the literatures are 
referenced. 
Iron(III)-Ligand FepB Kd /nM CeuE Kd /nM VctP Kd /nM 
Enterobactin 24 ± 2 3500 ± 300 369 ± 25 
MECAM 28 ± 6 30 ± 11 <1 
bisDHBS >1000 10 ± 4 (lit.90) <1 
4-LICAM >1000 21 ± 6 (lit.310) <1 
5-LICAM >1000 <10 (lit.310) <1 
Sal-4-LICAM >1000 15600 ± 2300 7 ± 3 
Sal-5-LICAM >1000 511 ± 76 9 ± 3 
 
FepB: Hexadentate vs Tetradentate 
FepB is optimised for binding of the hexadentate siderophore iron(III)-enterobactin, with 
nanomolar affinity, as previously reported,143-145 and can bind the iron(III)-MECAM 
siderophore mimic with similar high affinity. In contrast, FepB has only weak affinity for 
tetradentate siderophores, which suggests that three catecholate units are required for tight 
binding of iron(III)-catecholate complexes. As E. coli has the cytoplasmic reductase YqjH, 
capable of reduction of iron(III)-enterobactin, it is logical that the hexadentate siderophore 
is taken up into the cytoplasm by the FepBCDG system, given that there is minimal 
hydrolysis of the trilactone in the extracellular matrix in the timescale before iron(III) 
sequestration.163 The outer membrane receptors Fiu and Cir are known to be involved in the 
uptake of iron(III)-linear hydrolysis products iron(III)-trisDHBS, iron(III)-bisDHBS and 
iron(III)-DHBS, so it is likely that a completely separate set of uptake proteins, possibly 
involving IroC, are required for cytoplasmic transport of tetradentate catecholate 
siderophores in E. coli.152, 157, 160 
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CeuE: Tetradentate vs Hexadentate 
In contrast to FepB, CeuE is optimised for tight binding of the tetradentate siderophore 
iron(III)-bisDHBS, and binds the iron(III)-n-LICAM siderophore mimics with nanomolar 
affinity (Table 22).90, 310 It is not optimised for binding of salmochelin mimics as much larger 
dissociation constants were achieved with these tetradentate iron(III)-siderophore mimics, 
and is unlikely to be involved in salmochelin S1 uptake. Interestingly CeuE binds iron(III)-
MECAM with comparable nanomolar affinity to FepB, but has only micromolar affinity for 
iron(III)-enterobactin. It would be of interest to take this study further to establish why CeuE 
can bind tightly to iron(III)-MECAM but not iron(III)-enterobactin, and whether the 
hexadentate binding mode of CeuE in solution resembles the binding mode established for 
FepB. 
VctP: Tetradentate and Hexadentate 
VctP has strikingly high affinity for almost all iron(III)-siderophores and siderophore mimics 
tested, with several tetradentate complexes having picomolar dissociation constants (Table 
22). The weakest binding affinity was for iron(III) enterobactin, 369 ± 25 nM, in the mid-
nanomolar range, but still of possible biological relevance.185, 308 That VctP binds both 
hexadentate and tetradentate iron(III)-siderophores may explain the confusion in the 
literature as to whether the VctACDGP system is able to uptake iron(III)-enterobactin or its 
hydrolysis products.161, 200, 201 VctP has very high affinity for the linear hydrolysis product 
iron(III)-bisDHBS, and weaker affinity for iron(III)-enterobactin, but may ultimately be able 
to use either siderophore. With picomolar affinity, it would be of interest to see whether 
iron(III)-bisDHBS can indeed be released from VctP for cytoplasmic uptake of the iron(III)-
complex, or whether the siderophore is too tightly bound to the protein. V. cholerae is able 
to survive in aquatic environments, in fish, crustaceans, zooplankton and as biofilms, as well 
as colonising humans, and an adaptable iron(III)-uptake system may enable survival in such 
a wide range of environments.190, 191, 200, 433 The fact that VctP is able to bind a wide range 
of siderophores with high affinity may be related to the persistence and virulence of V. 
cholerae.132, 190, 193 
Features Favouring Tetradentate Siderophore Binding 
E. coli is the only species of the three that synthesises enterobactin. While C. jejuni and V. 
cholerae do not synthesise enterobactin, it is apparent that their periplasmic binding proteins 
can bind the iron(III)-bound linear hydrolysis products, but are less optimised for uptake of 
the full trilactone.  
Chapter 5  
 
223 
The differences in binding affinities of FepB, CeuE and VctP can be explained by differences 
in the siderophore binding clefts. FepB lacks the histidine and tyrosine residues conserved 
in CeuE and VctP (Section 5.1) that are fundamental to chelation of iron(III) to complete 
hexadentate coordination when a tetradentate siderophore is present.90, 186, 310 In solution, 
iron(III) complexes of tetradentate siderophore complexes are either in the biscatecholate 
1:1 form with two coordination sites filled with coordinating solvent, or in the triscatecholate 
2:3 triple helicate form.90, 260, 322 The 2:3 complex is too large to be accommodated in the 
FepB binding pocket, however, the 1:1 complex with only two catecholate units around the 
iron(III) centre, would need to employ water molecules from the surrounding solvent to fulfil 
octahedral co-ordination. Without direct coordination from the protein by a histidine and 
tyrosine (or equivalent side chains), the tetradentate siderophores can only bind weakly in 
the FepB binding pocket. Inspection of the published crystal structure of FepB-iron(III)-
enterobactin (PDB ID: 3TLK), reveals that key hydrogen bonding residues Gly126, Arg242 
and Arg301 chelate the catecholate oxygens of enterobactin with multiple hydrogen bonds 
in a specific orientation, allowing the accommodation of the full triscatecholate as described 
in section 5.1 (Figure 106).Without the potential for direct iron(III)-coordination from FepB, 
it is clear that the binding cleft is not optimised for tetradentate siderophores.  
Scavenger Versus Exporter Species 
For C. jejuni and V. cholerae to take advantage of enterobactin that is exported by species 
such as E. coli, these scavenger species may not encounter fresh enterobactin unless they are 
in close proximity to the exporter species. In addition, direct competition with the exporter 
species for one specific siderophore is a much greater challenge than utilising the full range 
of hydrolysed siderophore products. 
The preference of CeuE for iron(III) tetradentate catecholate siderophores over hexadentate 
enterobactin may exist in C. jejuni as the species relies entirely on exogenous siderophores, 
and produces no siderophores of its own.115, 168, 172 Enterobactin is known to possess a degree 
of aqueous instability, and it may be advantageous for C. jejuni to acquire the more stable 
tetradentate hydrolysis product as well as enterobactin.86, 87  In addition, iron(III) release via 
a reductase in the cytoplasm from the linear hydrolysis products is likely to be more efficient 
than from iron(III)-enterobactin which has a very low redox potential of E1/2= -750 mV.
28, 
55, 56, 72, 163, 434 If the majority of available iron(III)-enterobactin is first hydrolysed in the 
periplasm of C. jejuni, by the known trilactone esterase Cee, then the hydrolysis product 
iron(III)-bisDHBS will readily bind to CeuE for transport into the cytoplasm.90, 159 This 
means that only one ABC transporter system CeuBCDE is required for uptake of iron(III) 
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into the cytoplasm from all enterobactin-derived sources.159 As bisDHBS is a lower 
denticity, less entropically favoured siderophore for iron(III)-chelation than enterobactin, 
iron(III) release should be more efficient from this complex when in the cytoplasm.73, 163, 261  
V. cholerae, as both a siderophore exporter and scavenger species, has the periplasmic 
binding protein VctP with similarities to both FepB and CeuE – which is able to bind both 
iron(III)-enterobactin and iron(III)-bisDHBS with biologically relevant affinities, allowing 
for maximum iron(III) sequestration. Based on the crystal structure of VctP (PDB ID: 3TEF) 
with very high structural similarity to CeuE, it is likely that His 248 and Tyr 310 directly 
coordinate the iron(III) centre when binding tetradentate complexes, and this provides very 
high binding affinity. The fact that VctP also seems to bind iron(III)-enterobactin with a 
medium-strength affinity may be due to the fact that V. cholerae produces its own 
hexadentate catecholate siderophore vibriobactin as well as scavenging iron(III)-
enterobactin.202 Vibriobactin is comprised of an amide bonded backbone, so cannot be 
hydrolysed by an esterase in the same way as enterobactin.84 Hence, the full hexadentate 
siderophore is taken up into the cytoplasm, and the iron released by the action of the 
reductase ViuB, which means that V. cholerae is already tuned for the uptake of hexadentate 
siderophores into the cytoplasm. 
 
Although the ViuACDGP system is known for vibriobactin uptake, it has been shown that 
the VctACDGP system can also be employed, and the same is true for iron(III)-enterobactin 
derivatives. Thus, there is a degree of flexibility in the catecholate iron uptake machinery in 
V. cholerae. Examination of the structure of ViuP in complex with vibriobactin reveals 
structural similarities to VctP, with an r.m.s.d. of 3.21 Å over 228 residues.208 There are a 
number of residues that are involved in vibriobactin binding, including arginines and 
hydrophobic phenylalanines. Interestingly, histidine and tyrosine residues are located on two 
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nearby flexible loops which may function in the binding of lower denticity iron(III)-
siderophore complexes. Further work is needed to study the mechanisms of VctACDGP and 
ViuACDGP for internalisation of iron(III)-enterobactin and the linear hydrolysis 
products.208 
 
Figure 139: A: Overlay of VctP (lilac ribbons) with ViuP (dark purple), the vibriobactin 
binding PBP from V. cholerae. B: Stereo view of vibriobactin (cylinders coloured by atom 
type) in the binding cleft, and residues involved in binding (cylinders coloured by atom type 
with carbon in dark purple). C: Stereo view of neighbouring His 239 and Tyr 146 (cylinders 
coloured by atom type with carbon in dark purple) that may be involved in binding of lower 
denticity siderophore complexes (PDB ID: 3R5T).208 Figure produced using CCP4mg. 
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MECAM as a Mimic for Enterobactin 
The fact that CeuE and VctP are able to bind iron(III)-MECAM with high affinity, but have 
a comparatively weak affinity for iron(III)-enterobactin suggests that MECAM is not a 
suitable mimic for enterobactin in these cases. Overlaying the coordinates for iron(III)-
enterobactin from the FepB-iron(III)-enterobactin crystal structure (PDB ID: 3TLK) into the 
CeuE binding pocket of the CeuE-iron(III)-MECAM crystal structure (PDB ID: 2CHU) 
shows no structural reason why iron(III)-enterobactin has weak binding affinity for CeuE.146, 
187 The catecholamides overlay well with the hexadentate iron(III)-MECAM arrangement 
(r.m.s.d of 1.83 over 33 atom positions), and the trilactone backbone would not cause steric 
clashes with the protein scaffold (Figure 140). 
 
 
Figure 140: Stereo view of the overlay of CeuE-iron(III)-MECAM crystal structure (PDB 
ID: 2CHU) with coordinates for iron(III)-enterobactin from FepB-iron(III)-enterobactin 
crystal structure (PDB ID: 3TLK). Iron(III)-enterobactin in shown in cylinders coloured by 
atom type with carbon in yellow. Iron(III)-MECAM is shown in cylinders coloured by atom 
type with carbon in white. A: The catecholamide units of each ligand superposed atom by 
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atom. B: CeuE is depicted in surface view, coloured by electrostatic potential.146, 187 Figure 
produced using CCP4mg. 
As there is no obvious structural reason why CeuE would oppose hexadentate iron(III)-
enterobactin binding, it may be that a different binding mode is preferred in solution. There 
are two possible suggestions for how a hexadentate iron(III)-complex may bind with CeuE 
or VctP. Either the protein binds the hexadentate structure by folding the histidine and 
tyrosine residues out of the way of the complex, or the complex may give up one bidentate 
unit to allow for the histidine and tyrosine to coordinate the iron(III) centre. The reason for 
such differences in affinity between iron(III)-enterobactin and iron(III)-MECAM are 
therefore likely to be entropic, and may lie in the structure of each hexadentate compound 
before iron(III) binding. From computational modelling, it has been suggested that 
enterobactin has all three catechol units organised on the same face of the trilactone 
backbone, due to the presence of a hydrogen bond network (Scheme 16).62, 64, 435-437 This 
preorganised structure enables a very high affinity iron(III) complex as discussed in Chapter 
1. For MECAM, there are fewer hydrogen bonds, and the planar aromatic backbone does 
not force pre-orientation of all three catechols towards one face. This property results in a 
weaker iron(III) binding affinity, but may allow MECAM to form a tetradentate binding 
mode, with one catechol unit folded away from the iron(III) centre, as is observed in the 
CeuE-iron(III)-MECAM crystal structure (PDB ID: 2CHU), where a 2:2:2 complex is 
achieved with each MECAM forming one tetradentate interaction and one bidentate 
interaction with the iron(III) centres (as discussed in Chapter 1).187 This could mean that the 
iron(III)-MECAM complex is able to allow for His and Tyr to coordinate to the iron(III) 
centre more readily than iron(III)-enterobactin, which may explain the differences in binding 
affinity for each complex with both CeuE and VctP (Scheme 17). Further crystal structure 
determination may help to explain whether this hypothesis is accurate.  




Scheme 16: Enterobactin has all catechol units organised on one face of the trilactone 
backbone before iron(III)-binding. Potential hydrogen bonds are shown in blue, and those 
involved in preorganisation are shown in red. 
 
Scheme 17: MECAM does not have a preorganised structure before iron(III)-binding 
(hydrogen bonds shown in blue) so may be able to adopt a tetradentate binding mode more 
easily in the CeuE or VctP binding clefts, by folding one catechol unit away from the 
iron(III) centre, allowing coordination of His and Tyr. 
Salmochelin S1 mimics 
Neither CeuE or FepB bound the salmochelin mimics iron(III)-Sal-4-LICAM or iron(III)-
Sal-5-LICAM tightly, with the lowest Kd achieved by CeuE with iron(III)-Sal-5-LICAM at 
511 ± 76 nM: at least 50 times weaker than the non-functionalised iron(III)-5-LICAM 
equivalent. The fact that FepB does not have high affinity for the salmochelin mimics is 
probably because the mimics are tetradentate, and FepB is optimised for the binding of 
hexadentate siderophores. It would be of interest to establish whether FepB can bind 
salmochelin S4 or a suitable hexadentate mimic. As E. coli is known to synthesise 
salmochelin S4, there must be dedicated iron(III)-salmochelin uptake machinery, whether 
this is the FepBCDG system, the IroC system or another.157, 235, 236 As CeuE is optimised for 
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binding tetradentate siderophores, it is more likely that the salmochelin mimics cannot be 
bound by CeuE with high affinity due to a steric clash of the glucose unit with protein 
residues adjacent to the siderophore binding cleft, indicating CeuE is unlikely to be 
optimised for uptake of salmochelin S1. As salmochelin S4 is known to support growth of 
C. jejuni, this suggests there is another yet uncharacterised system capable of iron(III)-
salmochelin import.182 
Interestingly, VctP bound the tetradentate salmochelin mimics with high affinity, indicating 
that the appended glucose unit does not cause significant steric clashes within the binding 
cleft, suggesting that the VctCDGP system may be capable of cytoplasmic uptake of 
iron(III)-salmochelin S1. This is the first indication that V. cholerae may be able to take 
advantage of salmochelin stealth siderophores. Salmochelins have been proven not to bind 
to siderocalin, as detailed in Chapter 1, and are synthesised and exported by E. coli for this 
purpose, to provide a method of iron uptake that evades the immune response of the host.218, 
236 As the main siderophores of V. cholerae, enterobactin and vibriobactin, are both 
sequestered by siderocalin,84, 220, 223 the potential use of salmochelin S1 by V. cholerae may 
be key to virulence of the species.158, 225 
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5.7 Summary and Conclusion 
E. coli synthesises and exports enterobactin, and then imports the intact cyclic iron(III)-
bound enterobactin via the Fep system, where it is bound with nanomolar affinity by FepB, 
in a Λ-configured binding mode. FepB is unable to bind the tetradentate iron(III)-bisDHBS 
linear hydrolysis product of enterobactin with high affinity, and has similar weak affinities 
for tetradentate siderophore mimics of both iron(III)-bisDHBS and iron(III)-salmochelin S1. 
This suggests that the Fep system is optimised for uptake of hexadentate iron(III)-
enterobactin rather than the linear hydrolysis products. The linear hydrolysis products are 
likely to be taken up by a separate set of uptake proteins, starting with the outer membrane 
receptors Fiu and Cir.152, 160 
C. jejuni appears to utilise enterobactin in a different way to E. coli. Instead of taking up the 
full hexadentate iron(III)-enterobactin, into the cytoplasm, CeuE is much better optimised 
for the binding of iron(III)-n-LICAM (n= 4, 5) and iron(III)-bisDHBS.90 It is likely that 
iron(III)-bisDHBS is acquired by C. jejuni from its environment, or iron(III)-enterobactin is 
first hydrolysed in the periplasm by the esterase Cee.159 This strategy can be rationalised by 
the fact that C. jejuni does not produce its own source of enterobactin, but scavenges from 
its environment. To maximise iron(III)-uptake from enterobactin sources, it is most efficient 
to be able to process the hydrolysis products as well as the full trilactone. Interestingly, CeuE 
is also able to bind the hexadentate siderophore mimic iron(III)-MECAM with low 
nanomolar affinity. This suggests that MECAM is not an adequate mimic of enterobactin, 
as the interaction of the two species with CeuE must be significantly different to produce 
such different dissociation constants. This raises a question as to whether CeuE may be able 
to bind other hexadentate catecholate siderophores or siderophore mimics with high affinity, 
and whether this finding is of biological relevance. Results from salmochelin mimic studies 
suggests that CeuE may not be optimised for salmochelin S1 binding.  
V. cholerae appears to be able to use enterobactin in both hexadentate and tetradentate forms. 
Since V. cholerae does not produce but scavenges enterobactin, and VctP contains the 
conserved histidine and tyrosine residues present in CeuE for iron(III)-chelation of 
tetradentate siderophore complexes, it is likely that VctP and CeuE are both optimised for 
tetradentate siderophore binding in a similar manner. Studies with salmochelin mimics make 
the first suggestion that the VctPDGC uptake system may be involved in the uptake of 
iron(III)-salmochelin S1. Such an adaptable iron(III)-siderophore binding periplasmic 
binding protein as VctP is likely a factor in the success of V. cholerae as a particularly 
persistent pathogen.  
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5.8 Future Work 
To further the salmochelin studies, the binding affinities of each periplasmic binding protein 
with the natural salmochelin S1 and salmochelin S4 should be measured. FepB may bind to 
iron(III)-salmochelin S4, since the glucosylated siderophore is known to be synthesised by 
E. coli, and although the salmochelins are known to support growth, there is currently no 
known dedicated cytoplasmic uptake system for salmochelin S4.138, 232, 235 It is necessary to 
establish whether the Fep system is responsible for uptake of iron(III)-salmochelin S4, 
whether there is an uncharacterised alternative set of uptake proteins, or whether salmochelin 
uptake first relies on periplasmic hydrolysis by IroE before cytoplasmic uptake of iron(III)-
salmochelin hydrolysis products. It would then be important to establish the binding affinity 
of iron(III)-salmochelin S4 with CeuE to determine whether the binding affinity is weak like 
that of iron(III)-enterobactin, or whether binding is tighter, similar to that of iron(III)-
MECAM. Extending the study to VctP would reveal whether the protein can bind both 
hexadentate and tetradentate salmochelin complexes, equivalent to its binding of iron(III)-
enterobactin and iron(III)-bisDHBS. Finally, studying each periplasmic binding protein with 
Salmochelin S1 would prove whether Sal-4-LICAM and Sal-5-LICAM make good mimics 
of this siderophore. If it again proved impossible to source salmochelin S4, then a synthetic 
mimic could be designed and synthesised. The same chemistry as employed in Chapter 4 
could be used for the installation of the necessary C5 β-ᴅ-glucose unit onto a catechol unit, 
and then amide bonds to a scaffold based on that of MECAM could be used to produce a 
hexadentate salmochelin S4 mimic. 
Growth studies with the tightest binding siderophores would establish whether the binding 
of iron(III)-siderophores to the periplasmic binding proteins are biologically relevant. It 
would be useful to establish whether the species could use the synthetic siderophore mimics 
as effective sources of iron(III) for uptake and growth. Since the dissociation constants of 
the tetradentate siderophores are in the picomolar range for VctP, this interaction may be too 
strong for effective delivery of iron(III) into the cytoplasm for release. If these siderophores 
instead block the periplasmic binding protein from being able to transport iron(III), this 
would be of interest for development of antimicrobial agents.  
Further efforts are required to co-crystallise iron(III)-siderophores and mimics with each 
periplasmic binding protein. As the binding mode of iron(III)-siderophores with VctP is 
currently unknown, with only an apo structure of the protein known (PDB ID: 3TEF), these 
structures would be of greatest interest. The structural explanation as to how VctP binds 
tetradentate n-LICAM and bisDHBS siderophores, as well as how the protein can 
Chapter 5  
 
232 
accommodate a C5 appended glucose unit in an adjacent binding cleft, would be particularly 
informative. Comparison of these structures with that of VctP bound to iron(III)-
enterobactin, would establish the differences in binding modes, and suggest structural 
rearrangements of the protein that might be required to switch between tetradentate and 
hexadentate binding modes. These binding modes could then be compared to those of FepB 
and CeuE. It would also be important to co-crystallise FepB with MECAM to establish 
whether it binds with a similar binding mode to iron(III)-enterobactin. Those iron(III)-
siderophore complexes that proved to have weak interactions with the associated periplasmic 
binding protein, such as FepB with the tetradentates, or CeuE with iron(III)-enterobactin 
would also be of interest to study via crystallography, however the weaker binding affinities 
may continue to prove challenging for obtaining the necessary co-crystals. 
The range of siderophores studied could be expanded. For example, it may be of interest to 
study other tetradentate catecholate siderophore such as serratiochelin or the amonabactins, 
to establish whether C. jejuni and/or V. cholerae are capable of poaching siderophores from 
a wider range of bacterial siderophore exporter species. The hexadentate linear enterobactin 
hydrolysis product trisDHBS would be a key siderophore to study, as this would allow the 
determination of whether the linear or cyclic nature of the siderophore or the denticity is key 
to recognition by each periplasmic binding protein. In addition, it would be interesting to 
establish the role of vibriobactin in V. cholerae by assessing the binding of iron(III)-
vibriobactin with VctP, as well as studying ViuP with enterobactin and the hydrolysis 
products. A study of whether C. jejuni can poach vibriobactin would require investigation if 
CeuE can bind iron(III)-vibriobactin. As vibriobactin has structural similarities to the 
hexadentate siderophore mimic MECAM, it could be that CeuE binds this hexadentate 
siderophore with high affinity. In addition, bidentate analogues such as DHBS could be 
studied to establish their role in bacterial iron(III) chelation and uptake. 
The project could be expanded to include more periplasmic binding proteins. Those 
identified by sequence alignment in Chapter 3 from pathogenic or thermophilic species could 
be expressed and purified. Studying many periplasmic binding proteins from a wide range 
of pathogenic species may be useful for a greater understanding of pathogen virulence or for 
the design of antibiotics. Thermophilic periplasmic binding proteins may be useful for the 
development of artificial metalloenzymes, and it is important to first establish the types of 
siderophores that each periplasmic binding protein scaffold can accommodate before 
designing the attached catalyst. 
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It is known that human and other mammalian siderocalins sequesters iron(III)-enterobactin, 
as explained in Chapter 1.219, 220 It is not known whether the linear hydrolysis products are 
also sequestered by siderocalin, however if their affinity with siderocalin is weaker than that 
of iron(III)-enterobactin, then they could prove to be a more effective source of iron(III), if 
iron(III)-enterobactin is taken up readily by the host immunoproteins. To test this idea, 
siderocalin fluorescence quenching binding assays could be performed to assess the 
dissociation constants of the tetradentate siderophores and siderophore mimics iron(III)-
bisDHBS, and iron(III)-n-LICAM. This study could then be extended to the linear 





6.1 General Remarks 
Materials 
Materials were obtained from the following commercial suppliers: Acros Organics, Alfa-
Aesar, Cambridge Isotope Laboratories Inc., Fluorochem, Fisher Scientific, Sigma-Aldrich, 
Tokyo Chemical Industry UK Ltd. Natural siderophores including enterobactin and 
salmochelins were obtained from EMC Microcollections. H4-bisDHBS was obtained from 
Dr. D. J. Raines. H4-n-LICAM (n= 4, 5, 6, 8) compounds were obtained from Dr. D. J. Raines 
and Prof. A.-K. Duhme-Klair. CeuE was obtained from Dr. E. V. Blagova, Dr D. J. Raines 
and Mr. A. Hughes. CeuE variant proteins and VctP were obtained from Dr. E. V. Blagova. 
All solvents and reagents were used as supplied, unless otherwise stated. 
Instrumentation 
1H, COSY, 13C, DEPT 135, HMQC, and HMBC NMR spectra were recorded on Jeol EX 
and ES 400 MHz instruments.  1H experiments were run at 399.78 MHz. 13C experiments 
were run at 100.53 MHz and were proton decoupled.  Data are reported as follows: chemical 
shift (multiplicity, proton environment assignment, coupling constants, number of protons).  
Chemical shifts are reported relative to residual solvent peaks. Chemical shifts were 
measured in ppm and are quoted to the nearest 0.01 ppm.  Multiplicity is reported as the 
following: s = single, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad. Coupling 
constants (J) are given in Hz, and are quoted to the nearest 0.1 Hz.  All 1H and 13C 
assignments were confirmed with COSY, DEPT 135 and HMQC experiments, and 
supplemented with HMBC experiments as required. All NMR spectra were processed with 
ACD/NMR Processor Academic Edition. 
Positive and negative ion electrospray ionisation mass spectrometry (ESI-MS) was 
performed on a Bruker microTOF electrospray mass spectrometer by Mr. K. Heaton, Ms. H. 
Robinson and Ms. R. Cercola. Elemental analysis was performed on an Exeter CE-440 
elemental analyser by Mr. G. McAllister and results are reported within ± 0.4%. Infrared 
(ATIR) spectra were recorded on a Perkin Elmer FT-IR spectrum two spectrophotometer at 
ambient temperature. Melting points were determined using a Stuart Scientific SMP3 
melting point apparatus. Specific rotation was recorded on a Jasco DIP-370 digital 
polarimeter. Fluorescence spectra were recorded on a Hitachi F-4500 fluorescence 
spectrophotometer at ambient temperature. Electronic absorption spectra were recorded on 




performed on a Jasco J810 CD spectropolarimeter at 20 °C under a constant flow of nitrogen. 
Analytical thin layer chromatography was performed using Merck silica gel 60 F253 
aluminium-backed plates using the specified solvent system and visualised under an 
ultraviolet lamp. Flash column chromatography was carried out using Fluka Silica, pore size 
60 Å, 220-440 mesh, 35-75 μm. Analytical HPLC was performed using a Shimadzu 
Prominence LC 20AD setup, with C18 column and SPD M20A diode array detector under 
the direction of Ms. A. Dixon. 
6.2 Synthesis 
2,3-Bis(benzyloxy)benzoic acid (Compound B) 
 
Molecular Formula: C21H18O4 
Molecular Mass: 334.37 g mol-1 
2,3-Bis(benzyloxy)benzoic acid was prepared based on a preparation from the literature.15 
2,3-Dihydroxybenzaldehyde (4.058 g, 29.30 mmol) was dissolved in 90 mL dry ethanol, to 
which benzyl chloride (8.33 mL, 72.40 mmol) and potassium carbonate (10.135 g, 72.40 
mmol) were added. The reaction mixture was refluxed at 82 °C under anhydrous conditions 
for 18 hours. The reaction mixture was cooled and the solid filtered and washed with water. 
This solid was dissolved in 150 mL ethyl acetate and washed with 2 portions of water (50 
mL) one of brine (30 mL) and one of 3:2 water brine mixture (50 mL). The organic layer 
was dried over magnesium sulfate and volatiles removed in vacuo. Without further 
purification, the crude aldehyde was dissolved in 40 mL acetone and 40 mL water. Sodium 
chlorite (3.169 g, 35.1 mmol) and sulfamic acid (4.229 g, 42.80 mmol) were each dissolved 
in 30 mL water and added alternately over 30 minutes. The mixture was stirred in air for one 
hour before removal of acetone in vacuo. The remaining solid in water was cooled and 
filtered. The resulting solid was recrystallised in a minimum hot ethanol. Filtration and 
vacuum desiccation for 48 hours resulted in a yellow crystalline solid (5.521 g, 16.50 mmol, 




1H NMR: (400 MHz, DMSO-d6) δ: 12.95 (br s, H18, 1H); 7.51 (d, J= 8.0 Hz, H6, 1H); 
7.23-7.29 (m, H10-12, H15-17, 10H); 7.26 (d, H4, J= 8.0 Hz, 1H); 7.14 (dd, H5, J= 8.0 Hz, 
1H); 5.19 (s, H8/13, 2H); 5.03 (s, H8/13, 2H). 
13C NMR: (100 MHz, DMSO-d6) δ: 168.17 (C7); 152.9 (C1) 147.22, 138.01 (C4,6); 137.28, 
128.93, 128.67, 128.26, 124.66, 122.04, 117.50 (C1-3, C5, C9-12, C14-17); 74.92, 70.37 
(C8,9).  
HRMS: Calcd. [M+H]+ (C21H19O4) m/z = 335.1278; Obs. [M+H]
+ m/z = 335.1271, Mean 
err 1.9ppm. Calcd. [M+Na]+ (C21H18NaO4) m/z = 35.1097; Obs. [M+H]
+ m/z = 357.1101, 
Mean err -0.9ppm.  
IR ATIR (cm-1): 3031 w br (O-H), 2873 w br (C-H), 1683 s (C=O), 1576 m (C=C ar). 
2,3-Bis(benzyloxy)benzoic acid N-hydroxysuccinimide ester (Compound R) 
 
Molecular formula: C25H21O6 
Molecular weight: 431.44 g mol-1 
2,3-Bis(benzyloxy)benzoic acid N-hydroxysuccinimide ester was prepared based on a 
preparation from the literature.405  
2,3-Bis(benzyloxy)benzoic acid (2.790 g, 8.35 mmol) and N-hydroxysuccinimide (1.026 g, 
8.91 mmol) were dissolved in dioxane (20 mL). DCC (2.066 g, 10.00 mmol) was added and 
stirred at 0 °C for 5 hours. The reaction mixture was left to stand overnight, and the resulting 
precipitate removed by filtration. The remaining filtrate was reduced in vacuo to yield an 
oily residue in a minimum dioxane, to which 3 mL isopropyl alcohol was added. A solid was 
obtained after one hour, which was isolated by filtration and washed with isopropyl alcohol 
(5 mL) and water (5 mL). The solid was recrystallised from a minimum amount of hot ethyl 
acetate. The resulting precipitate was isolated and dried under vacuum for 12 hours yielding 
a yellow crystalline solid (2.342 g, 5.43 mmol, 65%) Rf = 0.65 (4:1 chloroform: ethyl 




1H NMR: (400 MHz, DMSO-d6) δ: 7.62-7.28 (m, H4-6, H12-14, H17-19, 13H); 5.26 (s, 
H10/15, 2H); 5.05 (s, H10/15, 2H); 2.89 (br s, H9, 4H). 
13C NMR: (100 MHz, DMSO-d6) δ: 171.06 (C7); 161.52 (C8); 153.19 (C1); 148.63 (C9); 
137.20, 136.89 (C2, C3); 128.98, 128.92, 128.63, 128.60, 125.43, 122.61, 121.01, 120.48 
(C4-6, C11-14, C16-19); 75.31, 70.60 (C10, C15). 
HRMS: Calcd. [M+Na]+ (C25H21NNaO6) m/z = 454.1261; Obs. [M+H]
+ m/z = 454.1248, 
Mean err 3.3ppm.  
IR ATIR (cm-1): 2936 m br (C-H), 1764 m (C=O), 1732 s (C=O), 1578 m (N-O). 
1-Amino, 4-(2,3-dibenzyloxybenzamide) butane (Compound C) 
 
Molecular formula: C25H29ClN2O3 
Molecular weight: 440.97 g mol-1 
1-Amino, 4-(2,3-dibenzyloxybenzamide) butane was prepared based on a procedure from 
the literature.85 
2, 3-Bis(benzyloxy)benzoic acid (0.300 g, 0.90 mmol) was dissolved in dry THF (5 mL) and 
carbonyldiimidazole (0.194 g, 0.90 mmol) was added. 1,4-diaminobutane (0.210 g, 1.79 
mmol) was dissolved in dry THF (5 mL) and the solution was stirred vigorously. The 
bis(benzyloxy)benzoic acid solution was then added dropwise to the 1,4-diaminobutane 
solution over 60 minutes. The resulting reaction mixture was stirred overnight at room 
temperature. The solvent was removed in vacuo and the residue taken up in chloroform (30 
mL), washed with saturated NaHCO3 (15 mL), brine (15 mL), 1M HCl (15 mL), and brine 
(15 mL). The organic portion was then dried over MgSO4 and partially reduced in vacuo. 
Ethyl acetate (10 mL) was added and the resulting solution was concentrated in vacuo to 
yield a white solid. The solid was recrystallised from a minimum hot ethyl acetate: 
chloroform 2:1 to yield a white solid (0.254 g, 0.58 mmol, 72%) Rf = 0.1 (1:1 chloroform: 




1H NMR: (400 MHz, MeOD-d4) δ: 7.50 (d, J= 7.8 Hz, H4/6, 2H); 7.39-7.29 (m, H11-13, 
H16-18, 10H); 7.16 (t, J= 7.8 Hz, H5, 1H); 5.20 (s, H9/14, 2H); 5.11 (s, H9/14, 2H); 3.28 
(m, H19, 2H); 2.86 (t, J= 7.6 Hz, H22, 2H); 1.60 (m, H20/21, 2H); 1.49 (m, H20/21, 2H).  
13C NMR: (100 MHz, MeOD-d4) δ: 153.56 (C7); 138.48, 138.30, 130.23, 129.97, 129.79, 
129.70, 129.64, 129.15, 125.69, 122.71, 118.28 (C1-6, C10-13, C15-18); 77.32, 72.37 
(C9,10); 40.44 (C20/21); 39.91(C20/21); 27.47, 26.04 (C18,19). 
HRMS (ESI): Calcd. [M+H]+ (C25H29N2O3) m/z = 405.2173; Obs. [M+H]
+ m/z = 405.2163, 
Mean err 3.6 ppm.  
IR ATIR (cm-1): 3365 m (N-H), 3075 m br (N-H), 2801 m br (C-H), 1641 m (C=O), 1571 
m (C=C ar). 
1-Amino, 5-(2,3-dibenzyloxybenzamide) pentane (Compound S) 
 
Molecular formula: C26H37ClN2O3 
Molecular weight: 455.00 g mol-1 
1-Amino, 5-(2,3-dibenzyloxybenzamide) pentane was prepared by student Ross P. Thomas. 
1, 5-Diaminopentane (1.427 g, 14.00 mmol) and triethylamine (1.396 g, 13.80 mmol) were 
dissolved in THF (120 mL). A solution of 2, 3-bis(benzyloxy)benzoic acid N-
hydroxysuccinimide ester (3.0076 g, 6.97 mmol) in THF (60 mL) was prepared and added 
dropwise over 2 hours. The mixture was left to stir overnight. The solvent was removed in 
vacuo yielding an off-white solid which was taken up in chloroform (120 mL) and washed 
with NaHCO3 (100 mL), brine (100 mL) and 2.25:1 1M HCl: brine (130 mL). The organic 
layer was then dried over MgSO4, filtered and the solvent removed in vacuo yielding a 
yellow oil. The oil was purified via silica column chromatography (90:10:1 CHCl3: MeOH: 
NH3(aq)). Diethyl ether was added to afford a white solid that was dried in vacuo (1.8592 g, 




1H NMR: (400 MHz, CDCl3) δ: 7.99 (t, J = 5.5 Hz, H8, 1H); 7.73-7.71 (m, H4/6, 1H); 7.49-
7.35 (m, H11-13, H16-18, 10H); 7.16 (d, J= 2.3 Hz, H6/4, 2H); 7.14 (t, J= 4.6 Hz, H5, 1H); 
5.16 (s, H9/14, 2H); 5.08 (s, H9/14, 2H); 3.27 (dd, J= 6.0 Hz J = 13.3 Hz, H19,  2H); 2.77 
(t, J= 6.6 Hz, H23, 2H); 1.48 (tt (appquint.), J= 7.3 Hz, H20, 2H); 1.37-1.20 (m, H21, H22, 
4H). 
13C NMR: (100 MHz, CDCl3) δ: 164.98 (C7); 151.66, 146.67, 136.35, 128.73, 128.64, 
128.622, 127.66 (C1-3, C10-13, C15-18); 124.43 (C4/6); 123.26 (C4/6); 116.74 (C5);76.31, 
71.21 (C9,14); 41.96 (C23); 39.56 (C19); 33.29, 29.08, (C20, C22); 24.23 (C21). 
HRMS (ESI): Calcd. [M+H]+ (C25H29N2O3) m/z = 405.2173; Obs. [M+H]
+ m/z = 405.2168, 
Mean err 3.5 ppm.  
IR ATIR (cm-1): 3365 m (N-H), 3078 m br (N-H), 2803 m br (C-H), 1641 m (C=O), 1571 
m (C=C ar). 
Methyl-5-iodo-3-methoxysalicylate (Compound E) 
 
Molecular formula: C9H9IO4 
Molecular weight: 308.07 g mol-1 
Methyl-5-iodo-3-methoxysalicylate was prepared based on a preparation from the 
literature.438,401 
AgNO3 (2.774 g, 16 mmol) was dissolved in chloroform (30 mL) and pyridine (20 mL) was 
added resulting in a clear yellow solution. ICl (2.673 g, 16 mmol) was dissolved in 
chloroform (25 mL) and added dropwise to the reaction mixture over 35 minutes. The 
combined pale green grey solution was stirred for 45 minutes. Methyl-3-methoxysalicylate 
(2.000 g,11 mmol) was dissolved in chloroform (30 mL) and added dropwise to the reaction 
mixture over 30 minutes. The resulting reaction mixture was stirred overnight at room 
temperature. The reaction mixture was diluted with diethyl ether (100 mL) and the silver 
salts removed by filtration. The filter cake was washed with 1:1 chloroform: diethyl ether 
mixture (200 mL). The organic portions were combined and the solvent reduced in vacuo to 
yield a brown residue. The residue was dissolved in chloroform (100 mL) and washed twice 




portion. The organic portion was then washed twice with saturated Na2S2O3 (100 mL) and 
H2O (100 mL). The organic portion was then dried over MgSO4, filtered and the solvent 
removed in vacuo, yielding a brown solid. The solid was recrystallised from a minimum 
amount of hot ethanol. The resulting orange crystals were collected by filtration. Cold H2O 
was added to the filtrate resulting in the formation of a yellow precipitate. The yellow powder 
was collected by filtration. Both the crystals and powder were dried in vacuo and combined. 
(2.379 g, 7.72 mmol, 73%) Rf = 0.5 (1:4 ethyl acetate : petroleum ether 40-60°C) M.P = 109-
111 °C. 
1H NMR: (400 MHz, CDCl3) δ: 10.99 (s, H9, 1H); 7.76 (d, J= 2.0 Hz, H4/6, 1H); 7.25 (d, 
J= 2.0 Hz, H4/6, 1H); 3.96 (s, H10, 3H); 3.89 (s, H8, 3H). 
13C NMR: (100 MHz, CDCl3) δ: 169.57 (C7); 151.97, 149.32, 114.15 (C1, 2, 3); 129.46, 
124.86 (C4,6); 56.37 (C8); 52.66 (C10). 
HRMS (ESI): Calcd. [M+H]+ (C9H9IO4) m/z = 308.9618; Obs. [M+H]
+ m/z = 308.9629, 
Mean err 3.7 ppm. Calcd. [M+Na]+ (C9H9INaO4) m/z = 330.9438; Obs. [M+Na]
+ m/z = 
330.9446, Mean err 2.9 ppm.  
IR ATIR (cm-1): 3090 br w (C-H), 2943 w (C-H), 1674 m (C=O), 1607 m (C=C ar), 1471 
s (C-H), 1343 m (O-H). 
Methyl-5-iodo-3-hydroxysalicylate (Compound F) 
 
Molecular formula: C8H7IO4 
Molecular weight: 294.04 g mol-1 
Methyl-5-iodo-3-hydroxysalicylate was prepared based on a preparation from the 
literature.268  
Methyl-5-iodo-3-methoxysalicylate (2.000 g, 6.49 mmol) was dissolved in anhydrous 
dichloromethane (10 mL) and the mixture was stirred whilst the reaction flask was purged 
with N2. BBr3 (1M in dichloromethane, 12mL, 12.00 mmol) was added dropwise with 
vigorous stirring. Resultant gas evolution was passed through a trap containing aqueous 
NaOH (1M). The reaction flask was then purged again with N2. The mixture was stirred 




was carefully added and the reaction mixture stirred for 1 hour. The resulting pale pink turbid 
mixture was dissolved in methanol (20 mL) and the solvent removed in vacuo yielding a red 
residue. Methanol (10 mL × 3) was added to the residue, the residue dissolved, and the 
solvent removed in vacuo. The resulting peach coloured solid was redissolved in methanol 
(50 mL) and concentrated H2SO4 (2 mL) and heated under reflux overnight. The reaction 
mixture was cooled to room temperature and the solvent removed in vacuo, yielding a 
colourless oil and a white solid. The residue was dissolved in ethyl acetate (150 mL) and 
was washed three times with saturated NaHCO3 (90 mL) and twice with brine (90 mL). The 
organic portion was dried over MgSO4, filtered and the solvent removed in vacuo yielding a 
white solid (1.710 g, 5.82 mmol, 89%) Rf = 0.47 (1:4 ethyl acetate : petroleum ether 40-
60°C) M.P = 136-138 °C (Lit. 133-134 °C).396  
1H NMR: (400 MHz, CDCl3) δ: 10.89 (s, H9, 1H); 7.69 (d, J= 1.6 Hz, H4/6, 1H); 7.40 (d, 
J= 1.6 Hz, H4/6, 1H); 5.70 (br s, H8, 1H); 3.97 (s, H10, 3H). 
13C NMR: (100 MHz, CDCl3) δ: 169.50 (C7); 148.79, 145.91, 113.99 (C1, 2, 3); 129.07, 
128.25 (C4, 6); 52.74 (C10). 
HRMS (ESI):  Calcd. [M+Na]+ (C9H9INaO4) m/z = 316.9281; Obs. [M+Na]
+ m/z = 
316.9282, Mean err 0.5 ppm. Calcd. [M+2Na]+ (C9H9INa2O4) m/z = 338.9101; Obs. 
[M+2Na]+ m/z = 338.9099, Mean err 0.2 ppm. 
IR ATIR (cm-1): 3450 s (O-H), 3087 w (C-H), 2956 w (C-H), 1665 s (C=O), 1595 m (C-
H), 1464 s (C-H), 1358 m (O-H). 
Methyl-5-iodo-3,4-benzyloxysalicylate (Compound G) 
 
Molecular formula: C22H19IO4 
Molecular weight: 474.29 g mol-1 
Methyl-5-iodo-3,4-benzyloxysalicylate was prepared based on standard preparations from 
the literature.439  
Methyl-5-iodo-3-hydroxysalicylate (1.651 g, 5.61 mmol) was dissolved in anhydrous 




mmol) were added, forming a suspension. Benzyl bromide (6.140 g, 4.30 mL, 35.91 mmol) 
was added and the mixture was stirred at room temperature overnight. The solvent was then 
removed in vacuo yielding a sandy brown residue. The residue was dissolved in ethyl acetate 
(100 mL) and H2O (60 mL) and the layers separated. The aqueous layer was washed twice 
with ethyl acetate (100 mL) and the organic layers combined. The organic portion was dried 
over MgSO4, filtered and the solvent removed in vacuo. The residue was dissolved in 1:1 
chloroform : ethyl acetate (10 mL) and purified by flash column chromatography (1:9 ethyl 
acetate : petroleum ether 40-60°C) followed by recrystallisation in a minimum amount of 
chloroform and an excess of petroleum ether 40-60°C. The white needle crystals were 
collected and dried in vacuo (1.613 g, 3.40 mmol, 61%) Rf = 0.37 (1:9 ethyl acetate : 
petroleum ether 40-60°C) M.P = 103-105 °C (Lit. 105-106 °C).396 
1H NMR: (400 MHz, CDCl3) δ: 7.69 (d, J= 2.0 Hz, H4/6, 1H); 7.45-7.31 (m, H4/6, H10-
12, H15-17, 11H); 5.11 (s, H8/13, 2H); 5.07 (s, H8/13, 2H); 3.84 (s, H18, 3H).  
13C NMR: (100 MHz, CDCl3) δ: 165.11 (C7); 153.43, 148.14, 136.85 135.76, (C2, 3, 9, 14); 
131.43 (C4/6); 128.58, 128.55, 128.30, 128.26, 128.22, 128.02, 127.56 126.44(C4/6, C10-
12, C15-17); 86.23 (C1); 75.64, 71.44, (C8, 13); 52.29 (C18). 
HRMS (ESI): [M+K]+ (C9H9INKO4) m/z = 512.9960; Obs. [M+K]
+ m/z = 512.9957, Mean 
err 0.1 ppm. 
IR ATIR (cm-1): 3028 w (C-H), 1716 s (C=O), 1564 m (C-H), 1497 s (C-H). 
5-Iodo-3,4-benzyloxysalicylate (Compound H) 
 
Molecular formula: C21H17IO4 
Molecular weight: 460.2675 g mol-1 
The synthesis of 5-iodo-3,4-benzyloxysalicylate was designed based on a preparation from 
the literature.396, 397  
Methyl-5-iodo-3-hydroxysalicylate (0.130 g, 0.27 mmol) was dissolved in THF (1.5 mL) 
and methanol (0.5 mL) and NaOH (5 M, 1 mL) was added. The reaction mixture was stirred 




resulting white precipitate was collected by filtration and dried in vacuo (0.108 g, 0.23 mmol, 
86%) Rf = 0.0 (1:9 ethyl acetate : petroleum ether 40-60°C) M.P = 168-180 °C. 
1H NMR: (400 MHz, MeOD-d4) δ: 7.64 (d, J= 2.2 Hz, H4/6, 1H); 7.58 (d, J= 1.8 Hz, H4/6, 
1H); 7.49-7.25 (m, H10-12, H15-17, 10H); 5.14 (s, H8/13, 2H); 5.04 (s, H8/13, 2H). 
13C NMR: (100 MHz, MeOD-d4) δ: 154.98 (C7); 138.56, 137.84 (C2/3) 132.31, 132.28, 
130.01, 129.79, 129.49, 129.37, 129.27, 129.24 (C1, C4, C5, C6, C9-12, 14-17); 76.83 
(C8/13); 72.62 (C8/13). 
HRMS (ESI): Calcd. [M-H]- (C21H16IO4) m/z = 459.0099; Obs. [M-H]
- m/z = 459.0078, 
Mean err 4.9 ppm.  
IR ATIR (cm-1): 3102 w (O-H), 2884 w br (C-H), 1688 s (C=O), 1562 m (C-H), 1497 m 
(C-H), 1375 m (O-H). 
5-Iodo-bis(2,3benzyloxy)-4-LICAM (Compound J) 
 
Molecular formula: C46H43IN2O6 
Molecular weight: 846.76 g mol-1 
The synthesis of 5-iodo-bis(2,3benzyloxy)-4-LICAM was designed based on a preparation 
from the literature.94 
5-Iodo-3-hydroxysalicylate (0.050 g, 0.11 mmol) was dissolved in anhydrous THF (1.0 mL) 
and CDI (0.021g, 0.13 mmol) was added. The reaction mixture was stirred under dry 
conditions for 3 hours. 1-Amino, 4-(2, 3-dibenzyloxybenzamide)butane (0.048 g, 1.09 
mmol) was dissolved in anhydrous THF (1 mL). The 5-iodo-3-hydroxysalicylate was added 
dropwise to the 1-amino, 4-(2, 3-dibenzyloxybenzamide)butane solution and the resulting 
reaction mixture was stirred under dry conditions overnight. The reaction mixture was 
reduced in vacuo and the residue taken up in chloroform (10 mL). The organic layer was 




mL). The organic layer was dried over MgSO4, filtered and solvent removed in vacuo to 
yield a white solid (0.076 g, 0.09 mmol, 82%) Rf = 0.84 (1:4 methanol : chloroform) M.P = 
98-100°C. 
1H NMR: (400 MHz, MeOD-d4) δ: 8.07 (d, J= 1.8 Hz, H4/6, 1H); 7.89 (t, J= 5.5 Hz H8/13, 
1H); 7.76-7.74 (m, H8/13, H4/6, 2H) 7.49-7.29 (m, H18/20, H23-25, H28-30, H33-35, H38-
40, 21H); 7.16 (d, J= 1.8 Hz, H20/18, 1H); 7.15 (t, J= 4.1 Hz, H19, 1H); 5.17 (s, 
H21/26/31/36, 2H); 5.12 (s, H21/26/31/36, 2H); 5.06 (s, H21/26/31/36, 2H); 5.01 (s, 
H21/26/31/36, 2H); 3.19-3.14 (m, H9, H12, 4H) 1.23-1.20 (m, H10, H11, 4H). 
13C NMR: (100 MHz, CDCl3) δ: 164.95 (C7/14); 163.42 (C7/14); 152.30 (C1/15); 151.64 
(C1/15); 146.74 (C5), 136.36, 136.30, 135.86, 135.68 (C2/3/16/17); 132.12 (C4/6); 128.85, 
128.73, 128.69, 128.67, 128.64, 128.48, 128.22, 127.77, 127.62, 127.23, (C22-25, C27-30, 
C32-35, C37-40); 125.48, 124.37 (H20/18); 123.26 (C4/6); 116.86 (C19); 76.42, 76.32, 
71.54, 71.22 (C21/26/31/36); 39.34, 39.18 (C9/12); 26.67, 26.61 (C10/11). 
HRMS (ESI): Calcd. [M+Na]+ (C46H43IN2NaO6) m/z = 869.2058; Obs. [M+Na]
+ m/z = 
869.2075, Mean err 1.9 ppm.  
IR ATIR (cm-1): 3413 w (N-H), 3287 w br (N-H), 2942 w (C-H), 1666 s (C=O), 1635 s 
(C=O), 1550 m (N-H), 1498 m (C-H). 
Elemental Analysis: Calculated for [C46H43IN2O6]: %C 65.25, %H 5.12, %N 3.31; 
Measured for [C46H43IN2O6]: %C 65.09, %H 5.15, %N 3.28. 
Methoxy-5-aceto-β-ᴅ-glucosyl-3, 4-benzyloxysalicylate (Compound M) 
 
Molecular formula: C36H38O13 
Molecular weight: 678.69 g mol-1 
Methoxy-5-aceto-β-ᴅ-glucosyl-3, 4-benzyloxysalicylate was prepared based on a 




Acetobromo-α-ᴅ-glucose (0.750 g, 1.82 mmol) was purified by column chromatography 
(100% ethyl acetate) before use. Solvent was removed in vacuo, and petroleum ether 40:60 
(3 × 10 mL) was added and removed in vacuo to afford a white solid. All glassware was 
flame dried in vacuo before use. Zinc (0.260 g, 2.97 mmol) and lithium chloride (0.112 g, 
2.65 mmol) were weighed into a Schlenk tube in a glovebox, sealed under nitrogen, and 
heated in vacuo at 70°C for 90 minutes. Iodine (0.034 g, 1.34 mmol) and methyl-5-iodo-3,4-
benzyloxysalicylate (1.153 g, 2.43 mmol) were weighed into a Schlenk tube, DMF (5.3 mL) 
added, and the resulting brown solution stirred under nitrogen for 15 minutes. The solution 
was then added to the zinc and lithium chloride, and the resulting mixture heated under 
nitrogen at 70°C for 90 minutes. In a glovebox, Ni(COD)2 (0.043 g, 0.16 mmol) and 4,4′,4″-
tri-tert-Butyl-2,2′:6′,2″-terpyridine (0.094 g, 0.23 mmol) were weighed into a Schlenk tube, 
and DMF (3 mL) was added. The resulting solution was stirred for 15 minutes, which 
darkened from pale grey to deep blue. Acetobromo-α-ᴅ-glucose (0.640 g, 1.55 mmol) was 
added to the Ni(COD)2 and 4,4′,4″-tri-tert-Butyl-2,2′:6′,2″-terpyridine mixture and the 
resulting pale green turbid solution was stirred for 15 minutes. The methyl-5-iodo-3,4-
benzyloxysalicylate solution was cooled, and then added to the acetobromo-α-ᴅ-glucose 
mixture. The resulting dark green solution was then stirred at room temperature under 
nitrogen overnight. The reaction mixture was opened to air, and the solvent removed in 
vacuo, yielding a brown residue. The residue was purified by column chromatography (1:1 
ethyl acetate : petroleum ether 40-60°C ) to afford an off-white solid product (0.701 g, 65%) 
Rf = 0.38 (1:1 ethyl acetate : petroleum ether 40-60°C) M.P = 120-121 °C (Lit. 128-129 
°C).396 
1H NMR: (400 MHz, CDCl3) δ: 7.48-7.30 (m, H4,8-17, 11H); 7.23 (d, H6, J = 1.8 Hz, 1H); 
5.37 (t, H20, J = 9.2 Hz, 1H); 5.24 (t, H21, J = 10.1 Hz, 1H); 5.16-5.13 (m, H19, H8/13, 3H); 
5.09 (d, H8/13, J = 3.7 Hz, 2H); 4.39 (d, H18, J = 10.1 Hz, 1H); 4.30 (dd, H23, J = 12.4 Hz, 
J = 4.6 Hz, 1H); 4.18 (dd, H23, J = 12.4 Hz, J = 2.3 Hz, 1H); 3.87-3.85 (m, H22, 1H); 3.84 
(s, H32, 3H); 2.11 (s, H25/27/29/31, 3H); 2.08 (s, H25/27/29/31, 3H); 2.02 (s, H25/27/29/31, 
3H); 1.83 (s, H25/27/29/31, 3H). 
13C NMR: (100 MHz, CDCl3) δ: 170.70, 170.31, 169.52, 168.94, (C24, 26, 28, 30); 166.26 
(C7); 153.10 (C3); 148.54 (C2); 137.14, 136.26 (C9, 14) 131.98 (C5); 128.61, 128.24, 
127.95, 127.65, 125.21 (C10, 11, 12, 15, 16, 17); 126.209 (C1); 122.16, 115.71 (C4, 6); 
79.48 (C18); 76.21 (C22); 75.56 (C8/13); 74.07 (C20); 72.23 (C19); 71.32 (C8/13); 68.50 




HRMS (ESI): Calcd. [M+Na]+ (C36H38NaO13) m/z = 701.2205; Obs. [M+Na]
+ m/z = 
701.2207, Mean err 0.3 ppm.  
IR ATIR (cm-1): 2962 w (C-H), 1739 s (C=O), 1715 s (C=O), 1483 w (C-H). 
Methoxy-5-benzyloxy-β-ᴅ-glucosyl-3,4-benzyloxysalicylate (Compound N) 
 
Molecular formula: C56H54O9 
Molecular weight: 871.0390 g mol-1 
Methoxy-5-benzyloxy-β-ᴅ-glucosyl-3, 4-benzyloxysalicylate was prepared based on a 
preparation from the literature.396, 397  
Methoxy-5-aceto-β-ᴅ-glucosyl-3, 4-benzyloxysalicylate (1.314 g, 1.94 mmol) was dissolved 
in dry methanol (100 mL) and Na2CO3 (1.026 g, 9.68 mmol) was added. The resulting 
suspension was stirred under reflux at 65°C overnight. When the reaction was deemed 
complete by thin layer chromatography (Rf = 0, 1:1 ethyl acetate : petroleum ether 40-60°C) 
and the presence of the intermediate confirmed by ESI-MS, the reaction mixture was cooled 
and filtered, and the resulting orange solution reduced in vacuo to a pale brown solid. The 
solid was transferred to a Schlenk tube, and NaH (533 mg, 60% in mineral oil, 13.3 mmol) 
was added. The solids were dried in vacuo for two hours, before the addition of DMF (25 
mL) and cooling of the solution to 0°C. Bu4NI was dried in vacuo for 15 minutes, to which, 
benzyl bromide (3.00 mL, 4.320 g, 25.26 mmol) and DMF (5 mL) were added. The solution 
was cooled to 0 °C for 5 minutes, and was then added dropwise to the methyl-5-aceto-β-ᴅ-
glucosyl-3,4-benzyloxysalicylate solution over 5 minutes at 0 °C. After 5 minutes of stirring 
at 0 °C, the pale brown reaction mixture was stirred at RT under N2 overnight. The reaction 
mixture was opened to air, and deionised water (40 mL) was carefully added. The resulting 
solution was extracted with ethyl acetate (3 × 50 mL). The organic portions were combined 




solid was purified by column chromatography 20% ethyl acetate in petroleum ether 40-60°C 
yielding the product as a white solid (0.719 g, 0.82 mmol, 42%) Rf = 0.20 (20% ethyl acetate 
in petroleum ether 40-60°C) M.P = 84-86 °C. 
1H NMR: (400 MHz, CDCl3) δ: 7.53 (d, H6, J = 1.8 Hz, 1H)  7.49-7.30 (m, H10, H15, H26-
28, H31-33, H36-38, H41-43, 24H); 7.23-7.21 (m, H4, H11, H16, 5H); 6.97-6.93 (m, H12, 
H17, 2H) 5.14 (d, H8, J = 1.8 Hz, 2H); 5.00 (s, H13, 2H); 4.98-4.87 (m, H24/29, H39, 3H) 
4.65-4.57 (m, H23/H24/H29, 3H); 4.44 (d, H23, J = 10.1 Hz 1H); 4.23 (d, H18, J = 9.6 Hz, 
1H); 3.87 (s, H44, 3H); 3.81-3.76 (m, H20/21/24/29, H34, 5H); 3.66-3.59 (m, H22, 1H); 
3.45 (t, H19, J = 9.2 Hz, 1H).  
13C NMR: (100 MHz, CDCl3) δ: 166.37 (C7); 152.50 (C3); 147.86 (C2); 138.53 (C25); 
138.09, 137.98, 137.31, 137.16, 136.36, 135.03, 133.84 (C1, C9, C14, C30, C35, C40); 
128.69, 128.45, 128.38, 128.32, 128.30, 128.26 128.20, 128.01, 127.96, 127.87, 127.73, 
127.68, 127.61, 127.58, 127.51, 126.89 (C5, C10-12, C15-17, C26-28, C31-33, C36-38, 
C41-43); 121.85 (C6); 116.62 (C4); 86.56 (C20/21); 83.85 (C19); 80.80 (C18); 79.17 (C22); 
78.10 (C20/21); 75.60 (C9); 75.60 (C24/29); 73.36 (C23); 70.93 (C13/39); 10.88 (C13/39); 
68.87 (C34); 65.12 (C24/29); 52.05 (C44). 
HRMS (ESI): Calcd. [M+Na]+ (C56H54NaO9) m/z = 893.3660; Obs. [M+Na]
+ m/z = 
893.3655, Mean err 0.6 ppm.  
IR ATIR (cm-1): 3030 w (C-H), 2866 w (C-H), 1728 s (C=O), 1586 w (C-H). 
Benzyloxy-5-benzyloxy-β-ᴅ-glucosyl-3,4-benzyloxysalicylate (Compound N) 
 
Molecular formula: C62H58O9 




Benzyloxy-5-benzyloxy-β-ᴅ-glucosyl-3, 4-benzyloxysalicylate was prepared by the same 
method as methyl-5-benzyloxy-β-ᴅ-glucosyl-3,4-benzyloxysalicylate. The compounds were 
then separated from each other by column chromatography yielding the product as a white 
solid. (0.381 g, 0.40 mmol, 21%) Rf = 0.26 (1:4 ethyl acetate : petroleum ether 40-60°C) 
M.P = 104-106 °C. 
1H NMR: (400 MHz, CDCl3) δ: 7.52 (d, H6, J = 1.7 Hz, 1H) 7.40-7.28 (m, H10, H15, H26-
28, H31-33, H36-38, H41-43, H46-48, 29H); 7.26-7.21 (m, H4, H11, H16, 5H) 6.94-6.92 
(m, H12, H17, 2H) 5.34 (d, H44, J = 12.4 Hz, 2H); 5.07 (d, H8, J = 10.1 Hz, 2H); 4.98 (d, 
H13, J = 2.2 Hz, 2H); 4.97-4.87 (m, H24/29, H39, 3H) 4.66-4.57 (m, H24/29/H23, 3H); 4.43 
(d, H23, J = 10.1 Hz 1H); 4.21 (d, H18, J = 9.5 Hz, 1H); 3.82-3.76 (m, H20/21/24/29, H34, 
5H); 3.61-3.59 (m, H22, 1H); 3.44 (t, H19, J = 9.0 Hz, 1H).  
13C NMR: (100 MHz, CDCl3) δ: 13C NMR (100MHz, CDCl3) δ: 165.88 (C7); 152.54 (C3); 
147.99 (C2); 138.60 (C25); 138.23, 138.07, 137.37, 137.17, 136.34, 135.88, (C1, 10, 15, 30, 
35, 41, 45 ); 128.62, 128.52, 128.41, 128.36, 128.35, 128.25, 128.23, 128.16, 128.13, 128.06, 
127.99, 127.94, 127.91, 127.87, 127.83, 127.77, 127.74, 127.66, 127.63, 127.60, 127.56, 
126.44 (C5, C10-12, C15-17, C26-28, C31-33, C36-38, C42-44, 46-48); 121.95 (C6); 
116.52 (C4); 86.63 (C20/21); 83.91 (C19); 80.88 (C18); 79.31 (C22); 78.19 (C20/21); 75.57 
(C8); 75.12 (C24/29/34); 73.23 (C23); 70.90 (C39); 68.94 (C24/29/34); 68.11 (C13); 
66.88(C44). 
HRMS (ESI): Calcd. [M+Na]+ (C62H58NaO9) m/z = 969.3973; Obs. [M+Na]
+ m/z = 
969.3982, Mean err 1.3 ppm.  
5-Benzyloxy-β-ᴅ-glucosyl-3, 4-benzyloxysalicylate (Compound P) 
 
Molecular formula: C55H52O9 




5-Benzyloxy-β-ᴅ-glucosyl-3,4-benzyloxysalicylate was prepared based on a preparation 
from the literature.396, 397  
Methoxy-5-aceto-β-ᴅ-glucosyl-3, 4-benzyloxysalicylate (0.500 g, 0.57 mmol) was dissolved 
in THF (7 mL) and methanol (3 mL) and NaOH 5 M in H2O (2 mL) was added. The mixture 
was stirred for 21 hours, before acidification to pH 1 with 1 M HCl. Upon acidification, a 
fine white precipitate formed. The turbid aqueous mixture was extracted with DCM (3 × 10 
mL). The organic portions were combined, dried over MgSO4, filtered and solvent removed 
in vacuo to yield a colourless oil. Petroleum ether 40-60 °C was added (3 × 10 mL) and 
removed in vacuo to yield an off white solid residue. The residue was purified by column 
chromatography (1:4 methanol : chloroform) yielding a white solid product (0.359 g, 0.42 
mmol, 73%) Rf = 0.56 (1:9 methanol : chloroform) M.P = 97-99 °C. 
1H NMR: (400 MHz, CDCl3) δ: 11.29 (br s, -OH, 1H,); 7.89 (d, H6, J = 1.8 Hz, 1H); 7.45-
7.29 (m, H11, H16, H26-28, H31-33, H36-38, H42-44, 24H); 7.22-7.20 (m, H4, H12, H17, 
5H); 6.97-6.94 (m, H10, H15, 2H); 5.26 (d, H8, J = 10.5 Hz, 2H); 4.99 (d, H13, J = 2.3 Hz, 
2H); 4.96-4.87 (m, H34, H29, 3H); 4.66-4.63 (m, H34/39, 2H); 4.60-4.57 (d, H39, J = 12.8 
Hz, 1H); 4.49 (d, H24, J = 10.5 Hz, 1H); 4.25 (d, H18, J = 9.6 Hz, 1H); 3.86-3.80 (m, H24, 
H20, 2H); 3.78-3.72 (m, H21, H23, 3H); 3.65-3.62 (m, H22, 1H); 3.44 (t, H19, J = 9.2 Hz, 
1H). 
13C NMR: (100 MHz, CDCl3) δ: 165.15 (C7); 150.91 (C3); 146.40 (C2); 138.52 (C30); 
138.14 (CC35/40); 137.98 (C35/40); 137.41 (C25); 136.39 (C5); 135.73 (C9); 134.48 (C14); 
129.32, 129.29, 128.78, 128.75, 128.51, 128.42, 128.38, 128.24, 128.13, 128.05, 128.01, 
127.81, 127.75, 127.70, 127.63, 127.60, 126.95 (C11-13, C16-18, C26-28, C31-33, C36-38, 
C42-44); 123.16 (C6); 122.76 (C1); 117.79 (C4); 86.69 (C20); 83.66 (C19); 80.57 (C18); 
79.29 (C22); 78.20 (C21); 76.90 (C8); 75.59 (C29); 75.141 (C34); 74.90 (C24); 73.39 (C39); 
71.25 (C13); 68.98 (C23). 
HRMS (ESI): Calcd. [M+Na]+ (C55H52NaO9) m/z = 879.3504; Obs. [M+Na]
+ m/z = 
879.3529, Mean err 3.1 ppm.  
IR ATIR (cm-1): 3063 w (C-H), 3030 w (C-H), 2867 w (C-H), 1740 m (C=O), 1697 w 





5-Benzyloxy-β-ᴅ-glucosyl-bis(3, 4-benzyloxy)-4-LICAM (Compound Q) 
 
Molecular formula: C80H78N2O11 
Molecular weight: 1243.51 g mol-1 
5-Benzyloxy-β-ᴅ-glucosyl-3, 4-benzyloxysalicylate (0.107 g, 0.13 mmol) was dissolved in 
DMF (10 mL) to which HATU (0.114 g, 0.30 mmol) was added. The mixture was stirred for 
one hour before the addition of DIPEA (78 µL, 0.058 g, 0.45 mmol) and 1-amino, 4-(2,3-
dibenzyloxybenzamide) butane (0.066 g, 0.15 mmol). The mixture was then heated to 50 °C 
and stirred overnight. The resulting brown solution was reduced in vacuo to a brown residue. 
The residue was purified twice by column chromatography (1:2 ethyl acetate : chloroform) 
(1:3 acetonitrile : chloroform) yielding a white solid product (0.071 g, 0.057 mmol, 46 %) 
Rf = 0.47 (1:2 ethyl acetate : chloroform) M.P = 84-86 °C. 
1H NMR: (400 MHz, CDCl3) δ: 7.94 (d, H6, J = 2.3 Hz, 1H); 7.91 (t, H18/23, J = 5.5 Hz, 
1H) 7.86 (t, H18/23, J = 5.5 Hz); 7.78 (dd, H28/30, J = 6.2 Hz, J = 3.2 Hz, 1H); 7.51-7.17 
(m, H4, H29, H9-11, H14-16, H33-35, H38-40, H48-50, H53-55, H58-60, H64-66, 42H); 
6.98 (d, H28/30, J = 2.7 Hz, 2H); 5.18 (s, H12, 2H); 5.10 (d, H31/36, J = 10.5 Hz, 1H); 5.08 
(s, H31/36, 2H); 5.03 (d, H31/H36, J = 10.5 Hz, 1H); 5.00 (br s, H7, 2H) 4.97-4.88 (m, H46, 
H51, 3H) 4.67-4.56 (m, H51, H62, 3H); 4.46 (d, H61 J = 10.5 Hz, 1H); 4.28 (d, H41, J = 9.6 
Hz, 1H); 3.88-3.75 (m, H61, H43, H56, H45, 5H); 3.65 (dt, H44, J = 9.6 Hz, J = 3.2 Hz, 1H); 
3.53 (t, H42, J = 9.2 Hz, 1H); 3.23-3.21 (m, H19, H22, 4H); 1.29-1.24 (m, H20, H21, 4H).  
13C NMR: (100 MHz, CDCl3) δ: 164.93 (C17/24); 164.65 (C17/24); 151.64 (C3/27); 
151.33(C3/27); 146.76 (C2/26); 146.27 (C2/26); 138.64, 138.22, 138.06, 137.66, 136.37, 
136.29, 136.15, 135.51 (C8, 13, 32, 37, 47, 52, 57, 63); 128.74, 128.70, 128.67, 128.65, 




127.53, 127.51, 127.27, 127.13 (C9-11, 14-16, 33-35, 38-40, 48-50, 53-55, 58-60, 64-66); 
124.35(C4/28/29/30); 123.29(C4/28/29/30); 122.18(C4/28/29/30); 116.87(C28/30); 115.85 
(C6); 86.65 (C43/45); 83.93(C42); 81.08(C41); 79.32 (C44); 78.26 (C43/45); 
76.33(C31/36); 75.52 (C31/36); 75.08 (C46/51); 74.81 (C61); 73.39 (C51/62); 71.22 
(C33/36); 70.99 (C46/51); 69.11 (C56); 39.31 (C19/22); 39.25 (C19/22); 26.72 (C20/21). 
HRMS (ESI): Calcd. [M+H]+ (C80H79N2O11) m/z = 1243.5678; Obs. [M+H]
+ m/z = 
1243.5687, Mean err 0.6 ppm. Calcd. [M+Na]+ (C80H79N2NaO11) m/z = 1265.5498; Obs. 
[M+Na]+ m/z = 1265.5488, Mean err 0.7 ppm. 
IR ATIR (cm-1): 3287 w br (N-H), 3026 w (N-H), 2863 w br (C-H), 1639 m (C=O), 1577 
m (C=C ar). 
Elemental Analysis: Calcd. for [C80H78N2O11]: %C 77.27, %H 6.32, %N 2.25; Measured 
for [C80H78N2O11]: %C 77.18, %H 6.31, %N 2.20 
5-β-ᴅ-glucosyl-4-LICAM  
 
Molecular formula: C24H30N2O11 
Molecular weight: 522.51 g mol-1 
5-β-ᴅ-Glucosyl-4-LICAM was prepared based on a preparation from the literature.396, 397  
5-Benzyloxy-β-ᴅ-glucosyl-3, 4-benzyloxy-4-LICAM (0.170 g, 0.33 mmol) was dissolved in 
1:1 ethyl acetate: methanol (30 mL) and 3 spatula tips of Pd(OH)2 20% on carbon were 
added. The system was purged with nitrogen before purging with hydrogen for 30 minutes. 
The reaction mixture was stirred under balloon pressure of hydrogen for 18 hours. The 
reaction mixture was then purged with nitrogen before opening to air. The catalyst was 
removed by filtration, and the solvent removed in vacuo to yield a pale brown oil. The solid 
off white product was obtained by cooling the obtained oil in liquid nitrogen and removing 
all residual solvent in vacuo (0.066 g, 0.12 mmol, 93 %) Rf= 0.00 (1:2 ethyl acetate : 




1H NMR: (400 MHz, MeOD) : 7.31 (d, H6, J = 1.8 Hz, 1H); 7.21 (dd, H20/22, J= 8.2 Hz, J 
= 1.4 Hz, 1H); 7.01 (d, H4, J = 1.8 Hz, 1H); 6.92 (dd, H20/22, J= 7.8 Hz, J = 1.4 Hz, 1H); 
7.61 (t, H21, J = 7.8 Hz, 1H); 4.02 (d, H25, J = 9.2 Hz, 1H); 3.86 (dd, H33, 2JH33a/H33b = 11.9 
Hz, 3JH33a/H29 = 2.4 Hz, 1H); 3.72 (dd, H33, 
2JH33a/H33b = 11.9 Hz,
 3JH33b/H29 = 5.2 Hz, 1H); 
3.46-3.43 (m, H11, H14, H26-29, 8H); 1.72-1.69 (m, H12-13, 4H). 
13C NMR: (100 MHz, MeOD) δ: 171.66 (C9/16); 171.66 (C9/16); 150.39 (C3/19); 
150.27(C3/19); 147.43 (C2/18); 147.04 (C2/18); 131.31 (C1/17); 119.71 (C20/22); 119.50 
(C4); 118.78 (C20/22); 118.15 (C6); 116.89 (C21); 116.19 (C5); 83.29 (C25); 82.11 
(C26/27/28/29); 79.82(C26/27/28/29); 76.43 (C26/27/28/29); 71.86 (C26/27/28/29); 63.05 
(C33); 40.29 (C11/14); 40.24 (C11/14); 28.03 (C12/13); 28.01 (C12/13). 
HRMS (ESI): Calcd. [M+H]+ (C24H29N2O11) m/z = 521.1777; Obs. [M+H]
+ m/z = 
521.1771, Mean err 0.8 ppm. 
IR ATIR (cm-1): 3284 s br (O-H), 2924 m (N-H), 1640 m (C=O), 1587 m (C=C ar), 1452 s 
(C-O). 
Elemental Analysis: Calcd. for [C24H30N2O11.2.1H2O]: %C 51.44, %H 6.15, %N 5.00; 
Measured for [C24H30N2O11.2.1H2O]: %C 51.18, %H 5.81, %N 4.96.  
Specific Rotation: [α]D (Methanol, conc 0.245 g/100 mL) + 3.2 
5-Benzyloxy-β-ᴅ-glucosyl-bis(3, 4-benzyloxy)-5-LICAM (Compound T) 
 
Molecular formula: C81H80N2O11 




5-Benzyloxy-β-ᴅ-glucosyl-3, 4-benzyloxysalicylate (0.252 g, 0.29 mmol) was dissolved in 
DMF (10 mL) to which HATU (0.268 g, 0.70 mmol) was added. The mixture was stirred for 
one hour before the addition of DIPEA (184 µL, 0.137 g, 1.06 mmol) and 1-amino, 5-(2, 3-
dibenzyloxybenzamide) pentane (0.160 g, 0.35 mmol). The mixture was then stirred 
overnight.  The resulting brown solution was reduced in vacuo to a brown residue. The 
residue was purified twice by column chromatography (1:2 ethyl acetate : chloroform) (1:4 
ethyl acetate : chloroform) yielding a white solid product (0.204 g, 0.16 mmol, 55 %) Rf = 
0.36 (1:4 ethyl acetate : chloroform) M.P = 96-98 °C. 
1H NMR: (400 MHz, CDCl3) δ: 7.93 (d, H6, J = 1.8 Hz, 1H); 7.90 (m, H18/24,1H); 7.87 (t, 
H18/24, J = 5.5 Hz, 1H); 7.76 (dd, H29/31, J = 6.4 Hz, J = 3.2 Hz, 1H); 7.50-7.14 (m, H4, 
H30, H9-11, H14-16, H34-36, H39-41, H50-52, H55-57, H60-62, H65-67, 42H); 6.98 (m, 
H29/31, 2H); 5.17 (s, H12, 2H); 5.11-5.01 (m, H32/37, 2H); 5.08 (s, H32/37, 2H); 4.98 (br 
s, H7, 2H); 4.95-4.86 (m, H48, H53, 3H); 4.67-4.56 (m, H53, H64, 3H); 4.45 (d, H47 J = 
10.5 Hz, 1H); 4.26 (d, H42, J = 9.6 Hz, 1H); 3.86-3.73 (m, H47, H44, H58, H46, 5H); 3.63 
(dt, H45, J = 9.2 Hz, J = 3.2 Hz, 1H); 3.52 (t, H43, J = 9.2 Hz, 1H); 3.25-3.18 (m, H19, H23, 
4H); 1.30-1.23 (m, H20, H22, 4H); 1.16-1.10 (m, H21, 2H).  
13C NMR: (100 MHz, CDCl3) δ: 164.93 (C17/25); 164.66 (C17/25); 151.67 (C3/28); 151.37 
(C3/28); 146.74 (C2/27); 146.27 (C2/27); 138.67, 138.25, 137.69, 136.40, 136.34, 136.27, 
136.27, 135.54 (C8, 13, 33, 38, 49, 54, 59, 64); 128.78, 128.71, 128.67, 128.64, 128.40, 
128.35, 128.24, 128.20, 128.15, 128.02, 127.77, 127.71, 127.65, 127.58, 127.54, 127.49, 
127.37, 127.24 (C9-11, C14-16, C34-36, C39-41, C50-52, C55-57, C60-62, C65-67); 124.40 
(C4/29/30/31); 123.31 (C4/29/30/31); 122.21 (C4/29/30/31); 116.81(C29/31); 115.78 (C6); 
86.68 (C44/46); 83.95 (C43); 81.13 (C42); 79.34 (C45); 78.29 (C44/46); 76.36 (C32/37); 
75.56 (C32/37); 75.13 (C48/53); 74.85 (C47); 73.42 (C53/63); 71.24 (C32/37); 71.01 
(C48/53); 69.11 (C58); 39.55 (C19/23); 39.48 (C19/23); 28.94(C20/22), 28.92 (C20/22), 
24.46 (C21). 
HRMS (ESI): Calcd. [M+H]+ (C81H81N2O11) m/z = 1257.5835; Obs. [M+H]
+ m/z = 
1257.5917, Mean err 4.7 ppm.  
IR ATIR (cm-1): 3384 w br (N-H), 3287 w br (N-H), 3063 w (C-H), 3030 w (C-H), 2920, 






Molecular formula: C25H32N2O11 
Molecular weight: 522.53 g mol-1 
5-β-ᴅ-Glucosyl-5-LICAM was prepared based on a preparation from the literature.396, 397 
5-Benzyloxy-β-ᴅ-glucosyl-3, 4-benzyloxy-4-LICAM (0.200 g, 0.1590 mmol) was dissolved 
in toluene (1 mL) and ethanol added (30 mL) followed by 3 spatula tips of Pd(OH)2 20% on 
carbon. The system was purged with nitrogen before purging with hydrogen for 30 minutes. 
The reaction mixture was stirred under balloon pressure of hydrogen for 18 hours. The 
reaction mixture was then purged with nitrogen before opening to air. The catalyst was 
removed by filtration, and the solvent removed in vacuo to yield a pale colourless oil. The 
solid off white product was obtained by cooling the obtained oil in liquid nitrogen and 
removing all residual solvent in vacuo (0.0855 g, 0.16 mmol, 90 %) Rf = 0.00 (1:2 ethyl 
acetate : chloroform) M.P = 180-182 °C. 
NMR: (400 MHz, MeOD) δ: 7.31 (s, H4/6, 1H); 7.20 (d, H20/22, J= 8.2 Hz 1H); 7.01 (s, 
H4/6, 1H); 6.91 (d, H20/22, J= 7.8 Hz, 1H); 6.70 (t, H21, J = 7.8 Hz, 1H); 4.02 (d, H26, J = 
9.2 Hz, 1H); 3.87 (d, H34, J= 10.5 Hz, 1H); 3.72 (dd, H34, 2JH34a/H34b = 11.9 Hz,
 3JH34/H30 = 
5.0 Hz, 1H); 3.46-3.35 (m, H11, H15, H27-30, 8H); 1.72-1.64 (m, H12, H14, 4H); 1.50-1.44 
(m, H13, 2H). 
13C NMR: (100 MHz, MeOD) δ: 171.64 (C9/17); 171.61 (C9/17); 150.41 (C3/19); 
150.27(C3/19); 147.46 (C2/18); 147.06 (C2/18); 131.32 (C1/23); 119.69 (C21/20/22); 
119.44 (C21/20/22); 118.75 (C4/6); 118.12 (C20/22); 116.91 (C4/6); 116.21 (C5); 83.32 
(C26); 82.14 (C27/28/29/30); 79.84 (C27/28/29/30); 76.46 (C27/28/29/30); 71.84 
(C27/28/29/30); 63.03 (C34); 40.54 (C11/15); 40.52 (C11/15); 30.33 (C12/14); 30.26 
(C12/14), 25.55 (C13). 
HRMS (ESI): Calcd. [M+H]+ (C25H32N2O11) m/z = 535.1933; Obs. [M+H]
+ m/z = 




IR ATIR (cm-1): 3288 s br (O-H), 2930 m br (C-H), 1641 m (C=O), 1589 m (C=C ar). 
Elemental Analysis: Calcd. for [C25H32N2O11.0.9EtOH.1.2H2O]: %C 53.68, %H 6.70, %N 
4.66; Measured for [C25H32N2O11.0.9EtOH.1.2H2O]: %C 53.76, %H 6.47, %N 4.52. 
Specific Rotation: [α]D (Methanol, conc. 0.311 g/100 mL) + 5.7 
6.3 Sequence Alignments 
For known proteins, where structures were identified in the PDB via PDBeFold, sequences 
were obtained by using a BLAST search for the sequence of CeuE against protein structure 
sequences.440 For unknown proteins, sequence alignment was carried out using a BLAST 
search for the full sequence of CeuE.440 Sequence matches from 1000 possible hits were 
selected for bacterial species of interest. All sequences were aligned using MUSCLE with 
ClustalW output format,426 and the sequence alignment image generated with ESPript.427 
6.4 Protein Production and Purification 
FepB was prepared under the guidance of Dr E. V. Blagova as follows. 
FepB Protein Sequence  







Primer Design and Cloning 
Primers were designed for the gene sequence coding for amino acid residues 27-318 FepB 
in K Strain MC1061 E. coli. Primers were designed using Regional Order Neural Network 
disorder predictions429, Uniprot including Reference Clusters, T-Coffee, ClustalW2 and 
Reverse Complement.441 The designed construct consisted of 873 base pairs. Gradient PCR 
of the construct was carried out using a 25 cycle procedure of denaturation at 94°C for 30 
seconds, annealing at 53 ± 10 °C for 30 seconds, and extension at 72 °C for 50 seconds, 
followed by a 3-minute final extension. The In-fusion protocol was used to insert the desired 
construct into the Lic+ vector. This was achieved by mixing the vector and the insert with 
the In-fusion enzyme and heating for 15 minutes at 50 °C, followed by cooling to 4°C.  The 




using a heat shock method. The method consisted of cooling 25 µL of cells with 2.5 µL 
diluted In-fusion mixture on ice for 10 minutes. The cells were then heated at 42 °C for 35 
seconds, and cooled on ice for a further 10 minutes. 90 µL of GS96 media was added and 
the cells were incubated at 37 °C for 1 hour. The culture was plated on agar containing 1% 
kanamycin and incubated overnight at 37°C.  
Colony PCR was carried out on 16 colonies resulting from the transformed Competent Nova 
Blue cells with the procedure as follows. Heating at 94 °C for 2 minutes, followed by 25 
cycles of heating to 94 °C for 30 seconds, cooling to 52 °C for 30 seconds and then heating 
to 72 °C for 40 seconds. The heating and cooling cycles were then followed by a final 
extension at 72 °C for 3 minutes, and cooling to 4 °C. 11 out of 16 colonies showed positive 
inserts of the desired vector. 8 of these colonies were taken forward for culture. Each colony 
was incubated at 37 °C overnight in 10 mL of sterile LB media, with 1% kanamycin. 
Plasmid DNA from the 8 resulting cultures was purified via the following protocol. Cells 
were centrifuged at 5000 rpm for 15 minutes, and the supernatant removed. The pellet was 
resuspended in buffer P1 (250 µL) and transferred to a microcentrifuge tube where buffer 
P2 (250 µL) was added and mixed by inversion. After a maximum of 5 minutes, buffer N3 
(350 µL) was added and mixed by inversion. The mixture was centrifuged at 13000 rpm for 
10 minutes. The supernatant was applied to a QIAprep spin column and centrifuged for 1 
minute. The flow-through was discarded and the column was washed with buffer PB (500 
µL) and centrifuged for 1 minute. The flow-through was discarded and the column was 
washed with buffer PE (750 µL) and centrifuged for 1 minute. The column was placed in a 
clean 1.5 mL collection tube, and DNA eluted with EB buffer (50 µL) by standing for 1 
minute followed by centrifugation for 1 minute. 
Test restriction was carried out using Nco1 and Nde1 enzymes and heating to 37 °C for 2 
hours. Restriction Cut software442 showed no predicted cleavage of the main sequence of the 
inserted gene. Positive results were produced for DNA obtained from 4 out of the 8 colonies.  
External sequencing of 2 of the 4 DNA samples gave positive results for further 
transformation of expression cells, with 100% sequence similarity to that of the initial K 
Strain MC1061 gene, as designed. 
Test Expression 
BL21 expression cells were transformed for test expression using the heat shock method. 
The method consisted of cooling 30 µL of cells with 1 µL diluted DNA (20 pmol/µL) on ice 




further 10 minutes. 90 µL if GS96 media was added and the cells were incubated at 37 °C 
for 1 hour. The culture was plated on agar containing 1% kanamycin and incubated overnight 
at 37 °C. 
LB media (10 mL) with 1% kanamycin was incubated overnight at 37 °C for two resulting 
colonies. 200 µL of each overnight culture was taken for inoculation in LB media (10 mL) 
with 1% kanamycin. The inoculation cultures were incubated for 100 minutes until the OD600 
reached 0.653 and 0.563. The cultures were taken forward for induction as well as a portion 
stored as 25% glycerol stocks at -80 °C for future use. 
 1% IPTG was used to induce the cells, keeping one culture at 37°C for 4 hours, and the 
other at 16 °C overnight. 4 stocks of 1 mL were centrifuged at 600 rpm and the supernatant 
removed. The cells were stored at -80°C. The pellet was defrosted and suspended in 50 mM 
Tris-HCl, 500 mM NaCl, pH 7.5 (100 µL) and sonicated for 15 seconds. The suspended cells 
were aliquoted into 10 equal tubes of 10 µL and centrifuged at 13000 rpm for 2 minutes to 
remove the cell pellet. 10 µL supernatant was deemed the soluble protein. The soluble 
protein was loaded onto a 12% SDS PAGE gel. The gel was run and stained with Coomassie 
Brilliant Blue R250. The gel was then soaked in a destaining solution for 24 hours, showing 
the presence of both soluble and insoluble protein of the correct molecular weight. Protein 
sequencing gave 100% sequence similarity to the desired product of the initial K Strain 
MC1061 gene. 
Overexpression 
Expression was scaled up to 2L BL21 cultures in LB broth. After 105 minutes at 37°C, OD600 
reached 0.6-0.8. The cells were induced with IPTG and incubated at 16 °C overnight. SDS 
PAGE gel showed good overexpression. 
The 2 L cultures were centrifuged and the cell pellet collected and frozen at -80 °C. The cell 
pellet (16 mL) was thawed for protein purification and resuspended in 50 mM Tris-HCl, pH 
7.5, 500 mM NaCl, 10 mM imidazole (80mL). The suspended cells were sonicated for 55 
seconds kept on ice and below 20 °C during sonication. When the temperature had fallen 
back to 8 °C, after around 15 minutes, a further 55 seconds of sonication were carried out. 
The process was repeated for 4 sonications. The cell pellet was removed via centrifugation 
in two portions at 4 °C. 
Purification 
The Lic+ vector provided a histidine tag labelled FepB, meaning the protein could be 




Nickel column buffer containing 50 mM Tris-HCl, pH 7.5, 500 mM NaCl, 10 mM imidazole 
was made on a 1 L scale by adding 50 mL 1M Tris-HCl stock, 29.22 g NaCl and 0.6808 g 
Imidazole to 900 mL of Millipore filtered deionised water. The buffer was adjusted to pH 
7.5 with 1 M HCl and made up to 1 L with Millipore filtered deionised water. The buffer 
was then degassed via vacuum pump filtration.  
High imidazole nickel column buffer containing 50 mM Tris-HCl, pH 7.5, 500 mM NaCl, 
500 mM imidazole was made on a 1 L scale by adding 50 mL 1M Tris-HCl stock, 29.22 g 
NaCl and 34.04 g Imidazole to 900 mL of Millipore filtered deionised water. The buffer was 
adjusted to pH 7.5 with 1 M HCl and made up to 1 L with Millipore filtered deionised water. 
The buffer was then degassed via vacuum pump filtration. 
Gel filtration buffer containing 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, was made on a 1 L 
scale by adding 50 mL 1M Tris-HCl stock and 8.76 g NaCl to 900 mL of Millipore filtered 
deionised water. The buffer was adjusted to pH 7.5 with 1 M HCl and made up to 1 L with 
Millipore filtered deionised water. The buffer was then degassed via vacuum pump filtration. 
The 5 mL volume nickel column was prepared by washing with 7.5 mL NaOH, 15 mL 
Millipore filtered deionised water, 7.5 mL 0.5M EDTA pH 8.0, 30 mL Millipore filtered 
deionised water. The column was then charged with 7.5 mL 0.1 M NiSO4 for 20 minutes, 
and washed with 10 mL Millipore filtered deionised water to removed excess NiSO4. 
The nickel column was connected to an Akta purifier and equilibrated with nickel column 
buffer and high imidazole nickel column buffer. A superloop of 50 mL volume was 
connected and washed with nickel column buffer at a flow rate of 5 mL/min. the nickel 
column was attached and washed with nickel column buffer at a flow rate of 1 mL/min. The 
superloop was then loaded with 45 mL crude FepB protein extract. 
Akta purifier was prepared for collection of 8 mL fractions in 18 mm tubes. Fractions of 
FepB in nickel column buffer were collected after passage through the nickel column at a 
flow rate of 3.5 mL/min and a column pressure limit of 0.5 mPa. Once the superloop was 
sufficiently emptied, the remaining 25 mL crude FepB protein extract was loaded. UV/Vis 
spectra were measured at 254, 280 and 420 nm. The column was washed with 35 mL nickel 
column buffer before introducing high imidazole nickel column buffer to create an imidazole 
gradient over 3 steps, of 35 mL 33%, 35 mL 66% and 35 mL 100% at a flow rate of 3.5 
mL/min and a column pressure limit of 0.5 MPa. The eluted protein was collected in 4 mL 
fractions in 18 mm tubes. The run was carried out for 67 minutes. The protein eluted in 14 




remaining protein in the flow-through fractions was discarded. The fractions were analysed 
for the presence of histidine tagged FepB via 15% SDS PAGE gel run at 200V for 48 
minutes. The gel was stained with Coomassie dye, heated for 70 seconds and shaken for 3 
minutes before being rinsed with destain solution and heated for a further 90 seconds. The 
excess dye was extracted via absorption with tissue and further shaking. The gel was imaged 
to reveal the histidine tagged FepB in the gradient fractions, which were then combined.  
The Bradford method was used to estimate the protein concentration using dilutions of 1000, 
2000 and 3000 fold. The absorbance at 595 nm of the protein mixed in a 1:1 ratio with 
Bradford reagent was measured after standing for 10 minutes. The equation y = 0.0297x + 
0.0267 was used to calculate protein concentration in mg/mL. The dilutions estimated 
concentration to be 5.6 mg/mL, 8.9 mg/mL and 10.8 mg / mL respectively, averaging to give 
an estimated concentration of 8.4 mg/mL. 
The histidine tag was cleaved via C3 protease, added dropwise in a 1:50 ratio (0.94 mL 
10mg/mL C3 protease stock, 56 mL, 8.4 mg/mL FepB) followed by the addition of DTT 
added dropwise (56 µL, 2.5 M). The mixture was placed into dialysis tubing and dialysed 
against 4 L 50 mM Tris-HCl, pH 7.5, 150 mM NaCl overnight at 4°C. 
The digest was deemed successful via 15% SDS PAGE gel of samples of FepB before and 
after the digest, showing a small shift in band position, indicating a loss of the histidine tag. 
The digested, dialysed protein was purified via a second nickel column to remove any 
remaining tagged protein. The nickel column was prepared as previously described, and the 
Akta purifier prepared and protein loaded via superloop. Gel filtration buffer was used to 
elute the protein followed by a gradient of high imidazole nickel column buffer to elute any 
remaining protein. The untagged protein eluted in the flow through portion, over 17 × 4 mL 
portions. UV spectra were measured at 254, 280 and 420 nm and the presence of untagged 
FepB was confirmed via 15% SDS PAGE gel. 
The flow-through FepB fractions were collected combined and concentrated in protein filter 
Falcon tubes at 5000 rpm for 12 minutes. The flow through was checked to be free of protein 
via the Bradford method, and the concentrated protein above the filter collected for size 
exclusion gel filtration chromatography. 
The gel filtration column (Superdex75 S75 Hiload 16/60, 120 mL volume) on the Akta 
purifier was equilibrated with 150 mL gel filtration buffer at a flow rate of 1 mL/min and 
pressure limit 0.5 mPa. The loop was washed by syringe with 30 mL gel filtration buffer. 




flow rate of 1.2 mL/min for a total volume of 130 mL. The run lasted 110 minutes. UV 
spectra were recorded at 256, 280 and 420 nm and 4 mL fractions collected in 18 mm tubes. 
When the UV spectra indicated the protein had eluted, the loop was washed with 30 mL gel 
filtration buffer and the gel filtration process repeated for two further portions of 
concentrated protein. 15% SDS PAGE gel confirmed the presence of FepB in 3 fractions of 
each gel filtration. The total 9 fractions were combined. 
The concentration of purified FepB was estimated via the Bradford method detailed above 
to give an estimated concentration of 13.2 mg/mL. As the total volume was 35 mL, the total 
protein was estimated to be 460 mg. 
The purified protein was concentrated to 7.5 mL via centrifugation in a protein filter Falcon 
tube at 5000 rpm. The final concentration was estimated via the Bradford method as 
52mg/mL. The total protein was estimated to be 450 mg and was aliquoted into portions and 
stored at -80°C until required. Correct protein folding was confirmed by circular dichroism, 
and ESI-MS confirmed a molecular weight of 31932.2 Da. 
For further use of the protein, a more accurate concentration was determined using UV-
visible spectroscopy. ProtParam was used to calculate an estimated molar absorption 
coefficient for FepB of 35410 M-1 cm-1 at 280 nm in water.443 The absorbance of each protein 
in 40 mM Tris-HCl pH 7.5, 150 mM NaCl at 280 nm was recorded, and the concentration 
of the solution determined using the Beer-Lambert Law. 
6.5 Preparation of CeuE variant proteins 
CeuE Mutants were prepared as follows by Dr. E. V. Blagova. PCR-based site directed 
mutagenesis was used on the CeuE construct containing residues 24–330. Each desired 
mutation was incorporated into amplification primers for plasmid DNA in the YSBLic3C 
vector. Three single CeuE mutants were constructed:  
H227L (FWD_H227_Lataaaagtaggcacactcggaaaaagtatcaat; Rev_H227_L 
attgatactttttccgagtgtgcctacttttat), 
 H227A (FWD_H227_Aataaaagtaggcacagccggaaaaagtatcaat; REV_H227_A 
attgatactttttccggctgtgcctacttttat) 
 Y288F (FWD_Y288_F gatccagaatactggtttttagcaagtggaaat; REV_Y288_F 
atttccacttgctaaaaaccagtattctggatc). 
The plasmid DNAs of the CeuE single variants were then subjected to a further PCR cycle 




expressed and purified according to the standard procedure detailed for FepB. Pure 
mutants were concentrated to 20–40 mg/ml and stored at − 80 °C. 
6.6 Protein Crystallography 
General Protein Crystallisation Procedure 
All protein crystals were obtained by sitting drop vapour diffusion crystallisation using 
commercial screens aliquoted into 96 well plates using a Mosquito nanolitre pipetting robot 
(TTP LabTech, UK). 
Crystallisation screens of CeuE and CeuE mutants were performed using the PACT 
(Molecular Dimensions) screen with each drop contained 150 nL protein complex solution 
and 150 nL reservoir solution. 
Crystals obtained were initially tested for diffraction at 120 K under the direction of Dr E. 
V. Blagova, using a MarResearch Mar345 Image Plate Detector with Rigaku VariMax HF 
Confocal X-ray Optics. Alternatively, crystals were tested by Mr S. Hart using a Rigaku 
Actor Robotic Sample Changer setup with Rigaku VariMax HF Confocal X-ray Optics and 
an RAXIS IV++ imaging plate detector. Both systems were supplied with X-rays via a 
Rigaku MicroMax-007 HF X-ray Generator, with crystals mounted under an Oxford 
Cryosystem 700 Series Cryostream. Crystals of acceptable quality were then sent for data 
collection at the Diamond Light Source. 
Preparation of Iron(III)-Ligand Complexes 
All iron(III)-n-LICAM complexes were prepared by stirring ~3 mg of the relevant n-
LICAM4- in 1 mL methanol with the relevant FeCl3 concentration from aqueous stock to 
produce 1:1 or 2:3 complexes over 1 hour. Solvent was removed in vacuo and the Fe-n-
LICAM complex taken up in DMF at the desired concentration. Iron(III)-5-LICAM and 
iron(III)-6-LICAM were each prepared in a 1:1 ratio in a 100 mM stock solution. Iron(III)-
8-LICAM was prepared via the same method to obtain a 1 M stock solution of a 2:3 complex. 
Co-crystallisation of Iron(III)-Ligand Complexes with CeuE and Mutant CeuE 
H227L 
For CeuE-iron(III)-6-LICAM-, 57 L of CeuE diluted to 20 mg mL-1 was mixed with 3 L 
of the iron(III)-6-LICAM- solution in a 1:10 molar ratio. The solution was centrifuged at 
13000 RPM for 2 minutes to remove any precipitate. The resulting supernatant was separated 




prepared in the same way as CeuE-iron(III)-6-LICAM but in a ligand: protein molar ratio of 
1:100. H227L-CeuE-iron(III)-5-LICAM was prepared in a 1:4 molar ratio.  
For CeuE-iron(III)-6-LICAM the best diffraction was observed for those grown from PACT 
conditions C4 (0.1 M PCB buffer comprising 2:1:2 molar ratio sodium propionate, sodium 
cacodylate, and BisTrisPropane, pH 7, 25% PEG 1500). A crystal from condition C4 was 
cryo-protected (0.1 M PCB buffer comprising 2:1:2 molar ratio sodium propionate, sodium 
cacodylate, and BisTrisPropane, pH 7, 32.5% PEG 1500) and used for data collection. For 
CeuE-iron(III)-8-LICAM the best diffracting crystals grew in PACT condition H6 0.2 M 
sodium formate, 0.1 M BisTrisPropane buffer, pH 8.5, 20% PEG 3350. A crystal from 
condition H6 was cryo-protected in 0.2 M sodium formate, 0.1 M BisTrisPropane buffer, 
pH 8.5, 32.5% PEG 3350 and used for data collection. For H227L-CeuE-iron(III)-5-LICAM 
the best diffracting crystals grew in PACT conditions, 0.1 M PCB buffer, pH 8, 20% PEG 
1.5 K. The CeuE-iron(III)-6-LICAM and CeuE-iron(III)-8-LICAM crystals were cryo-
protected with 32.5% PEG 1500 and 32.5% PEG 3350 respectively and vitrified at 110 K. 
H227L-Fe-5-Lic was cryo-protected with 32.5 % PEG 1.5 K vitrified at 110 K. 
Crystallisation of CeuE Native Mutants  
Crystals were grown, cryo-protected and sent for data collection by Dr E. V. Blagova. 
Crystals were obtained from the following sitting drop vapour diffusion screening 
conditions: CeuE-H227L (0.2 M NaBr; 0.1 M BTP, pH 8.5; 20% PEG 3350); CeuE-H227A 
(0.1 M MMT, pH 9.0; 25% PEG 1.5K) CeuE-Y288F (0.01 M ZnCl2; 0.1 M MES, pH 6.0; 
20% PEG 6 K); CeuE-H227L/Y288F (0.1 M MIB, pH 9.0; 25% PEG 1.5 K); CeuE-
H227A/Y288F (0.1 M SPG, pH 9.0; 25% PEG 1.5 K). All crystals were cryo-protected in 
the relevant well solution with an increased PEG concentration (20% increased to 36%, 25% 
increased to 41%) before vitrification at 110 K.  
6.7 Structure Solution  
Data were collected at the Diamond Light Source. Computations were carried out using 
programs from the CCP4 suite.444 Diffraction images were processed with XIA2445-447. The 
structures were solved using MOLREP448 or PHASER 449, and refined with cycles of 





Spacegroups and Structure Solution for CeuE Co-crystal Structures 
CeuE-iron(III)-6-LICAM was in space group P212121, with a single protein monomer in the 
asymmetric unit. The CeuE-iron(III)-8-LICAM crystal was also in space group P212121, but 
with quite different cell dimensions and crystal packing. H227L-CeuE-iron(III)-5-LICAM 
was in space group P1. The structures were solved starting with CeuE-iron(III)-4-LICAM 
(PDB ID: 5A1J) as a search model using MOLREP448  for H227L-CeuE-iron(III)-5-LICAM 
and using PHASER449 for CeuE-iron(III)-6-LICAM and CeuE-iron(III)-8-LICAM. 
Restraints for the ligands were modelled using JLigand.452 
Spacegroups and Structure Solution for CeuE Variant Proteins  
CeuE-H227L, CeuE-H227A, CeuE-H227L/Y288F and CeuE-H227A/Y288F were in space 
group P1 with three protein monomers in the asymmetric unit. CeuE-Y288F was in space 
group P3221 with one protein monomer in the asymmetric unit. Structures were solved 
starting with apo wild-type CeuE (PDB ID: 3ZKW) as a search model using MOLREP.448 
The overall protein fold for each mutant was very similar to that of wild-type CeuE. There 
was no well-defined electron density for a small number of surface loops (Table 23). 
Table 23: Disordered regions that were not modelled in protein crystal structures of CeuE 
variant proteins. 
CeuE Variant Residues not modelled 
H227L None 
H227A A/252-254, B/98, C/222-227 
Y288F None 
H227L/ Y288F A/99, 193-194, 223-225, 254, B/ 96-97, 184, 223-225, C/ 221-225 
H227A/ Y288F A/253-254, C/221-225 
 
There was clear electron density confirming the presence of phenylalanine in place of 
tyrosine in all three Y288F containing structures. However, residue 227, located on a flexible 
loop lacked electron density in the majority of structures, resulting in limited modelling of 
H227A and H227L side chains.  
Crystallographic Statistics 
Crystallographic statistics for crystal structures of CeuE-iron(III)-6-LICAM and CeuE-
iron(III)-8-LICAM are displayed in Table 24 (values in parentheses are for the highest 




Table 25 (Route mean square deviations from ideal geometry are listed with target values 
in parentheses). Crystallographic statistics for all mutant structures are detailed in Table 26 
and Table 28 with related refinement statistics detailed in Table 27 and Table 29, 
respectively. CC(1/2) is defined as the Pearson correlation coefficient for two half datasets. 
Rmerge is defined as 100x ΣI - <I>/ Σ I, where I is the intensity of the reflection. 
 
Table 24: Crystallographic statistics for crystal structures of CeuE-iron(III)-6-LICAM and 
CeuE-iron(III)-8-LICAM 
Structure CeuE-iron(III)-6-LICAM CeuE-iron(III)-8-LICAM 
Beamline Diamond 104 Diamond 104 
Wavelength (Å) 0.979 0.979 
Space group P212121 P212121 







Resolution range (Å) 44.96-2.04 55.98-1.32 
Observations 146372 457991 
Unique Reflections 18467 77761 
Monomers in AU 1 1 
Completeness % 100.0 (100.0) 99.4 (76.0) 
I/I(σ) 9.6 (1.7) 11.0 (1.3) 
CC(1/2) 0.993 (0.583) 0.998 (0.536) 
Average Multiplicity 7.9 (8.2) 5.9 (3.1) 





Table 25: Refinement statistics for crystal structures of CeuE-iron(III)-6-LICAM and CeuE-
iron(III)-8-LICAM 
Structure CeuE-iron(III)-6-LICAM CeuE-iron(III)-8-LICAM 
%Rcryst (%) 21.3 14.0 
Free R factor (%) 26.3 18.1 
Bond distances (Å) 0.014 (0.019) 0.020 (0.019) 
Bond angles (°) 1.638 (1.997) 1.960 (1.999) 
Chiral centres (Å3) 0.094 (0.200) 0.133 (0.200) 
Planar groups (Å) 0.007 (0.021) 0.010 (0.021) 
Average B value (Å2) 23.4 13.9 
Main chain B (Å2) 23.3 11.0 
Side chain B (Å2) 19.4 14.8 
No. of waters 80 412 
Ramachandran 
Preferred regions % 
96.4 97.8 
Ramachandran 










Table 26: Crystallographic statistics for crystal structures of CeuE-H227L, CeuE- H227L-





Beamline Diamond 103 Diamond 102 Diamond 103 
Wavelength (Å) 0.976 0.979 0.976 
Space group P1 P1 P1 










Resolution range (Å) 65.52-1.52 67.13-1.90 66.02-1.33 
Observations 631986 254669 598024 
Unique Reflections 189953 70811 192548 
Monomers in AU 3 3 3 
Completeness % 95.4 (94.6) 95.9 (96.0) 99.8 (41.0) 
I/I(σ) 9.5 (2.3) 6.2 (1.3) 11.8 (1.4) 
CC(1/2) 0.996 (0.710) 0.991 (0.418) 0.998 (0.604) 
Average Multiplicity 3.5 (3.5) 3.4 (3.5) 3.4 (3.0) 





Table 27: Refinement statistics for crystal structures of CeuE-H227L, CeuE-H227L-





%Rcryst (%) 18.5 17.1 14.8 
Free R factor (%) 22.2 21.5 19.3 
Bond distances (Å) 0.024 (0.019) 0.018 (0.019) 0.033 (0.019) 
Bond angles (°) 2.338 (1.983) 2.002 (1.850) 2.736 (1.985) 
Chiral centres (Å3) 0.169 (0.200) 0.114 (0.200) 0.200 (0.200) 
Planar groups (Å) 0.011 (0.021) 0.009 (0.021) 0.013 (0.021) 
Average B value (Å2) 25.7 34.8 25.2 
Main chain B (Å2) 25.3 32.5 23.4 
Side chain B (Å2) 28.0 37.5 27.1 
No. of waters 301 153 526 
Ramachandran 
Preferred regions % 
96.1 96.3 96.2 
Ramachandran 
Allowed regions % 
3.7 3.2 3.7 
Ramachandran 
Outliers % 
0.2 0.5 0.1 





Table 28: Crystallographic statistics for crystal structures of CeuE-Y288F, CeuE- 
H227L/Y288F and CeuE- H227A/Y288F. 
Structure Y288F H227L/Y288F H227A/Y288F 
Beamline Diamond 102 Diamond 103 Diamond 103 
Wavelength (Å) 0.979 0.979 0.979 
Space group P3221 P1 P1 










Resolution range (Å) 56.74-1.40 60.77-1.80 65.80-1.81 
Observations 668348 271678 262644 
Unique Reflections 71359 78620 77003 
Monomers in AU 1 3 3 
Completeness % 99.8(85.2) 96.2 (96.4) 99.6 (96.2) 
I/I(σ) 19.2 (0.8) 7.4 (1.2) 8.8 (1.6) 
CC(1/2) 1.000 (0.239) 0.995 (0.459) 0.996 (0.599) 
Average Multiplicity 9.4 (6.4) 3.5 (3.4) 3.4 (3.3) 





Table 29: Refinement statistics for crystal structures of CeuE-Y288F, CeuE- H227L/Y288F 
and CeuE- H227A/Y288F. 
Structure Y288F H227L/Y288F H227A/Y288F 
%Rcryst (%) 13.6 19.4 20.0 
Free R factor (%) 16.7 23.9 23.9 
Bond distances (Å) 0.031 (0.019) 0.018 (0.019) 0.019 (0.019) 
Bond angles (°) 12.532 (1.994) 1.864 (1.983) 1.961 (1.981) 
Chiral centres (Å3) 0.213 (0.200) 0.117 (0.200) 0.123 (0.200) 
Planar groups (Å) 0.006 (0.020) 0.008 (0.021) 0.009 (0.021) 
Average B value (Å2) 24.4 36.0 35.9 
Main chain B (Å2) 22.1 34.1 34.7 
Side chain B (Å2) 26.7 38.1 37.4 
No. of waters 193 121 109 
Ramachandran 
Preferred regions % 
96.4 97.1 96.4 
Ramachandran 
Allowed regions % 
3.6 2.8 2.9 
Ramachandran 
Outliers % 
0 0.1 0.7 





6.8 Fluorescence Quenching Titration 
Experimental Parameters 
Intrinsic fluorescence quenching titrations were carried out at room temperature. An 
excitation slit width of 10 nm and an emission slit width of 20 nm, scan speed of 60 nm/min 
with an automatic response used.  The detector voltage was set at 950 V for CeuE and FepB 
titrations, and 700 V for VctP and FepB titrations.  Each protein solution was excited at 280 
nm and the emission spectrum was recorded from 295 nm to 415 nm.   
Stock Solutions 
Tris(hydroxymethyl)aminomethane, (0.02 mol, 2.4228 g) and sodium chloride (0.075 mol, 
4.3830 g) was dissolved in approximately 400 mL distilled water.  The pH was adjusted to 
7.5 with 2 M HCl.  The volume of the solution was made up to 500 mL with distilled water. 
A stock solution of 10 mM of each ligand was prepared in DMSO. 
Nitrilotriacetic acid trisodium salt (0.1 mmol) was dissolved in 0.0179 mol dm-3 standard 
Fe(NO3)3 solution (5.587 mL).  This solution was then made up to 10 mL with distilled 
water, leaving a final solution of 0.01 mol dm-3 Fe(NO3)3 with 0.01 mol dm
-3 NTA. 
A 12 M stock solution of ferric-ligand was prepared by pipetting 2 L of the ligand stock 
solution and 2 L of the Fe(NTA) stock solution into 1696 L of 40 mM Tris-HCl pH 7.5, 
150 mM NaCl and thoroughly mixed. 
Protein Concentration Determination for Fluorescence Titrations 
The protein was diluted to 240 nM in 40 mM Tris-HCl pH 7.5, 150 mM NaCl, and the 
concentration verified by and UV-vis absorbance at 280 nm, using the molar absorbance 
coefficient predicted by ProtParam 443 (CeuE: 15930 M-1 cm-1, FepB: 33920 M-1 cm-1, VctP: 
34380 M-1 cm-1).  
Standard Binding Method 
For each measurement a protein solution of 240 nM in 2000 L, 40 mM Tris-HCl (pH 7.5) 
NaCl 150 mM was placed in a 1 cm quartz cuvette, and titrated stepwise over 15 8 µL 
aliquots, with 2 final 40 µL aliquots of concentrated ferric-ligand stock solution. The titration 
gave a final ligand concentration of 1.19 µM.  After each addition the solution was 
thoroughly mixed and allowed to rest for 1 minute.  Integration of the emission between 310 
and 410 nm was normalised and used for plotting and binding constant calculation, using 




Weak Binding Method 
For each measurement, a protein solution of 2.4 µM in 2000 L, 40 mM Tris-HCl (pH 7.5) 
NaCl 150 mM was placed in a 1 cm quartz cuvette, and titrated stepwise over 15 8 µL 
aliquots, with 2 final 40 µL aliquots of 120 µM ferric-ligand stock solution. The titration 
gave a final ligand concentration of 11.9 µM.  After each addition the solution was 
thoroughly mixed and allowed to rest for 1 minute.  Integration of the emission between 310 
and 410 nm was normalised and used for plotting and binding constant calculation, using 
the fitting program DynaFit.  
VctP Tight Binding Method 
For each measurement, a protein solution of ~6 nM in 40 mM Tris-HCl (pH 7.5) NaCl 150 
mM was placed in a 1 cm quartz cuvette. The solution was subjected to mechanical stirring, 
and titrated stepwise with 24 0.25 µL aliquots of 6 µM ferric ligand stock solution every 4 
minutes using a micro-dosing DOSTAL DOSY and stirred for 1 minutes before spectra were 
recorded. Spectra were integrated between 305-380 nm and the data normalised to produce 
a binding curve. Data were fitted with Dynafit, allowing variable VctP concentration, and 
dissociation constants calculated. 
CeuE Fluorescence Control Experiments 
Spectra were recorded over 75 minutes to gauge whether CeuE fluorescence might be 
quenched over time, or via repeat exposure to the UV radiation set at the excitation 
wavelength of 280 nm. Spectral scans lasting 2 minutes each were recorded every 5 minutes 
over 75 minutes. The fluorescence peak was integrated between 310 nm and 410 nm and the 
data normalised. Normalised fluorescence was plotted against time, showing that 
fluorescence intensity was no lower than 94% of the original fluorescence intensity 
throughout the full 75 minutes. Fluorescence emission did not decrease significantly when 
CeuE was subjected to repeat exposure to the excitation wavelength of 280 nm. This 
indicates that the stability of CeuE under the titration conditions was adequate. 
To ensure that any fluorescence quenching observed was a direct consequence of the 
addition of iron(III)-ligand and not due to dilution or mixing, a control titration with buffer 
(40 mM Tris-HCl pH 7.5, 150 mM NaCl) was carried out. It was observed that the 
fluorescence of CeuE decreased to around 83% of the intensity of the initial signal with the 
addition of 200 µL (10% dilution) buffer. Employing a linear dilution correction shows a 
decrease to around 92% of the original signal. Although there is a small decrease observed, 
it was decided that this would not impact significantly on the result of the fluorescence 




significant, the final normalised emission must be below 0.4- significantly lower than is 
observed for dilution effects. All spectra and plotted data is included in Appendix 1. 
VctP Fluorescence Control Experiments 
VctP in 40 mM Tris-HCl pH 7.5, 150 mM NaCl was titrated with 40 mM Tris-HCl pH 7.5, 
150 mM NaCl to explore whether the protein fluorescence is quenched via dilution or 
mixing. It was observed over 24 0.25 µL aliquots of 40 mM Tris-HCl pH 7.5 every 4 minutes 
using a micro-dosing DOSTAL DOSY and constant overhead stirring, that fluorescence was 
at around 75% of the original signal. It was decided that titrations should not exceed 24 
points, to minimise the decrease in fluorescence of the protein over time. Spectra and plotted 
data are included in Appendix 1. For the fluorescence quenching titration, 24 aliquots of 0.25 
µL of 6 µM iron(III)-5-LICAM in 40 mM Tris-HCl pH 7.5, 150 mM NaCl were titrated into 
0.012 µM VctP in 40 mM Tris-HCl pH 7.5, 150 mM NaCl every 4 minutes using a micro-
dosing DOSTAL DOSY with constant overhead stirring. The resulting spectra were 
integrated between 305 nm and 380 nm and the data normalised. A fitting curve and 
dissociation constant were calculated for each run using Dynafit.326 
Ligand Absorbance Control Experiments 
The absorbance of iron(III)-5-LICAM in a 1:1 ratio in 40 mM Tris-HCl pH 7.5, 150 mM 
NaCl buffer was monitored over a range of concentrations to establish the absorbance of the 
complex at 280 nm. If ligand absorbance exceeded 0.1, it was deemed unacceptable due to 
significant contribution of primary inner filter effect. The UV/Vis spectra are shown in 






Figure 141: UV/Vis spectra of iron(III)-5-LICAM over a range of concentrations in 40 mM 
Tris-HCl pH 7.5, 150 mM NaCl. 
 
Figure 142: Absorbance of iron(III)-5-LICAM at 280 nm plotted against concentration. y= 




The equation of the line of best fit was used to establish the concentration at which 
absorbance of 0.1 is exceeded. The maximum ligand concentration was calculated as 67.3 
µM. 
The study was repeated for iron(III)-6-LICAM as well as iron(III)-8-LICAM. 
The UV spectra for iron(III)-n-LICAM (n= 6, 8) in a 1:1 ratio were recorded at varying 
concentrations in 40 mM Tris-HCl pH 7.5, 150 mM NaCl buffer until an absorbance of 0.2 
was exceeded (Figure 143 and Figure 144). The resulting data was plotted to produce a linear 
relationship between absorbance at 280 nm and concentration (Figure 145 and Figure 146).  
 
 






Figure 144: UV/visible spectra of iron(III)-8-LICAM in a 1:1 ratio at varying concentrations. 
 
Figure 145: Plot of iron(III)-6-LICAM absorbance at 280 nm vs concentration in µM, 
showing good adherence to the Beer Lambert law. Equation of the line of best fit: y= 0.0027x 





Figure 146: Linear relationship between iron(III)-8-LICAM absorbance at 280 nm vs 
concentration in µM. Equation of the line of best fit: y= 0.0024x + 0.0029 R2= 0.9996. 
In accordance with the Beer-Lambert law, the resulting lines of best fit could be used to 
determine that at absorbance of 0.1 the concentration of iron(III)-6-LICAM was 37.34 µM 
and iron(III)-8-LICAM was 41.07 µM meaning these were the maximum concentrations 
permissible for this system.  
UV spectra of iron(III)-enterobactin were used to confirm the upper iron(III)-enterobactin 
concentration that could be used in fluorescence quenching titration experiments (Figure 
147). The absorbance at 280 nm was plotted against concentration to produce Figure 148. 
The equation of the line of best fit could then be used to calculate the concentration of 
iron(III)-enterobactin that provides an absorbance of 0.1, of 18.40 µM. As five equivalents 
of ligand are required to provide adequate saturation of the CeuE binding pocket, the 
maximum protein concentration that could be used in fluorescence quenching titrations of 






Figure 147: UV/visible spectra of iron(III)enterobactin in a 1:1 ratio at varying 
concentrations. 
 
Figure 148: Absorbance at 280 nm of iron(III)-enterobactin vs concentration. y= 0.005x + 




Averages and Error Calculation 
Each titration was performed in triplicate. The average was calculated and an overall error 
calculated using the uncertainty in average method, classically used instead of standard 
deviation when a data set is small (Figure 149).453 
  
Figure 149: Equations used for calculation of weighted average and errors for Kd values. ai 
= raw data value, σi = raw error, N = number of data values used453  
6.9 Circular Dichroism 
Protein Folding Experiments 
VctP was diluted to 0.4 mg mL-1 in 5 mM Tris-HCl pH 8. FepB was diluted to 0.4 mg mL-1 
in 5 mM Tris-HCl pH 7.5. Spectra were recorded from 190-240 nm with data pitch 0.5 mm 
in continuous scanning mode with speed of 100 nm min-1and response of 2 seconds. The 
bandwidth was set to 2 nm, with a path length of 1cm. The spectra were recorded 5 times 
and averaged. 
Ligand Binding Experiments 
The spectra were recorded from 300-700 nm with data pitch 0.5 mm in continuous scanning 
mode with speed of 100 nm min-1and response of 2 seconds. The bandwidth was set to 2 nm, 
with a path length of 1cm. The spectra were recorded 5 times and averaged. 
Proteins including wild type CeuE and all mutants, FepB and VctP were diluted to 2.5 × 10-
3 M in 0.11 M Tris-HCl pH 7.5, 150 mM NaCl buffer. An iron(III)-ligand stock solution 
containing equimolar NTA was made at a concentration of 5 × 10-4 M. This was done by 
adding 10 µL of both 10mM ligand in DMSO and 10 µL 10mM Fe(III)NTA in H2O to 180 




Spectra were recorded by making a final solution comprising 880 µL 0.11 M Tris-HCl pH 
7.5, 150 mM NaCl buffer, 100 µL (iron(III)-ligand NTA stock solution and 20 µL 2.5 × 10-
3 M CeuE, resulting in a 1:1 ratio of ligand to protein at 5 × 10-5 M. 
The spectrum of buffer was subtracted from all spectra including the spectra for free ligand 
and apo protein. 
CeuE Iron(III)-5-β-ᴅ-glucosyl-4-LICAM and Iron(III)-5-β-ᴅ-glucosyl-5-
LICAM Circular Dichroism Titrations 
A 980 µL solution of iron(III)-5-β-ᴅ-glucosyl-n-LICAM (n = 4, 5) containing equimolar 
NTA was made at a concentration of 5 × 10-5 M as above. CD spectra were run over a series 
of additions of CeuE. Additions were made in 0.2 equivalents of protein until 3 equivalents 
were achieved, after which 1 equivalent additions were made. The final concentration of 
CeuE was 3 × 10-4 M, equal to a 1:6 ligand to protein ratio, at which point the addition of 
further protein did not change the spectral signal observed. The ellipticity value in mdeg was 
recorded at 330 nm for each spectrum, and plotted against CeuE concentration to obtain a 
binding curve. The binding constant was calculated using Dynafit Software.326 The titrations 
were repeated in triplicate and the average and an overall error calculated using the 
uncertainty in average method as detailed for the above fluorescence titrations. 
6.10 Job Plot  
5-β-ᴅ-Glucosyl-n-LICAM (n = 4, 5) were analysed for their iron(III) binding stoichiometries 
via a Job plot method established in the literature.90  5-β-ᴅ-glucosyl-n-LICAM (n = 4, 5) 
was combined with varying concentrations of iron(III) to establish preferred metal to ligand 
binding ratios. The ratios spanned 100% ligand to 100% iron(III), with 5% intervals. 
Between 60:40 and 50:50 ligand to iron(III) ratios, 2% intervals were used. This protocol 
resulted in 24 samples over the full range. Stock solutions of 10 mM Fe(III)NTA in H2O and 
10 mM 5-β-ᴅ-glucosyl-n-LICAM (n = 4, 5) in DMSO were used in the necessary ratios 
totalling 200 µL to make up a 2 mL solution of each ratio in 1800 µL 0.11 M Tris-HCl pH 
7.5, 150 mM NaCl, resulting in an overall iron(III)-ligand concentration of 400 nM. DMSO 
was kept at 5% v/v for all final solutions. A UV/Vis spectrum from 400 nm to 700 nm was 
run for each solution after 1 hour of equilibration. The spectra were then rerun after 7 days 
of equilibration. λmax values were observed at 498 nm and 552 nm for iron(III)-5-β-ᴅ-
glucosyl-4-LICAM and 495 nm and 555 nm for iron(III)-5-β-ᴅ-glucosyl-5-LICAM. The 
absorbance at these wavelengths was plotted against ligand to protein ratio, and the 




6.11 Analytical HPLC 
Purchased enterobactin, salmochelin S1 and salmochelin S4 were examined by analytical 
HPLC. For enterobactin, the method was based on several reports from literature.86, 87, 454 
Enterobactin was dissolved in water containing 0.1% TFA and filtered through a PTFE 
syringe filter with pore size of 0.22 µm. The column oven temperature was set at 35 ºC. For 
enterobactin, the method comprised of a 10-80% gradient of acetonitrile in water with 0.1% 
TFA throughout, over 35 minutes at a flow rate of 1 mL/min. After 35 minutes the gradient 
was reduced back to 10% acetonitrile in water with 0.1% TFA for a further 10 minutes. 
For salmochelin S1 and salmochelin S4, the method was based on a reports from the 
literature.235 Salmochelin S1 and salmochelin S4 were dissolved in water containing 0.1% 
formic acid and filtered through a PTFE syringe filter with pore size of 0.22 µm. The column 
oven temperature was set at 35 ºC. For both samples, the method comprised of a 6-40% 
gradient of acetonitrile in water with 0.1% formic acid throughout, over 30 minutes at a flow 
rate of 1 mL/min. After 30 minutes the gradient was increased from 40% to 90% over 15 
minutes. The gradient was then reduced back to 6% acetonitrile in water with 0.1% formic 
acid for a further 9 minutes. 
The sample of salmochelin S4 was stored at room temperature for 24 hours before the sample 
was rerun using the same HPLC setup and conditions. 
6.12 ESI-MS for Natural Salmochelins 
Enterobactin  
HRMS: Calcd. [M-H]- (C30H26N3O15) m/z = 668.1369; Obs. [M-H]
- (C30H26N3O15) m/z = 
668.1369, Mean err 0.3 ppm. Calcd. [M+OH]- (C30H28N3O16) m/z = 686.1475; Obs. 
[M+OH]- (C30H28N3O16) m/z =686.1475, Mean err 0.1 ppm. 
Salmochelin S1 
HRMS: Calcd. [M-H]- (C26H29N2O16) m/z = 625.1523; Obs. [M-H]
- (C26H29N2O16) m/z = 




Appendix 1: Fluorescence Quenching Titration Data and 
Controls 
 
Figure 150: Fluorescence spectra of CeuE recorded over 75 minutes. 
 
Figure 151: Fluorescence emission of CeuE monitored over time, showing adequate stability 





Figure 152: Decrease in fluorescence observed when CeuE is titrated with 40 mM Tris-HCl 
pH 7.5, 150 mM NaCl, shown as both uncorrected normalised data and a linear dilution 
correction across the titration. 
 
Figure 153: Fluorescence quenching titration curves, as a plot of normalised fluorescence 
emission vs ligand concentration in µM for FepB-Fe(III)-bisDHBS, FepB-Fe(III)-n-LICAM 
(n = 4, 5) and FepB-Fe(III)Sal-n-LICAM (n = 4, 5) and their associated non-linear regression 
fitting data from Dynafit. 240 nM FepB in 40 mM Tris-HCl pH 7.5, 150 mM NaCl was 





Figure 154: Fluorescence quenching titration curves, as a plot of normalised fluorescence 
emission vs ligand concentration in µM for VctP titrated with buffer and Fe(III)-NTA. VctP 
was at concentration of 240 nM in 40 mM Tris-HCl pH 7.5, 150 mM NaCl and was titrated 
with aliquots of 12 M Fe(III)-NTA in 40 mM Tris-HCl pH 7.5, 150 mM NaCl, and the 
equivalent volume of 40 mM Tris-HCl pH 7.5, 150 mM NaCl.  
 
 
Figure 155: Fluorescence quenching titration curves for VctP-Fe(III)-enterobactin, as a plot 
of normalised emission vs ligand concentration in µM for VctP-Fe(III)-enterobactin and 
their associated non-linear regression fitting data from Dynafit. 240 nM VctP in 40 mM Tris-
HCl pH 7.5, 150 mM NaCl was titrated with aliquots of 12 M Fe(III)-enterobactin- in 40 





Figure 156: Fluorescence quenching titration curve for VctP-Fe(III)-bisDHBS Fluorescence 
quenching titration curve, as a plot of normalised fluorescence emission vs ligand 
concentration in µM for VctP-Fe(III)-bisDHBS and the associated non-linear regression 
fitting data from Dynafit. VctP at a concentration of 240 nM in 40 mM Tris-HCl pH 7.5, 150 
mM NaCl was titrated with aliquots of 12 M Fe(III)-bisDHBS- in 40 mM Tris-HCl pH 7.5, 
150 mM NaCl. 
 
Figure 157: Fluorescence quenching titration curve for VctP-Fe(III)-bisDHBS Fluorescence 
quenching titration curve, as a plot of normalised fluorescence emission vs ligand 
concentration in µM for VctP-Fe(III)-bisDHBS and the associated non-linear regression 
fitting data from Dynafit. VctP at a concentration of 48 nM in 40 mM Tris-HCl pH 7.5, 150 
mM NaCl was titrated with aliquots of 2.4 M Fe(III)-bisDHBS- in 40 mM Tris-HCl pH 





Figure 158: Fluorescence quenching titration curve for VctP-Fe(III)-5-LICAM Fluorescence 
quenching titration curve, as a plot of normalised fluorescence emission vs ligand 
concentration in µM for VctP-Fe(III)-5-LICAM and the associated non-linear regression 
fitting data from Dynafit. VctP at a concentration of 240 nM in 40 mM Tris-HCl pH 7.5, 150 
mM NaCl was titrated with aliquots of 12 M Fe(III)-5-LICAM- in 40 mM Tris-HCl pH 7.5, 
150 mM NaCl. 
 
Figure 159: Fluorescence quenching titration curve for VctP-Fe(III)-5-LICAM Fluorescence 
quenching titration curve, as a plot of normalised fluorescence emission vs ligand 
concentration in µM for VctP-Fe(III)-5-LICAM and the associated non-linear regression 
fitting data from Dynafit. VctP at a concentration of 48 nM in 40 mM Tris-HCl pH 7.5, 150 
mM NaCl was titrated with aliquots of 2.4 M Fe(III)-5-LICAM- in 40 mM Tris-HCl pH 





Figure 160: Fluorescence quenching titration curve for VctP-Fe(III)-4-LICAM Fluorescence 
quenching titration curve, as a plot of normalised fluorescence emission vs ligand 
concentration in µM for VctP-Fe(III)-4-LICAM and the associated non-linear regression 
fitting data from Dynafit. VctP at a concentration of 240 nM in 40 mM Tris-HCl pH 7.5, 150 
mM NaCl was titrated with aliquots of 12 M Fe(III)-4-LICAM- in 40 mM Tris-HCl pH 7.5, 





data = equilibria  
task = fit  
[mechanism] 
PBP + FeL <==> PBP.FeL : Kd dissoc 
 
[constants] 
Kd = V ? 
 
[concentrations] 
CeuE = W uM / approx 5.00 mgmL-1 3 uL  
  
[responses] 
CeuE = X ?, CeuE.FeLD = Y ? ; Initial fluorescence divided by amount of CeuE i.e. 










Figure 161: Dynafit script used for a general fluorescence titration. V is edited with an 
estimate of an approximate dissociation constant. W is edited for protein concentration 




Iron(III)-Siderophore Complex Nomenclature 
For simplicity, all iron(III) complexes have been reported in a simplified format: PBP-
iron(III)-ligand. This naming system does not necessarily reflect the true stoichiometry of 
iron(III) to ligand, and there may be multiple iron(III) to ligand ratios in equilibrium, with 
associated charges on each overall complex. For complexes with proteins, the overall charge 
of the system cannot be accurately estimated due to the large number of charged protein 
sidechains. ‘PBP’ refers to CeuE, FepB or VctP. The most likely formulae are listed for each 
term, but are not exhaustive and do not consider the potential for solvent coordination: 
Simplified name Possible true complex(es) 
Iron(III)-n-LICAM (n= 4, 5, 6, 8) [Fe(III)-n-LICAM]- 
[{Fe(III)}2{n-LICAM}3]
6- 













Iron(III)-Sal-n-LICAM (n= 4, 5) [Fe(III)-Sal-n-LICAM]- 
[{Fe(III)}2{Sal-n-LICAM}3]
6- 





°C degrees Celcius 
Å Angstrom 
ABC ATP-binding cassette 
A. fulgidus Archaeoglobus fulgidus 
Ala alanine 





ATIR attenuated total reflectance infrared 
atm atmosphere 
ATP adenosine triprosphate 
B. subtilis Bacillus subtilis 
BnBr benzyl bromide 
c (prefix) centi 
Calcd. calculated 
CD circular dichroism 
CDCl3 deuterated chloroform 
CDI 1,1'-carbonyldiimdazole 
CD3OD deuterated methanol 
CHN carbon hydrogen nitrogen 
C. jejuni Campylobacter jejuni 
COSY correlation spectroscopy 
C. trachomatis Chlamydia trachomatis 





DEPT Distortionless Enhancement by Polarisation Transfer 







DNA deoxyribonucleic acid 
DTT dithiothreitol 
DtxR diphtheria toxin regulator 
E1/2 half cell potential 
E. coli Escherichia coli 
E. faecium Enterococcus faecium 
Ent enterobactin 
E. raffinosus Enterococcus raffinosus 
Err. error 
ESI-MS electrospray ionisation mass spectrometry 
Et3N triethylamine 
EtOAc ethyl acetate 
EtOH ethanol 
FAD flavin adenine dinucleotide 
Flu fluvibactin 
Fur ferric uptake regulator 




G. thermoglucosidasius Geobacillus thermoglucosidasius 
H. influenzae Haemophilus influenzae 
HATU 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-
b]pyridinium 3-oxid hexafluorophosphate 
His histidine 
HMBC heteronuclear multiple-bond correlation 
HMQC heteronuclear multiple quantum correlation 
HPLC high performance liquid chromatography 
HRMS high resolution mass spectrometry 
Hz hertz 
Ile isoleucine 
IPTG isopropyl β-D-1-thiogalactopyranoside  
J Joule 
k (prefix) kilo 
K Kelvin 
Kd dissociation constant 
Kf formation constant 
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λmax wavelength of maximum absorbance 
L litre 
L ligand in complexation 
LB lysogeny broth 
Leu leucine 
LICAM linear catecholamide 
LMCT ligand to metal charge transfer 
Lys lysine 
M (prefix) mega 
m metre 
M molar 






M.P melting point 
m/z mass/charge 
n (prefix) nano 
NADH reduced nicotinamide adenine dinucleotide 
NADPH reduced nicotinamide adenine dinucleotide phosphate 
NMR  nuclear magnetic resonance 
NSPD norspermidine 
NTA  nitriloacetic acid 
NVT Constant number volume and temperature 
Obs. observed 
OD600 optical density at 600 nm 
p (prefix) pico 
Pa pascal 
P. aeruginosa Pseudomonas aeruginosa 
PBP periplasmic binding protein 
PCR polymerase chain reaction 
PDB ID Protein Data Bank identifier code 
PEG polyethylene glycol 
Phe phenylalanine 




Rf retardation factor 
r.m.s.d root mean square deviation 
RNA ribonucleic acid 
rpm revolutions per minute 
s seconds 
SSM secondary structure matching 
S. aureus Staphylococcus aureus 
SDS PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
S. enterica Salmonella enterica 
Ser serine 
S. pneumoniae Streptococcus pneumoniae 
STEC shiga toxin-producing E. coli 
S. typhimurium Salmonella typhimurium 
TE tris-EDTA 
TFA trifluoracetic acid 
THF tetrahydrofuran 
Thr threonine 
TRENCAM β,β',β''-triaminotriethylamine catecholamide 
Tris-HCl tris(hydroxymethyl)aminomethane hydrochloride 
Trp tryptophan 
Tyr tyrosine 
µ (prefix) micro 
UV-visible ultra violet-visible 
V volts 
v/v volume by volume 
Val valine 
V. cholerae Vibrio cholerae 
Vib vibriobactin 
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